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CommentaryThe Centers for Disease Control and Prevention 
(CDC) collects data to monitor progress toward 
achieving national goals [1, 2] and the objectives set 
forth in other federal directives, including the 
updated strategic plan [3] of the Division of HIV/
AIDS Prevention (DHAP). This surveillance supple-
mental report complements the 2017 HIV Surveil-
lance Report [4] and presents the results of focused 
analyses of National HIV Surveillance System 
(NHSS) [5] data to measure progress toward achiev-
ing national goals [1]. Data in this report are also 
used to assess Department of Health and Human Ser-
vices (HHS) core indicators [6, 7] and monitor prog-
ress toward attainment of HIV-related national 
objectives in Healthy People 2020 [8]. This report 
addresses the following objectives:
• Reduce the percentage of persons whose HIV 
infection is classified as stage 3 (AIDS) at diagno-
sis (DHAP strategic plan, HHS core indicator) 
(Tables 1a–d)
• Increase to 85% or more the percentage of persons 
linked to HIV medical care ≤ 1 month after diag-
nosis of HIV infection (NHAS 2020, DHAP stra-
tegic plan, HHS core indicator, Healthy People 
2020) (Tables 3a–d)
• Increase to 90% or more the percentage of persons 
with HIV who are in continuous HIV medical care 
(i.e., retained in care) (NHAS 2020, DHAP strate-
gic plan, HHS core indicator, Healthy People 
2020) (Tables 4a–d)
• Increase to 80% or more the percentage of persons 
with diagnosed HIV infection who are virally sup-
pressed (NHAS 2020, DHAP strategic plan, 
Healthy People 2020) (Tables 5a/b)
• Increase to 80% or more the percentage of youth 
with diagnosed HIV infection who are virally sup-
pressed (NHAS 2020, Healthy People 2020) 
(Table 5a)
• Among persons with diagnosed HIV infection 
who inject drugs, increase to 80% or more the per-
centage who are virally suppressed (NHAS 2020, 
DHAP strategic plan, Healthy People 2020) 
(Table 5a)HIV Surveillance Supplemental Report 5• Reduce by 33% or more the death rate among per-
sons with diagnosed HIV infection (NHAS 2020, 
Healthy People 2020) (Table 6c)
• Reduce the number of perinatally acquired HIV 
cases (Healthy People 2020) (Table 8a)
• Increase to 90% or more the percentage of persons 
living with HIV who know their HIV status 
(NHAS 2020, DHAP strategic plan, Healthy Peo-
ple 2020) (Table 11)
• Reduce the disparities in the rate of new diagnoses 
among gay and bisexual men, young black gay 
and bisexual men, black females, and persons liv-
ing in the South (NHAS 2020, DHAP strategic 
plan) (Table 11)
Monitoring the stage of disease at diagnosis, linkage 
to HIV medical care, retention in HIV medical care, 
and viral suppression (on the basis of NHSS data) is 
dependent upon complete reporting of HIV-related 
laboratory results (including CD4+ T-lymphocyte 
[CD4] and viral load results) to HIV surveillance pro-
grams and CDC. Although most jurisdictions have 
regulations that require laboratories and providers to 
report at least a subset of CD4 and viral load test 
results to health departments, not all jurisdictions have 
mandatory reporting of all levels of CD4 and viral 
load (i.e., detectable and undetectable) results. As of 
December 2018, 42 jurisdictions (41 states and the 
District of Columbia) required reporting of all levels 
of CD4 and viral load test results and had reported to 
CDC ≥ 95% of the test results they had received by 
December 2018 (for specimens collected from at least 
January 2016 through September 2018). (For a list of 
the 42 jurisdictions, see Technical Notes.)
In this report, data from the 42 jurisdictions that 
reported complete CD4 and viral load laboratory 
results to CDC were used for the analyses that require 
laboratory data (Tables 2a–d, 3a–d, 4a–d, and 5a/b). 
Data from these 42 jurisdictions represent 89% of all 
persons aged ≥ 13 years living with diagnosed HIV 
infection at year-end 2016 in the United States and are 
therefore not representative of data on all persons liv-
ing with diagnosed HIV infection in the United States. 
Data from the 50 states, the District of Columbia, and 
6 U.S. dependent areas (where indicated) were used Vol. 24, No. 3
for analyses of stage 3 (AIDS) at the time of diagnosis 
of HIV infection (Tables 1a–d), deaths and survival of 
persons with  diagnosed HIV infection (Tables 6a–f 
and 7a–f), and diagnosed perinatally acquired HIV 
infection (Tables 8a/b). 
For tables that include data by transmission cate-
gory, the data were statistically adjusted to account for 
missing transmission category (see Technical Notes). 
The term diagnosis of HIV infection refers to a 
diagnosis of HIV infection regardless of the 
person’s stage of disease (stage 0, 1, 2, 3 [AIDS], or 
unknown) at the time of diagnosis. Please use caution 
when interpreting data on diagnosed HIV infection. 
HIV surveillance data on persons with diagnosed HIV 
infection may not represent all persons with HIV 
because not all infected persons have been (1) tested 
or (2) tested at a time when the infection could be 
detected and diagnosed. Also, some states offer 
anonymous HIV testing; the results of anonymous 
tests are not reported to the confidential name-based 
HIV registries of state and local health departments. 
Therefore, reports of confidential test results may 
not represent all persons who tested positive for 
HIV infection.
REPORT CHANGES
Tables 2a–d, 3a–d, 4a–d, and 5a/b include data from 
42 jurisdictions that reported complete CD4 and viral 
load data. The jurisdictions included in this report 
differ from those in previous reports. A jurisdiction’s 
data are included only if that jurisdiction met CDC’s 
criteria (see Technical Notes) for the collection and 
reporting of CD4 and viral load test results for all the 
data years examined. In comparison with the 2016 
report, the 2017 report includes data from 2 addi-
tional states that met the criteria. 
Tables 2a/b now display data on persons with infec-
tion classified as stage 0 at diagnosis. In previous 
reports, data on persons with infection classified as 
stage 0 were included in the unknown category (i.e., 
not displayed). 
New to this report are the following:
• Tables 2c/d, 3c/d, and 4c/d display stage at diag-
nosis, linkage to care, receipt of care, and viral 
suppression data by race/ethnicity and selected 
characteristics (c tables) and for males with HIV 
infection attributed to male-to-male sexual con-
tact by race/ethnicity and age group (d tables).HIV Surveillance Supplemental Report 6• Tables 7a/b display survival for > 3 years after 
diagnosis of HIV infection; Tables 7d/e display 
survival after stage 3 (AIDS) classification by 
selected demographics for the United States and 6 
dependent areas (where indicated).
• Table 9 displays prevalence-based (diagnosed and 
undiagnosed infection) estimates of HIV care out-
comes (diagnosis, receipt of care, and viral sup-
pression) for the United States.
DEFINITIONS AND DATA SPECIFICATIONS
In 2014, the HIV surveillance case definition was 
revised to adapt to changes in diagnostic criteria used 
by laboratories and clinicians [9]. The laboratory cri-
teria for defining a confirmed case of HIV infection 
were changed to accommodate multitest algorithms 
that did not include previously required tests (e.g., 
Western blot). New to the case definition is the inclu-
sion of criteria for differentiating HIV-1 and HIV-2 
infections and for recognizing early HIV infection 
(stage 0), during which viral loads may be high 
enough and CD4 T-lymphocyte counts low enough to 
be misclassified as stage 3 (AIDS). In addition, the 
revised definition consolidates the staging systems for 
adults/adolescents and children, simplifies surveil-
lance criteria for opportunistic illnesses indicative of 
stage 3, and incorporates revisions of clinical criteria 
(i.e., medical record documentation) for reporting 
diagnoses without laboratory evidence. Because retro-
active implementation of some features (e.g., the new 
staging system) of the 2014 case definition would be 
impractical, the following criteria were used to clas-
sify cases in this report:
• Cases diagnosed before 2014 were classified 
according to the 2008 HIV case definition [10]. 
• Cases diagnosed in 2014 and later were classified 
according to the 2014 HIV case definition.
HIGHLIGHTS OF ANALYSES
Please read all table titles and footnotes carefully to 
ensure a complete understanding of the displayed data.
Stage 3 (AIDS) classification at HIV diagnosis
Among persons with an HIV diagnosis during 2017, 
20.9% of infections were classified as stage 3 (AIDS) 
at the time of diagnosis (Table 1a). The overall per-
centages decreased from 2010 through 2017. Vol. 24, No. 3
The following percentages are for persons with 
stage 3 (AIDS) classification at the time of HIV diag-
nosis during 2017.
• Age group: The percentage increased as age
increased (e.g., 9.1% of persons aged 13–24 years
and 35.0% of persons aged ≥ 55 years).
• Race/ethnicity: The highest percentages were
for Native Hawaiians/other Pacific Islanders
(25.9%) and Asians (24.9%), followed by whites
(21.5%), Hispanics/Latinos (21.4%), persons of
multiple races (20.7%), American Indians/
Alaska Natives (20.5%), and blacks/African
Americans (20.1%). Please use caution when
interpreting data on American Indians/Alaska
Natives and Native Hawaiians/other Pacific
Islanders: the numbers are small.
• Transmission category: The highest percentage
was for males with infection attributed to hetero-
sexual contact (34.7%), followed by males with
infection attributed to injection drug use (27.0%),
females with infection attributed to heterosexual
contact (22.6%), females with infection attributed
to injection drug use (19.8%), males with infec-
tion attributed to male-to-male sexual contact
(19.0%), and males with infection attributed to
male-to-male sexual contact and injection drug
use (15.7%).
Stage of disease at diagnosis of HIV infection
Stage of disease at diagnosis (i.e., HIV infection, 
stage 0, 1, 2, 3 [AIDS], or unknown) was based on 
data for persons with HIV infection diagnosed during 
2017 in the 42 jurisdictions that reported complete 
CD4 and viral load test results to CDC. Among 
33,955 persons, the stage of disease at diagnosis was 
classified as follows (Table 2a): stage 0 (6.2%), stage 
1 (25.6%), stage 2 (30.4%), stage 3 (AIDS) (20.9%), 
stage unknown (17.0%). 
• Age group: Among persons whose infection was
diagnosed at an earlier stage (stage 0, 1, or 2), the
highest percentages were for persons aged 13–24
(9.1% [stage 0]; 28.1% [stage 1]; 35.0% [stage
2]), followed by those for persons aged 25–34
(6.9% [stage 0]; 27.7% [stage 1]; 31.7% [stage
2]). In general, the percentages of early diagnosis
decreased as age increased. Among persons with
a stage 3 classification, the higher percentages
were for persons in older age groups.
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infections were diagnosed at an earlier stage
(stage 0, 1, or 2), except Native Hawaiian/Other
Pacific Islanders. Among persons whose infection
was diagnosed at an earlier stage (stage 0, 1, or 2),
the highest percentages were for American
Indians/Alaska Natives (7.6% [stage 0]; 30.4%
[stage 1]; 27.8% [stage 2]), followed by those for
persons of multiple races (8.3% [stage 0]; 26.6%
[stage 1]; 30.8% [stage 2]), whites (6.9% [stage
0]; 29.8% [stage 1]; 27.7% [stage 2]), Hispanics/
Latinos (6.4% [stage 0]; 25.4% [stage 1]; 31.4%
[stage 2]), Asians (4.8% [stage 0]; 19.6% [stage
1]; 36.3% [stage 2]), and blacks/African
Americans (5.7% [stage 0]; 23.4% [stage 1];
31.0% [stage 2]). The stage-unknown percentages
were slightly higher among blacks/African
Americans, Hispanics/Latinos, and American
Indians/Alaska Natives (19.7%, 15.3%, and
15.2%, respectively). Please use caution when
interpreting data for American Indians/Alaska
Natives and for Native Hawaiians/other Pacific
Islanders: the numbers are small.
• Transmission category: Among persons whose
infection was diagnosed at an earlier stage (stage
0, 1, or 2), the highest percentages were for males
with infection attributed to male-to-male sexual
contact and injection drug use (7.4% [stage 0];
30.2% [stage 1]; 29.7% [stage 2]) and male-to-
male sexual contact (7.0% [stage 0]; 25.6% [stage
1]; 31.5% [stage 2]). The lowest percentages were
for males with infection attributed to heterosexual
contact (3.1% [stage 0]; 17.8% [stage 1]; 27.4%
[stage 2]) and for males with infection attributed
to injection drug use (4.5% [stage 0]; 23.1%
[stage 1]; 28.0% [stage 2]).
Linkage to HIV medical care after diagnosis of 
HIV infection
Linkage to HIV medical care was based on data for 
persons with infection diagnosed during 2017 in the 
42 jurisdictions that reported complete CD4 and viral 
load test results to CDC. Linkage to HIV medical care 
was measured by documentation of at least 1 CD4 or 
viral load test performed ≤ 1 month or ≤ 3 months after 
diagnosis. Of the 33,955 persons whose infection was 
diagnosed during 2017, 78.3% were linked to HIV 
medical care ≤ 1 month after diagnosis, and 86.8% Vol. 24, No. 3
were linked to HIV medical care ≤ 3 months after 
diagnosis (Table 3a). 
The following percentages are for persons who 
were linked to HIV medical care ≤ 1 month after diag-
nosis (Table 3a).
• Age group: Linkage to HIV medical care 
increased as age at diagnosis increased. The high-
est percentage was for persons aged ≥ 55 years 
(81.6%), followed by that for persons aged 45–54 
years (81.4%). The lowest percentage was for 
persons aged 13–24 years (75.0%). 
• Race/ethnicity: The highest percentage was for 
American Indians/Alaska Natives (84.8%). The 
percentages for other races/ethnicities were as 
follows: Native Hawaiians/other Pacific 
Islanders (83.7%), whites (81.3%), Asians 
(80.7%), persons of multiple races (80.3%), 
Hispanics/Latinos (79.3%), and blacks/African 
Americans (75.8%). 
• Transmission category: The percentages were 
relatively similar for all transmission categories. 
The highest percentage was for females with 
infection attributed to heterosexual contact 
(79.3%), followed by males with infection 
attributed to male-to-male sexual contact 
(78.5%) and males with infection attributed to 
heterosexual contact (77.3%). The lowest per-
centage was for males with infection attributed to 
male-to-male sexual contact and injection drug 
use (75.3%). 
The following percentages are for persons who 
were linked to HIV medical care ≤ 3 months after 
diagnosis (Table 3a).
• Age group: Linkage to HIV medical care 
increased as age at diagnosis increased. The high-
est percentage was for persons aged ≥ 55 years 
(89.3%), followed by that for persons aged 45–54 
years (88.3%). The lowest percentage was for per-
sons aged 13–24 years (85.1%). 
• Race/ethnicity: The highest percentages were for 
Native Hawaiians/other Pacific Islanders (95.3%) 
and American Indians/Alaska Natives (89.9%). 
The percentages for other races/ethnicities were 
89.6%, whites; 89.1%, persons of multiple races; 
87.7%, Asians; 87.2%, Hispanics/Latinos; and 
84.7%, blacks/African Americans. HIV Surveillance Supplemental Report 8• Transmission category: The percentages were 
relatively similar for all transmission categories. 
The highest percentage was for females with 
infection attributed to heterosexual contact 
(87.8%), followed by males with infection 
attributed to male-to-male sexual contact 
(86.8%) and males with infection attributed to 
heterosexual contact (86.2%). The lowest per-
centage was for males with infection attributed to 
injection drug use (84.9%). 
Receipt of HIV medical care
Receipt of HIV medical care was based on data for 
persons with HIV infection diagnosed by year-end 
2015 and alive at year-end 2016 in the 42 jurisdictions 
that reported complete CD4 and viral load test results 
to CDC. Receipt of any HIV medical care was mea-
sured by documentation of ≥ 1 CD4 or viral load tests 
performed during 2016; retention in HIV medical care 
(receipt of continuous care) was measured by docu-
mentation of ≥ 2 CD4 or viral load tests performed at 
least 3 months apart during 2016. During 2016, 74.2% 
of 836,640 persons received HIV medical care, and 
57.6% met the criteria for continuous HIV medical 
care (Table 4a).
The following percentages are for persons who 
received any HIV medical care.
• Age group: The highest percentage was for persons 
aged 13–24 years (76.3%). The lowest percentages 
were for persons aged 35–44 (73.2%) and persons 
aged ≥ 55 years (73.2%).
• Race/ethnicity: The highest percentage was for 
persons of multiple races (85.9%), followed by 
whites (77.8%), Asians (73.5%), American 
Indians/Alaska Natives (73.4%), Hispanics/
Latinos (71.9%), blacks/African Americans 
(71.7%), and Native Hawaiians/other Pacific 
Islanders (71.4%).
• Transmission category: The highest percent-
age was for males with infection attributed to 
male-to-male sexual contact and injection 
drug use (78.4%), followed by males with 
infection attributed to male-to-male sexual 
contact (75.8%). The lowest percentage was 
for males with infection attributed to injection 
drug use (63.6%). 
The following percentages are for persons who 
were retained in continuous HIV medical care.Vol. 24, No. 3
• Age group: The highest percentages were for 
persons aged ≥ 55 years (59.7%) and persons 
aged 45–54 years (58.9%). In general, the per-
centage increased as age increased; however, the 
lowest percentage was for persons aged 25–34 
years (54.0%).
• Race/ethnicity: The highest percentage was for 
persons of multiple races (67.5%), followed by 
whites (59.3%), Hispanics/Latinos (58.6%), 
Asians (58.2%), American Indians/Alaska 
Natives (56.2%), blacks/African Americans 
(54.9%), and Native Hawaiians/other Pacific 
Islanders (51.0%).
• Transmission category: The highest percent-
ages were for males with infection attributed to 
male-to-male sexual contact and injection drug 
use (61.8%), males with infection attributed to 
male-to-male sexual contact (58.4%), and 
females with infection attributed to heterosexual 
contact (57.7%). The lowest percentage was for 
males with infection attributed to injection drug 
use (51.0%). 
Viral suppression 
Viral suppression was measured for persons with HIV 
infection diagnosed by year-end 2015 and alive at 
year-end 2016 in the 42 jurisdictions that reported 
complete CD4 and viral load test results to CDC. 
Viral suppression was measured by a viral load 
result of < 200 copies/mL at the most recent viral 
load test during 2016. 
During 2016, 74.2% of 836,640 persons had at least 
1 CD4 or viral load test (i.e., received any care in 
2016), and 71.1% had at least 1 viral load test. At the 
most recent viral load test during 2016, viral load was 
suppressed in 82.9% of persons who received care (at 
least 1 CD4 or viral load test) in 2016 and in 86.4% of 
persons with a viral load test during 2016. The per-
sons with suppressed viral load represented 61.5% of 
the total number of persons with an HIV diagnosis by 
year-end 2015 and alive at year-end 2016 in the 42 
jurisdictions (Table 5a).
The following percentages are for persons whose 
most recent viral load test result in 2016 indicated 
viral suppression (denominator: persons who were 
alive at year-end 2016).
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increased (53.8% [persons aged 13–24 years]; 
64.2% [persons aged ≥ 55 years]).
• Race/ethnicity: The highest percentage was for 
persons of multiple races (69.8%), followed by 
whites (67.8%), Asians (66.6%), Native 
Hawaiians/other Pacific Islanders (63.4%), 
Hispanics/Latinos (61.3%), American Indians/
Alaska Natives (59.6%), and blacks/African 
Americans (56.1%).
• Transmission category: The highest percentage 
was for males with infection attributed to male-to-
male sexual contact (64.4%), followed by males 
with infection attributed to male-to-male sexual 
contact and injection drug use (62.3%). 
Deaths
Annual rates of death were calculated per 100,000 
population and per 1,000 persons living with diag-
nosed HIV infection or living with infection ever clas-
sified as stage 3 (AIDS). Age-adjusted rates per 
100,000 population and per 1,000 persons living with 
diagnosed HIV infection or living with infection ever 
classified as stage 3 (AIDS) were also calculated and 
are presented by area of residence.
Deaths of persons with diagnosed HIV infection
From 2010 through 2016 in the United States and 6 
dependent areas, the annual rate of deaths per 100,000 
population and the annual rate per 1,000 persons liv-
ing with diagnosed HIV infection decreased (Table 
6b). Trends in rates varied by area of residence at 
death (Table 6c). In 2016, the age-adjusted rates were 
5.7 per 100,000 population and 14.2 per 1,000 per-
sons living with diagnosed HIV infection.
Deaths of persons with stage 3 (AIDS) classification
From 2010 through 2016 in the United States and 6 
dependent areas, the annual rate of deaths per 100,000 
population and the annual rate per 1,000 persons liv-
ing with stage 3 (AIDS) decreased (Table 6e). Trends 
in rates varied by area of residence at death (Table 6f). 
In 2016, the age-adjusted rates were 4.5 per 100,000 
population and 20.6 per 1,000 persons living with 
stage 3 (AIDS).
Survival for > 3 years after diagnosis of 
HIV infection
In the United States and 6 dependent areas, sur-
vival after a diagnosis of HIV infection increased Vol. 24, No. 3
for diagnoses that were made during 2008–2013 
(Table 7b). The following percentages are for per-
sons who survived > 3 years after receiving a diag-
nosis in 2013.
• Age group: The highest percentage was for per-
sons aged 13–24 years (99%). The lowest percent-
age was for persons aged ≥ 55 years (80%).
• Race/ethnicity: The highest percentage was for 
Asians (96%), followed by blacks/African 
Americans (94%), Hispanics/Latinos (94%), per-
sons of multiple races (94%), whites (93%), and 
American Indians/Alaska Natives (90%). Per-
centages for Native Hawaiians/other Pacific 
Islanders are not displayed because the number of 
cases was too small for the calculation of mean-
ingful survival estimates.
• Transmission category: The highest percentage 
was for males with infection attributed to male-to-
male sexual contact (95%), followed by males 
with infection attributed to male-to-male sexual 
contact and injection drug use (94%). The lowest 
percentage was for males with infection attributed 
to injection drug use (84%). 
• By area of residence, at least 90% of persons sur-
vived > 3 years after diagnosis in all but 1 area 
(Table 7c).
Survival after stage 3 (AIDS) classification 
increased over time (Table 7d). The following per-
centages are for persons who survived > 3 years after 
receiving a stage 3 (AIDS) classification in 2013.
• Age group: The highest percentage was for per-
sons aged 13–24 years (96%). The lowest percent-
age was for persons aged ≥ 55 years (71%).
• Race/ethnicity: The highest percentage was for 
Asians (91%), followed by persons of multiple 
races (88%), Hispanics/Latinos (88%), blacks/
African Americans (86%), and whites (84%). Data 
for American Indians/Alaska Natives and Native 
Hawaiians/other Pacific Islanders are not displayed 
because the numbers of cases were too small for 
the calculation of meaningful survival estimates.
• Transmission category: The highest percentage 
was for males with infection attributed to male-to-
male sexual contact (88%), followed by females 
with infection attributed to heterosexual contact 
(85%) and males with infection attributed to male-
to-male sexual contact and injection drug use (84%). HIV Surveillance Supplemental Report 1The lowest percentage was for males with infec-
tion attributed to injection drug use (76%). 
• By area of residence, at least 80% of persons sur-
vived > 3 years after stage 3 (AIDS) classification 
in all but 2 areas (Table 7f).
Perinatally acquired HIV infection
The overall annual rate of perinatally acquired HIV 
infections in the United States (regardless of place of 
birth) decreased from 2.7 per 100,000 live births in 
2010 to 1.2 in 2016 (Table 8a). However, annual rates 
differed by race/ethnicity. Although the annual rate 
among blacks/African Americans decreased from 
10.5 in 2010 to 5.4 in 2016, the 2016 rate among 
blacks/African Americans (5.4) was substantially 
higher than the 2016 rates among Hispanics/Latinos 
(1.3) and whites (0.1).
Among infants born in the United States, the over-
all annual rate of perinatally acquired HIV infections 
decreased from 1.8 per 100,000 live births in 2010 to 
1.1 in 2016 (Table 8b). However, annual rates dif-
fered by race/ethnicity. Although the annual rate 
among blacks/African Americans decreased from 6.8 
in 2010 to 5.0 in 2016, the 2016 rate among blacks/
African Americans (5.0) was substantially higher than 
the 2016 rates among Hispanics/Latinos (1.1) and 
whites (0.1). 
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Technical NotesSURVEILLANCE OF HIV INFECTION 
This report includes data reported to the Centers for 
Disease Control and Prevention (CDC) through 
December 31, 2018, from all 50 states, the District of 
Columbia, and 6 U.S. dependent areas (American 
Samoa, Guam, the Northern Mariana Islands, Puerto 
Rico, the Republic of Palau, and the U.S. Virgin 
Islands). After the removal of personally identifiable 
information, data were submitted to CDC.
Please use caution when interpreting data on diag-
nosed HIV infection. HIV surveillance data on per-
sons with diagnosed HIV infection may not represent 
all persons with HIV because not all infected persons 
have been (1) tested or (2) tested at a time when the 
infection could be detected and diagnosed. Also, 
some states offer anonymous HIV testing; the results 
of anonymous tests are not reported to the confiden-
tial name-based HIV registries of state and local 
health departments. Therefore, reports of confidential 
test results may not represent all persons who tested 
positive for HIV infection.
Please also use caution when interpreting laboratory 
data for persons with diagnosed HIV infection. Labo-
ratory data presented in this report are from 42 juris-
dictions (41 states and the District of Columbia) that 
reported complete CD4+ T-lymphocyte (CD4) and 
viral load test results to CDC as of December 2018. 
Data from these 42 jurisdictions represent 89% of all 
persons aged ≥ 13 years living with diagnosed HIV 
infection at year-end 2016 in the United States and are 
therefore not representative of data on all persons liv-
ing with diagnosed HIV infection in the United States. 
Areas with Complete Laboratory Reporting
As of December 2018, 42 jurisdictions (41 states and 
the District of Columbia) had met the following crite-
ria for the collection and reporting of CD4 and viral 
load test results: 
• The jurisdiction’s laws/regulations required the 
reporting of all CD4 and viral load results to the 
state or local health department.
• Laboratories that perform HIV-related testing 
for the jurisdictions had reported a minimum of 
95% of HIV-related test results to the state or 
local health department.
HIV Surveillance Supplemental Report 1• By December 31, 2018, the jurisdiction had 
reported (to CDC) at least 95% of all CD4 and 
viral load test results received from January 2016 
through September 2018. 
The 41 states are Alabama, Alaska, California, 
Colorado, Connecticut, Delaware, Florida, Georgia, 
Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, 
Maryland, Massachusetts, Michigan, Minnesota, 
Mississippi, Missouri, Montana, Nebraska, New 
Hampshire, New Mexico, New York, North Carolina, 
North Dakota, Ohio, Oklahoma, Oregon, Rhode 
Island, South Carolina, South Dakota, Tennessee, 
Texas, Utah, Virginia, Washington, West Virginia, 
Wisconsin, and Wyoming. Data from these states and 
the District of Columbia were used to populate Tables 
2a–d, 3a–d, 4a–d, and 5a/b.
TABULATION AND PRESENTATION OF DATA 
Stages of HIV Infection
Both the 2008 and 2014 HIV case definitions were 
used to classify HIV infection among adults and ado-
lescents and among children [9, 10].
The 2008 case definition was used to classify cases 
diagnosed from the beginning of the epidemic 
through 2013. For adults and adolescents, this defini-
tion incorporates an HIV infection staging system that 
includes AIDS (HIV infection, stage 3). The 2008 
stages of HIV infection are defined as follows:
• HIV infection, stage 1: No AIDS-defining condi-
tion and either a CD4 count of ≥ 500 cells/µL or a 
CD4 percentage of total lymphocytes of ≥ 29.
• HIV infection, stage 2: No AIDS-defining condi-
tion and either a CD4 count of 200–499 cells/µL or 
a CD4 percentage of total lymphocytes of 14–28.
• HIV infection, stage 3 (AIDS): Documentation 
of an AIDS-defining condition or either a CD4 
count of < 200 cells/µL or a CD4 percentage of 
total lymphocytes of < 14. Documentation of an 
AIDS-defining condition supersedes a CD4 count 
or percentage that would not, by itself, be the basis 
for a stage 3 (AIDS) classification.
• HIV infection, stage unknown: No reported in-
formation on AIDS-defining conditions and no 
information available on CD4 count or percentage.2 Vol. 24, No. 3
The 2014 case definition was used to classify cases 
diagnosed in 2014 and later. It is similar to the 2008 
case definition except for the following: (1) inclusion 
of criteria for stage 0, (2) the inclusion of CD4 test-
ing criteria for stage 3 in children, and (3) changes in 
the cutoffs for CD4 percentage of total lymphocytes 
used for classification of stages 1 and 2 in persons 
aged ≥ 6 years. The stages of HIV infection in the 
2014 case definition are based on age-specific CD4 
counts or percentages of total lymphocytes and are 
defined as follows:
• HIV infection, stage 0: First positive HIV test 
result within 6 months after a negative HIV test 
result. The stage remains stage 0 until 6 months 
after the first positive test result. After 6 months, 
the stage may be classified as 1, 2, 3, or unknown 
if based on a CD4 test result or the diagnosis of an 
opportunistic illness. The diagnosis of an AIDS-
defining condition or a low CD4 test result before 
the 6 months have elapsed does not change the 
stage from stage 0 to stage 3. 
• HIV infection, stages 1, 2, and 3: Documentation 
of an AIDS-defining condition (excluding stage 0 
as described above) is stage 3. Otherwise, the stage 
is determined by the lowest CD4 test result.
• HIV infection, stage unknown: No reported in-
formation on AIDS-defining conditions and no 
information available on CD4 count or percentage.
Data on persons with HIV infection, stage 3 (AIDS), 
include persons whose infection has ever been classi-
fied as stage 3 (AIDS). These data do not necessarily 
represent the current stage of disease.
Information on stage 3 (AIDS) is available for all 
50 states, the District of Columbia, and 6 U.S. 
dependent areas, even when not all CD4 values are 
reportable; therefore, stage 3 (AIDS) at the time of 
HIV diagnosis was calculated for persons in all 
areas (Tables 1a–d). Because a complete assessment 
of stage of disease at HIV diagnosis relies on com-
plete laboratory data (all CD4 values) so that earlier 
stages of disease (stage 0, 1, or 2) can be assessed, 
stage of disease at diagnosis was calculated for the 
42 jurisdictions that reported complete laboratory 
data (Tables 2a/b). 
Stage 3 (AIDS) at the time of HIV diagnosis (Tables 
1a–d) and stage of disease at diagnosis (Tables 2a–d) 
were determined by using the first CD4 test result or 
documentation of an AIDS-defining condition ≤ 3 
months after the HIV diagnosis date, unless documen-HIV Surveillance Supplemental Report 1tation indicated disease stage 0. If ≥ 2 events occurred 
during the same month and could thus qualify as 
“first,” the following conditions were applied:
• If an AIDS-defining condition was documented, 
the AIDS-defining condition was used; if a CD4 
count or a CD4 percentage had been reported and 
an AIDS-defining condition was documented, the 
AIDS-defining condition was used.
• If an AIDS-defining condition was not docu-
mented, but a CD4 count and a CD4 percentage 
had been reported, the CD4 count was used.
• If an AIDS-defining condition was not docu-
mented, but > 1 CD4 count had been reported, the 
lowest CD4 count (indicative of the most severe 
disease state) was used.
• If an AIDS-defining condition was not docu-
mented and a CD4 count had not been reported, 
but a CD4 percentage had been reported, the CD4 
percentage was used. If > 1 CD4 percentage was 
reported, the lowest CD4 percentage (indicative 
of the most severe disease state) was used.
For stage of disease at diagnosis, infections were 
classified as “stage unknown” if the month of HIV 
diagnosis was missing, or if, ≤ 3 months after HIV 
diagnosis, neither a CD4 count nor a CD4 percentage 
had been determined and no AIDS-defining condition 
was documented.
Linkage to, and Receipt of, HIV 
Medical Care
National guidelines for the clinical care and treatment of 
adults and adolescents living with HIV [11] recommend 
CD4 and viral load testing during the first care visit after 
HIV diagnosis to direct the course of treatment. For 
patients who are not taking antiretroviral therapy 
(ART), CD4 count should be monitored every 3–6 
months. For virally suppressed patients who have taken 
ART for ≤ 2 years, viral load testing is recommended 
every 3 to 4 months or as clinically indicated to confirm 
continuous viral suppression. For virally suppressed 
patients who have taken ART for > 2 years, viral load 
testing at 6-month intervals may be considered. For 
virally suppressed patients whose CD4 counts have 
consistently ranged from 300 to 500 cells/µL for ≥ 2 
years, annual monitoring of CD4 count is recom-
mended. For virally suppressed patients whose CD4 
counts have consistently been > 500 cells/µL for ≥ 2 
years, continued CD4 monitoring is optional. 3 Vol. 24, No. 3
Frequent monitoring of CD4 count, especially 
among persons with higher counts (> 300 cells/µL) 
and consistently suppressed viral loads, is generally 
not required for patient management. However, if clin-
ically indicated, the CD4 count should be monitored 
more frequently (e.g., when changes in a patient’s 
clinical status decrease CD4 count and thus prompt the 
need for prophylaxis for opportunistic infection).
The data on linkage to HIV medical care were 
based on persons whose infection was diagnosed 
during 2017 and who resided in any of the 42 jurisdic-
tions at the time of diagnosis (Tables 3a–d). Linkage 
to HIV medical care within 1 month after HIV diag-
nosis was measured by documentation of ≥ 1 CD4 
(count or percentage) or viral load tests performed ≤ 1 
month after HIV diagnosis, including tests performed 
on the same date as the date of diagnosis. Linkage to 
HIV medical care within 3 months after HIV diagno-
sis was measured by documentation of ≥ 1 CD4 
(count or percentage) or viral load tests performed ≤ 3 
months after HIV diagnosis, including tests per-
formed on the same date as the date of diagnosis. 
The data on receipt of HIV medical care were 
based on persons whose infection was diagnosed by 
year-end 2015, who resided in any of the 42 jurisdic-
tions as of their most recent known address, and who 
were alive at year-end 2016 (Tables 4a–d). Receipt 
of any HIV medical care was measured by documen-
tation of ≥ 1 CD4 or viral load tests performed during 
2016. Retention in care (receipt of continuous HIV 
medical care) was measured by documentation of ≥ 2 
CD4 or viral load tests performed ≥ 3 months apart 
during 2016. 
For analyses of linkage to, and retention in, care, the 
month and the year of the earliest HIV-positive test 
result reported to the surveillance system were used to 
determine the diagnosis date. Test results were 
excluded if the month of the sample collection was 
missing. For linkage to care, data were excluded if the 
month of diagnosis was missing. For retention in care, 
data were excluded if the date of death (where applica-
ble) was missing. 
Viral Suppression
Viral suppression was measured among persons 
whose infection was diagnosed by year-end 2015, 
who resided in any of the 42 jurisdictions as of their 
most recent known address during 2016, and who 
were alive at year-end 2016. Viral suppression was 
defined as a viral load result of 200 copies/mL at the HIV Surveillance Supplemental Report 1most recent viral load test during 2016. The cutoff 
value of 200 copies/mL was based on the following 
definition of virologic failure: viral load of ≥ 200 cop-
ies/mL. If multiple viral load tests were performed 
during the same month and could thus qualify as 
“most recent,” the highest viral load (most severe) 
was selected. If the numerical result was missing or 
the result was a logarithmic value, the interpretation 
of the result (e.g., below limit) was used to determine 
viral suppression. Virologic failure may indicate lack 
of adherence to ART.
Deaths
Persons whose HIV infections are reported to the 
National HIV Surveillance System (NHSS) are 
assumed to be alive unless their deaths have been 
reported to CDC. Death data were based on deaths of 
persons with diagnosed HIV infection and of persons 
with infection ever classified as stage 3 (AIDS), 
regardless of the cause of death. Jurisdiction-level data 
were based on area of residence at death. If information 
on residence at death was not available, the state where 
a person’s death occurred was used. Because of delays 
in the reporting of deaths, 7 years (2010–2016) of 
death data are displayed. The exclusion of data from 
the most recent year allowed ≥ 18 months for deaths to 
be reported to CDC. Please use caution when interpret-
ing trend data on the numbers of deaths: the numbers 
for the most recent year are subject to uncertainty.
Survival Analyses
The Kaplan-Meier method was used to estimate the 
probability of survival (Tables 7a–f) for > 3 years (36 
months) for persons with diagnosed HIV infection and 
for persons whose infection had ever been classified as 
stage 3 (AIDS). To allow ≥ 3 years from the time of 
HIV diagnosis to a death date on or before December 
31, 2016, tables were limited to data on persons whose 
diagnosis or stage 3 (AIDS) classification was made 
during 2008–2013. The results of survival analyses for 
areas with < 100 diagnoses per year (i.e., 600 during 
the 6-year period) were unstable and therefore are not 
presented in this report.
Perinatally Acquired HIV Infection
Table 8a presents data for infants with infection 
attributed to perinatal transmission and reported to 
NHSS through December 2018. The data include all 
persons reported to NHSS with infection attributed to 4 Vol. 24, No. 3
perinatal exposure, regardless of place of birth. Table 
8b presents a subset of data from Table 8a: the data 
include only the persons whose case record denoted 
the United States as place of birth or residence at 
birth. The data on persons with perinatally acquired 
infection that are presented in Table 8b do not include 
persons who were born in a U.S. dependent area or a 
foreign country or whose residence at birth was 
unknown or missing from the case record.
Age
All tables in this report reflect data on persons aged 
≥ 13 years, with the exception of Tables 8a/b (perina-
tally acquired HIV infection; birth years 2010–2016). 
• Tables 4a–d and 5a/b (receipt of care and viral 
suppression): age was based on the person’s age at 
year-end 2015.
• Tables 6a–f (deaths): age was based on the per-
son’s age at the time of death.
• Table 9 (prevalence): age was based on the per-
son’s age at year-end 2016.
• All other tables: age was based on the person’s 
age at the time of HIV diagnosis.
Race and Ethnicity
In the Federal Register for October 30, 1997 [12], 
the Office of Management and Budget (OMB) 
announced the Revisions to the Standards for the 
Classification of Federal Data on Race and Ethnicity 
and mandated implementation by January 1, 2003. At 
a minimum, data should be collected for the following 
race categories:
• American Indian or Alaska Native
• Asian
• black or African American
• Native Hawaiian or other Pacific Islander
• white
Additionally, systems must be able to retain infor-
mation when multiple race categories are reported. In 
addition to data on race, data on 2 categories of eth-
nicity should be collected:
• Hispanic or Latino
• not Hispanic or Latino
The Asian or Pacific Islander category displayed in 
annual surveillance reports published prior to the 
2007 surveillance report was split into 2 categories: 
(1) Asian and (2) Native Hawaiian or other Pacific HIV Surveillance Supplemental Report 1Islander. The Asian category (in tables where foot-
noted) includes persons categorized as Asian/Pacific 
Islander (referred to as legacy cases) that were 
reported before the new race categories were imple-
mented in 2003 (e.g., diagnoses of HIV infection that 
were reported to CDC before 2003 but that were 
classified as stage 3 [AIDS] after 2003) and a small 
percentage of persons that were reported after 2003 
but that were reported according to the old race cate-
gory (Asian/Pacific Islander). In tables of diagnoses 
of HIV infection during 2008–2017, the Asian cate-
gory does not include persons categorized as Asian/
Pacific Islander because their diagnosis was made 
after 2003 and reported to CDC in accordance with 
OMB’s Revisions to the Standards for the Classifica-
tion of Federal Data on Race and Ethnicity [12].
This report also presents data for persons for whom 
multiple race categories are specified. In this report, 
persons categorized by race were not Hispanic or 
Latino. The number of persons reported in each race 
category may, however, include persons whose eth-
nicity was not reported.
Demographic information for the live birth registry 
is based on that of the mother [13]. Therefore, Tables 
8a/b, which present estimated numbers and rates of 
perinatally acquired HIV infection, categorize race/
ethnicity according to the mother’s race/ethnicity.
Geographic Designation
Data by area of residence reflect the address at the 
time of diagnosis of HIV infection or at the time of 
stage 3 (AIDS) classification for Tables 1c/d, 2b, 3b, 
and 7c/f. In Tables 4a–d and 5a/b, area of residence 
is based on most recent known address as of Decem-
ber 31 of the specified year. For the death tables (6c 
and 6f), area of residence is based on residence at 
death. When information on residence at death is not 
available, the state where a person’s death occurred 
is used.
Transmission Categories
Transmission category is the term used to summarize 
a person’s possible HIV risk factors; the summary 
classification results from selecting, from the pre-
sumed hierarchical order of probability, the 1 risk 
factor most likely to have been responsible for trans-
mission. For surveillance purposes, a diagnosis of 
HIV infection is counted only once in the hierarchy of 
transmission categories. Persons with > 1 reported risk 5 Vol. 24, No. 3
factor for HIV infection are classified in the transmis-
sion category listed first in the hierarchy. The excep-
tion is the category for male-to-male sexual contact 
and injection drug use; this group makes up a separate 
transmission category.
Persons whose transmission category is classified 
as male-to-male sexual contact include men who have 
ever had sexual contact with other men (i.e., homo-
sexual contact) and men who have ever had sexual 
contact with both men and women (i.e., bisexual con-
tact). Persons whose transmission category is classi-
fied as heterosexual contact are persons who have 
ever had heterosexual contact with a person known to 
have, or to be at high risk for, HIV infection (e.g., a 
person who injects drugs).
Cases of HIV infection reported without a risk 
factor listed in the hierarchy of transmission catego-
ries are classified as “no risk factor reported or identi-
fied.” Cases classified as no identified risk factor 
(NIR) include cases that are being followed up by 
local health department staff; cases in persons whose 
risk-factor information is missing because they died, 
declined to be interviewed, or were lost to follow-up; 
and cases in persons who were interviewed or for 
whom other follow-up information was available but 
for whom no risk factor was identified.
Because a substantial proportion of cases of HIV 
infection are reported to CDC without an identified 
risk factor, multiple imputation is used to assign a 
transmission category [14]. Multiple imputation is a 
statistical approach in which each missing transmission 
category is replaced with a set of plausible values that 
represent the uncertainty about the true, but missing, 
value [15]. The plausible values are analyzed by using 
standard procedures, and the results of these analyses 
are then combined to produce the final results. 
Rates
In tables displaying data on deaths of persons with 
diagnosed HIV infection and deaths of persons with 
infection ever classified as stage 3 (AIDS) (Tables 
6a–f), rates were calculated in 3 ways: 
• Rates of deaths per 100,000 population: The 
population denominators used to compute the 
rates for the 50 states, the District of Columbia, 
and Puerto Rico were based on the Vintage 2017 
file (for years 2010 to 2016) from the U.S. Census 
Bureau [16]. The population denominators for 
American Samoa, Guam, the Northern Mariana 
HIV Surveillance Supplemental Report 1Islands, the Republic of Palau, and the U.S. Virgin 
Islands were based on estimates and projections 
from the U.S. Census Bureau’s International Data 
Base [17]. Each rate was calculated by dividing 
the estimated total number of diagnoses (or deaths 
or prevalence) for the calendar year by the popu-
lation for that calendar year and then multiplying 
the result by 100,000. 
• Rates of deaths per 1,000 persons living with 
diagnosed HIV infection or living with infec-
tion ever classified as stage 3 (AIDS): Rates 
were calculated by dividing the estimated total 
number of deaths of persons with diagnosed HIV 
infection (or with infection classified as stage 3 
[AIDS]) during the calendar year by the sum of 
the estimated number of persons living with a 
diagnosis of HIV infection (or with infection clas-
sified as stage 3 [AIDS]) at the end of the previous 
calendar year plus the number of diagnoses of 
HIV infection (or stage 3 [AIDS] classification) 
during the current calendar year; the result was 
then multiplied by 1,000. 
• Age-adjusted rates of deaths per 100,000 popu-
lation and per 1,000 persons living with diag-
nosed HIV infection or living with infection 
ever classified as stage 3 (AIDS): Tables 6c and 
6f include age-adjusted rates by area of residence 
in addition to crude rates. A standard population 
distribution was used to adjust death rates per 
100,000 population and per 1,000 persons living 
with diagnosed HIV infection (or with infection 
ever classified as stage 3 [AIDS]). The age-
adjusted rates are rates that would have existed if 
the age distribution of the designated population 
and the age distribution of the standard population 
were the same. The use of the U.S. 2000 standard 
population in calculating age-adjusted rates was 
based on recommendations by the National Cen-
ter for Health Statistics [18, 19]. 
In the tables displaying data on perinatally acquired 
HIV infection (Tables 8a/b), rates were calculated per 
100,000 live births [13].6 Vol. 24, No. 3
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States
2016 2017
 3 (AIDS) 
gnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa
% No. % No. %
4 21.2 32,032 6,726 21.0 30,939 6,391 20.7
2 23.4 7,537 1,685 22.4 7,285 1,616 22.2
5 8.5 8,641 759 8.8 8,209 749 9.1
2 16.6 13,615 2,240 16.5 13,319 2,161 16.2
4 27.9 7,507 2,042 27.2 7,275 1,873 25.7
4 33.9 5,988 1,976 33.0 5,611 1,889 33.7
1 37.3 3,818 1,394 36.5 3,810 1,335 35.0
5 24.5 227 54 23.8 210 43 20.5
7 22.5 963 221 22.9 948 236 24.9
0 20.3 17,170 3,487 20.3 16,525 3,320 20.1
9 22.5 9,921 2,184 22.0 9,602 2,058 21.4
6 21.9 41 8 19.5 54 14 25.9
6 22.9 10,054 2,219 22.1 9,920 2,136 21.5
3 21.6 1193 238 19.9 965 200 20.7
1 19.3 26,146 5,014 19.2 25,445 4,830 19.0
7 29.4 1,221 336 27.5 1,314 355 27.0
1 19.9 975 201 20.7 1,015 201 19.8
6 18.9 1,338 231 17.3 1,290 203 15.7
8 34.2 3,302 1,134 34.4 2,856 991 34.7
5 24.0 6,516 1,475 22.6 6,222 1,408 22.6
3 37.8 26 10 38.4 34 11 33.1
6 21.8 47 9 18.9 47 7 14.6
6 21.6 39,569 8,411 21.3 38,224 8,007 20.9
Abbreviation: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data are based on residence at diagnosis.a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection.b Hispanics/Latinos can be of any race.c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Table 1a. Stage 3 (AIDS) at HIV diagnosis, among persons aged ≥ 13 years, by year of diagnosis and selected characteristics, 2010–2017—United 
2010 2011 2012 2013 2014 2015
Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage
at dia
No. % No. % No. % No. % No. % No.
Sex
Male 33,773 9,725 28.8 32,766 9,238 28.2 32,530 8,864 27.2 31,689 8,668 27.4 32,424 7,212 22.2 32,439 6,88
Female 9,492 2,554 26.9 8,750 2,385 27.3 8,189 2,235 27.3 7,622 2,090 27.4 7,589 1,833 24.2 7,388 1,73
Age at diagnosis (yr)
13–24 9,133 1202 13.2 9,084 1,201 13.2 9,082 1,137 12.5 8,771 1,204 13.7 9,123 805 8.8 9,036 76
25–34 11,758 2,692 22.9 11,544 2,607 22.6 11,852 2,672 22.5 11,842 2,574 21.7 12,640 2,184 17.3 13,056 2,17
35–44 10,188 3,464 34.0 9,186 3,093 33.7 8,559 2,759 32.2 7,887 2,656 33.7 8,018 2,335 29.1 7,673 2,14
45–54 8,266 3,247 39.3 7,858 3,043 38.7 7,444 2,901 39.0 6,880 2,640 38.4 6,503 2,251 34.6 6,333 2,14
≥ 55 3,920 1,674 42.7 3,844 1,679 43.7 3,782 1,630 43.1 3,931 1,684 42.8 3,729 1,470 39.4 3,729 1,39
Race/ethnicity
American Indian/Alaska Native 159 57 35.8 137 45 32.8 170 50 29.4 144 39 27.1 178 45 25.3 184 4
Asian 673 213 31.6 720 204 28.3 768 220 28.6 778 232 29.8 909 221 24.3 921 20
Black/African American 19,649 5,259 26.8 18,692 4,928 26.4 17,957 4,736 26.4 17,117 4,424 25.8 17,353 3,777 21.8 17,312 3,52
Hispanic/Latinob 9,253 2,884 31.2 9,065 2,704 29.8 9,102 2,618 28.8 9,016 2,632 29.2 9,565 2,232 23.3 9,684 2,17
Native Hawaiian/Other 
Pacific Islander
47 24 51.1 53 22 41.5 48 15 31.3 48 16 33.3 42 10 23.8 73 1
White 11,532 3,338 28.9 11,040 3,234 29.3 10,915 3,047 27.9 10,541 3,002 28.5 10,495 2,442 23.3 10,342 2,36
Multiple races 1,952 504 25.8 1,809 486 26.9 1,759 413 23.5 1,667 413 24.8 1471 318 21.6 1311 28
Transmission categoryc 
Male-to-male sexual contact 26,037 6,900 26.5 25,791 6,751 26.2 26,034 6,543 25.1 25,571 6,504 25.4 26,472 5,346 20.2 26,471 5,11
Injection drug use
Male 1,934 746 38.6 1,592 608 38.2 1,431 523 36.5 1,348 488 36.2 1,286 452 35.2 1,315 38
Female 1,407 374 26.6 1,271 370 29.1 1,155 306 26.5 999 275 27.5 962 222 23.1 1011 20
Male-to-male sexual contact 
and injection drug use
1,697 437 25.8 1,571 373 23.7 1,494 366 24.5 1,379 293 21.2 1,344 231 17.2 1,352 25
Heterosexual contactd 
Male 4,058 1,622 40.0 3,772 1,491 39.5 3,523 1,414 40.1 3,351 1,367 40.8 3,285 1,170 35.6 3,267 1,11
Female 8,051 2,167 26.9 7,440 2,000 26.9 7,001 1,921 27.4 6,578 1,804 27.4 6,595 1,601 24.3 6,348 1,52
Othere
Male 48 19 40.8 41 15 37.5 47 18 39.1 40 16 40.1 36 13 37.6 33 1
Female 34 14 39.9 39 15 39.8 33 8 23.7 45 12 25.6 32 10 31.8 29
Total 43,265 12,279 28.4 41,516 11,623 28.0 40,719 11,099 27.3 39,311 10,758 27.4 40,013 9,045 22.6 39,827 8,61
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tates and 6 dependent areas
2016 2017
 3 (AIDS) 
gnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa
% No. % No. %
0 21.2 32,481 6,841 21.1 31,305 6,455 20.6
7 23.4 7,640 1,707 22.3 7,376 1,640 22.2
3 8.5 8,728 770 8.8 8,282 754 9.1
4 16.6 13,749 2,259 16.4 13,446 2,178 16.2
1 27.8 7,633 2,079 27.2 7,364 1,897 25.8
3 33.8 6,093 2,012 33.0 5,704 1,911 33.5
6 37.2 3,918 1,428 36.4 3,885 1,355 34.9
5 24.5 227 54 23.8 210 43 20.5
7 22.4 964 221 22.9 951 238 25.0
5 20.4 17,176 3,489 20.3 16,528 3,320 20.1
1 22.4 10,458 2,316 22.1 10,046 2,142 21.3
8 23.7 47 10 21.3 57 16 28.1
8 22.9 10,056 2,220 22.1 9,923 2,136 21.5
3 21.6 1193 238 19.9 966 200 20.7
7 19.3 26,437 5,070 19.2 25,678 4,868 19.0
5 28.8 1,261 354 28.0 1,348 361 26.8
2 19.8 985 202 20.6 1,023 201 19.7
0 19.0 1,350 237 17.6 1,301 204 15.7
5 34.1 3,408 1,171 34.4 2,944 1,010 34.3
8 24.0 6,609 1,496 22.6 6,306 1,432 22.7
3 37.6 26 10 38.5 35 11 33.0
7 22.2 47 9 18.9 47 7 14.6
7 21.6 40,121 8,548 21.3 38,681 8,095 20.9
Abbreviation: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data are based on residence at diagnosis.a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection.b Hispanics/Latinos can be of any race.c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Table 1b. Stage 3 (AIDS) at HIV diagnosis, among persons aged ≥ 13 years, by year of diagnosis and selected characteristics, 2010–2017—United S
2010 2011 2012 2013 2014 2015
Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage
at dia
No. % No. % No. % No. % No. % No.
Sex
Male 34,383 9,894 28.8 33,325 9,398 28.2 33,083 8,998 27.2 32,201 8,797 27.3 32,933 7,317 22.2 32,908 6,98
Female 9,703 2,609 26.9 8,960 2,434 27.2 8,384 2,289 27.3 7,786 2,132 27.4 7,734 1,873 24.2 7,498 1,75
Age at diagnosis (yr)
13–24 9,236 1211 13.1 9,190 1,219 13.3 9,207 1,146 12.4 8,878 1,217 13.7 9,266 814 8.8 9,126 77
25–34 11,966 2,727 22.8 11,731 2,641 22.5 12,051 2,706 22.5 12,016 2,602 21.7 12,797 2,205 17.2 13,211 2,19
35–44 10,410 3,528 33.9 9,377 3,146 33.6 8,722 2,806 32.2 8,020 2,691 33.6 8,168 2,377 29.1 7,803 2,17
45–54 8,450 3,317 39.3 8,048 3,114 38.7 7,607 2,963 39.0 7,035 2,685 38.2 6,610 2,288 34.6 6,456 2,18
≥ 55 4,024 1,720 42.7 3,939 1,712 43.5 3,880 1,666 42.9 4,038 1,734 42.9 3,826 1,506 39.4 3,810 1,41
Race/ethnicity
American Indian/Alaska Native 159 57 35.8 137 45 32.8 170 50 29.4 144 39 27.1 178 45 25.3 184 4
Asian 675 213 31.6 721 205 28.4 769 221 28.7 778 232 29.8 911 223 24.5 925 20
Black/African American 19,663 5,265 26.8 18,708 4,932 26.4 17,961 4,738 26.4 17,133 4,427 25.8 17,369 3,784 21.8 17,321 3,52
Hispanic/Latinob 10,051 3,097 30.8 9,813 2,907 29.6 9,839 2,801 28.5 9,670 2,799 28.9 10,191 2,367 23.2 10,244 2,29
Native Hawaiian/Other 
Pacific Islander
51 26 51.0 54 22 40.7 51 16 31.4 49 16 32.7 44 10 22.7 76 1
White 11,534 3,340 29.0 11,042 3,234 29.3 10,916 3,048 27.9 10,546 3,003 28.5 10,502 2,443 23.3 10,344 2,36
Multiple races 1,953 505 25.9 1,810 487 26.9 1,761 413 23.5 1,667 413 24.8 1472 318 21.6 1312 28
Transmission categoryc 
Male-to-male sexual contact 26,340 6,973 26.5 26,068 6,816 26.1 26,339 6,607 25.1 25,863 6,567 25.4 26,803 5,392 20.1 26,773 5,16
Injection drug use
Male 2,067 785 38.0 1,702 642 37.7 1,521 548 36.0 1,430 507 35.5 1,347 467 34.7 1,374 39
Female 1,431 380 26.5 1,303 372 28.5 1,177 309 26.3 1,025 281 27.4 976 226 23.2 1019 20
Male-to-male sexual contact 
and injection drug use
1,724 443 25.7 1,595 378 23.7 1,520 370 24.3 1,399 295 21.1 1,353 231 17.1 1,373 26
Heterosexual contactd 
Male 4,205 1,675 39.8 3,917 1,546 39.5 3,657 1,455 39.8 3,469 1,412 40.7 3,394 1,213 35.7 3,354 1,14
Female 8,238 2,216 26.9 7,618 2,047 26.9 7,174 1,972 27.5 6,715 1,840 27.4 6,726 1,637 24.3 6,450 1,54
Othere
Male 48 19 40.8 42 16 39.0 47 18 39.1 40 16 40.1 36 13 37.6 34 1
Female 34 14 39.9 39 15 39.8 33 8 23.7 45 12 25.6 32 10 31.8 29
Total 44,086 12,503 28.4 42,285 11,832 28.0 41,467 11,287 27.2 39,987 10,929 27.3 40,667 9,190 22.6 40,406 8,73
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tes and 6 dependent areas 
2016 2017
AIDS) 
osisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa
% No. % No. %
24.1 664 144 21.7 653 142 21.7
20.0 37 6 16.2 29 7 24.1
21.5 717 144 20.1 727 137 18.8
22.8 311 69 22.2 286 51 17.8
18.5 5,148 961 18.7 4,767 908 19.0
26.2 424 84 19.8 441 80 18.1
25.8 261 68 26.1 275 65 23.6
28.2 111 34 30.6 125 32 25.6
14.9 344 59 17.2 305 40 13.1
21.5 4,684 998 21.3 4,590 976 21.3
20.5 2,493 474 19.0 2,584 567 21.9
19.2 78 11 14.1 78 13 16.7
35.0 45 7 15.6 45 11 24.4
21.3 1,489 309 20.8 1,354 274 20.2
19.1 483 109 22.6 516 124 24.0
37.1 133 31 23.3 126 27 21.4
22.9 146 35 24.0 117 26 22.2
23.3 336 109 32.4 365 86 23.6
22.0 1,118 261 23.3 1,008 229 22.7
28.3 53 12 22.6 31 12 38.7
21.9 1,105 229 20.7 1,020 249 24.4
22.8 634 138 21.8 597 121 20.3
22.3 744 178 23.9 761 149 19.6
24.7 295 67 22.7 276 76 27.5
23.4 422 118 28.0 426 115 27.0
20.6 510 120 23.5 504 84 16.7
31.6 21 4 19.0 31 6 19.4
27.8 76 18 23.7 88 13 14.8
22.6 514 113 22.0 491 107 21.8
12.0 41 11 26.8 35 5 14.3
26.1 1,214 281 23.1 1,133 238 21.0
23.7 144 30 20.8 135 29 21.5
Table 1c. Stage 3 (AIDS) at HIV diagnosis, among persons aged ≥ 13 years, by year of diagnosis and area of residence, 2010–2017—United Sta
2010 2011 2012 2013 2014 2015
Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (
at diagn
No. % No. % No. % No. % No. % No.
Alabama 681 144 21.1 682 160 23.5 666 164 24.6 633 165 26.1 673 147 21.8 664 160
Alaska 35 12 34.3 24 8 33.3 28 10 35.7 23 7 30.4 38 4 10.5 25 5
Arizona 619 218 35.2 565 169 29.9 623 155 24.9 691 193 27.9 744 153 20.6 693 149
Arkansas 235 61 26.0 240 53 22.1 248 61 24.6 263 70 26.6 312 66 21.2 272 62
California 5,281 1,485 28.1 5,061 1,352 26.7 5,064 1,364 26.9 4,714 1,223 25.9 5,167 1,016 19.7 5,116 948
Colorado 421 142 33.7 363 108 29.8 371 101 27.2 312 92 29.5 379 102 26.9 378 99
Connecticut 390 140 35.9 352 124 35.2 288 112 38.9 328 103 31.4 293 90 30.7 275 71
Delaware 126 45 35.7 113 35 31.0 136 47 34.6 110 48 43.6 115 34 29.6 103 29
District of Columbia 802 176 21.9 642 150 23.4 573 116 20.2 492 102 20.7 418 72 17.2 370 55
Florida 4,648 1,279 27.5 4,589 1,229 26.8 4,391 1,164 26.5 4,302 1,227 28.5 4,485 1,030 23.0 4,587 986
Georgia 2,697 731 27.1 2,720 760 27.9 2,677 720 26.9 2,340 617 26.4 2,385 564 23.6 2,621 536
Hawaii 105 33 31.4 82 28 34.1 81 28 34.6 97 35 36.1 99 31 31.3 120 23
Idaho 44 20 45.5 35 10 28.6 36 11 30.6 26 8 30.8 22 7 31.8 40 14
Illinois 1,676 495 29.5 1,632 455 27.9 1,675 443 26.4 1,603 410 25.6 1,538 326 21.2 1,556 331
Indiana 486 131 27.0 467 140 30.0 491 132 26.9 474 118 24.9 465 116 24.9 632 121
Iowa 114 51 44.7 114 35 30.7 116 46 39.7 120 54 45.0 94 33 35.1 124 46
Kansas 136 50 36.8 135 42 31.1 152 52 34.2 147 50 34.0 130 37 28.5 153 35
Kentucky 332 99 29.8 309 103 33.3 360 96 26.7 354 99 28.0 344 90 26.2 339 79
Louisiana 1,114 331 29.7 1,194 366 30.7 1,024 347 33.9 1,135 338 29.8 1,206 275 22.8 1,098 242
Maine 55 16 29.1 49 15 30.6 48 11 22.9 35 14 40.0 55 7 12.7 46 13
Maryland 1,761 422 24.0 1,436 367 25.6 1,336 321 24.0 1,311 350 26.7 1,238 283 22.9 1,185 260
Massachusetts 705 220 31.2 690 225 32.6 700 205 29.3 670 191 28.5 641 146 22.8 597 136
Michigan 762 225 29.5 769 199 25.9 787 196 24.9 747 224 30.0 777 176 22.7 723 161
Minnesota 336 93 27.7 296 85 28.7 314 85 27.1 307 94 30.6 310 79 25.5 296 73
Mississippi 457 150 32.8 524 161 30.7 445 116 26.1 471 141 29.9 477 130 27.3 508 119
Missouri 571 124 21.7 524 152 29.0 529 139 26.3 464 120 25.9 467 110 23.6 461 95
Montana 20 5 25.0 22 5 22.7 20 8 40.0 22 7 31.8 14 5 35.7 19 6
Nebraska 115 40 34.8 79 27 34.2 82 25 30.5 79 29 36.7 88 28 31.8 79 22
Nevada 376 124 33.0 382 124 32.5 363 117 32.2 433 134 30.9 429 113 26.3 477 108
New Hampshire 50 11 22.0 39 13 33.3 47 20 42.6 35 10 28.6 41 9 22.0 25 3
New Jersey 1,369 415 30.3 1,192 345 28.9 1,296 374 28.9 1,207 359 29.7 1,243 331 26.6 1,201 314
New Mexico 148 53 35.8 137 41 29.9 118 38 32.2 142 38 26.8 134 39 29.1 135 32
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21.4 2,829 578 20.4 2,744 580 21.1
22.0 1,391 273 19.6 1,301 265 20.4
42.9 46 11 23.9 37 10 27.0
21.1 982 228 23.2 1,006 212 21.1
21.7 293 74 25.3 299 63 21.1
30.3 226 57 25.2 202 49 24.3
25.8 1,130 274 24.2 1,083 261 24.1
29.7 70 19 27.1 83 24 28.9
25.6 744 179 24.1 707 182 25.7
47.8 43 12 27.9 38 6 15.8
17.4 709 114 16.1 713 121 17.0
21.5 4,519 961 21.3 4,309 860 20.0
20.8 139 25 18.0 115 22 19.1
28.6 5 3 60.0 22 9 40.9
19.3 903 192 21.3 864 171 19.8
23.2 428 104 24.3 438 97 22.1
36.1 67 20 29.9 76 22 28.9
20.4 229 47 20.5 258 50 19.4
17.6 21 8 38.1 10 4 40.0
21.6 39,569 8,411 21.3 38,224 8,007 20.9
0.0 0 0 0.0 0 0 0.0
33.3 4 2 50.0 6 4 66.7
50.0 0 0 0.0 1 0 0.0
20.1 533 130 24.4 443 84 19.0
0.0 2 0 0.0 0 0 0.0
50.0 13 5 38.5 7 0 0.0
20.9 552 137 24.8 457 88 19.3
21.6 40,121 8,548 21.3 38,681 8,095 20.9
tes and 6 dependent areas (cont)
2016 2017
AIDS) 
osisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa
% No. % No. %
Abbreviation: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data are based on residence at diagnosis.a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection.
New York 3,942 1,073 27.2 3,787 991 26.2 3,547 891 25.1 3,253 818 25.1 3,329 720 21.6 3,063 657
North Carolina 1,444 358 24.8 1,439 358 24.9 1,231 280 22.7 1,282 335 26.1 1,310 282 21.5 1,324 291
North Dakota 13 3 23.1 12 1 8.3 11 4 36.4 19 7 36.8 21 5 23.8 21 9
Ohio 982 273 27.8 1,048 282 26.9 1,019 284 27.9 1,042 273 26.2 952 213 22.4 933 197
Oklahoma 285 71 24.9 314 82 26.1 285 78 27.4 332 66 19.9 304 71 23.4 314 68
Oregon 240 87 36.2 240 87 36.2 271 86 31.7 228 87 38.2 239 79 33.1 221 67
Pennsylvania 1,486 474 31.9 1,385 412 29.7 1,420 449 31.6 1,296 362 27.9 1,200 313 26.1 1,177 304
Rhode Island 115 36 31.3 100 40 40.0 78 27 34.6 78 32 41.0 89 24 27.0 64 19
South Carolina 768 280 36.5 742 295 39.8 701 254 36.2 707 251 35.5 761 169 22.2 667 171
South Dakota 32 6 18.8 21 10 47.6 25 8 32.0 31 11 35.5 29 7 24.1 23 11
Tennessee 856 234 27.3 847 201 23.7 853 194 22.7 770 226 29.4 757 158 20.9 742 129
Texas 4,453 1,259 28.3 4,274 1,218 28.5 4,317 1,167 27.0 4,336 1,123 25.9 4,416 948 21.5 4,505 967
Utah 85 26 30.6 106 29 27.4 122 46 37.7 110 27 24.5 114 23 20.2 120 25
Vermont 20 5 25.0 13 6 46.2 14 3 21.4 13 5 38.5 17 4 23.5 14 4
Virginia 994 291 29.3 903 245 27.1 937 255 27.2 952 238 25.0 902 197 21.8 955 184
Washington 539 165 30.6 481 160 33.3 497 139 28.0 445 118 26.5 439 103 23.5 452 105
West Virginia 73 26 35.6 87 33 37.9 82 29 35.4 73 27 37.0 86 23 26.7 72 26
Wisconsin 252 63 25.0 244 77 31.6 217 78 35.9 242 75 31.0 217 56 25.8 225 46
Wyoming 19 8 42.1 15 10 66.7 7 3 42.9 15 7 46.7 10 1 10.0 17 3
Subtotal 43,265 12,279 28.4 41,516 11,623 28.0 40,719 11,099 27.3 39,311 10,758 27.4 40,013 9,045 22.6 39,827 8,616
U.S. dependent areas
American Samoa 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0
Guam 6 2 33.3 1 0 0.0 7 2 28.6 1 0 0.0 3 0 0.0 6 2
Northern Mariana 
Islands 
0 0 0.0 2 1 50.0 0 0 0.0 0 0 0.0 1 1 100 2 1
Puerto Rico 785 208 26.5 737 199 27.0 728 181 24.9 649 165 25.4 624 133 21.3 558 112
Republic of Palau 0 0 0.0 1 1 100 0 0 0.0 1 0 0.0 0 0 0.0 1 0
U.S. Virgin Islands 30 14 46.7 28 8 28.6 13 5 38.5 25 6 24.0 26 11 42.3 12 6
Subtotal 821 224 27.3 769 209 27.2 748 188 25.1 676 171 25.3 654 145 22.2 579 121
Total 44,086 12,503 28.4 42,285 11,832 28.0 41,467 11,287 27.2 39,987 10,929 27.3 40,667 9,190 22.6 40,406 8,737
Table 1c. Stage 3 (AIDS) at HIV diagnosis, among persons aged ≥ 13 years, by year of diagnosis and area of residence, 2010–2017—United Sta
2010 2011 2012 2013 2014 2015
Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (AIDS) 
at diagnosisa Total 
No.
Stage 3 (
at diagn
No. % No. % No. % No. % No. % No.
Abbreviation: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data are based on residence at diagnosis.a Hispanics/Latinos can be of any race.b Includes American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and multiple races.c Based on first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection.
Table 1d. Stage 3 (AIDS) at HIV diagnosis, among persons aged ≥ 13 years, by race/ethnicity and area of residence, 2017—United States 
Black/African American Hispanic/Latinoa White Otherb
Stage 3 (AIDS) 
at diagnosisc
Stage 3 (AIDS) 
at diagnosisc
Stage 3 (AIDS) 
at diagnosisc
Stage 3 (AIDS) 
at diagnosisc
Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Alabama 430 91 21.2 22 7 31.8 180 39 21.7 21 5 23.8
Alaska 4 1 25.0 3 1 33.3 9 2 22.2 13 3 23.1
Arizona 116 9 7.8 296 60 20.3 246 49 19.9 69 19 27.5
Arkansas 145 24 16.6 19 6 31.6 113 20 17.7 9 1 11.1
California 794 123 15.5 2,227 451 20.3 1,234 228 18.5 512 106 20.7
Colorado 56 8 14.3 156 32 20.5 209 36 17.2 20 4 20.0
Connecticut 109 24 22.0 83 15 18.1 77 22 28.6 6 4 66.7
Delaware 76 20 26.3 20 5 25.0 28 7 25.0 1 0 0.0
District of Columbia 221 30 13.6 43 4 9.3 31 5 16.1 10 1 10.0
Florida 1,930 425 22.0 1,452 280 19.3 1,104 238 21.6 104 33 31.7
Georgia 1,864 392 21.0 193 56 29.0 437 99 22.7 90 20 22.2
Hawaii 4 1 25.0 13 1 7.7 22 2 9.1 39 9 23.1
Idaho 4 1 25.0 5 1 20.0 33 8 24.2 3 1 33.3
Illinois 687 130 18.9 275 60 21.8 321 70 21.8 71 14 19.7
Indiana 235 47 20.0 60 22 36.7 191 50 26.2 30 5 16.7
Iowa 37 8 21.6 18 3 16.7 63 15 23.8 8 1 12.5
Kansas 36 6 16.7 23 4 17.4 50 15 30.0 8 1 12.5
Kentucky 112 22 19.6 23 6 26.1 220 57 25.9 10 1 10.0
Louisiana 696 150 21.6 71 18 25.4 228 58 25.4 13 3 23.1
Maine 4 2 50.0 1 0 0.0 25 9 36.0 1 1 100
Maryland 715 158 22.1 100 32 32.0 150 42 28.0 55 17 30.9
Massachusetts 163 53 32.5 180 28 15.6 221 31 14.0 33 9 27.3
Michigan 438 79 18.0 62 10 16.1 241 60 24.9 20 0 0.0
Minnesota 129 33 25.6 32 10 31.3 95 25 26.3 20 8 40.0
Mississippi 340 92 27.1 11 3 27.3 68 20 29.4 7 0 0.0
Missouri 258 37 14.3 39 9 23.1 190 35 18.4 17 3 17.6
Montana 0 0 0.0 4 1 25.0 22 5 22.7 5 0 0.0
Nebraska 26 4 15.4 15 2 13.3 37 6 16.2 10 1 10.0
Nevada 146 25 17.1 139 38 27.3 172 36 20.9 34 8 23.5
New Hampshire 6 0 0.0 5 1 20.0 22 4 18.2 2 0 0.0
New Jersey 508 105 20.7 397 80 20.2 176 37 21.0 52 16 30.8
New Mexico 9 3 33.3 62 12 19.4 37 10 27.0 27 4 14.8
New York 1,081 241 22.3 950 188 19.8 456 94 20.6 257 57 22.2
North Carolina 843 162 19.2 121 29 24.0 288 63 21.9 49 11 22.4
North Dakota 13 4 30.8 3 0 0.0 15 5 33.3 6 1 16.7
Ohio 447 94 21.0 69 21 30.4 429 85 19.8 61 12 19.7
Oklahoma 80 9 11.3 56 16 28.6 121 27 22.3 42 11 26.2
Oregon 17 3 17.6 44 10 22.7 123 31 25.2 18 5 27.8
Pennsylvania 547 124 22.7 181 38 21.0 316 89 28.2 39 10 25.6
Rhode Island 16 5 31.3 24 4 16.7 39 14 35.9 4 1 25.0
South Carolina 442 107 24.2 69 25 36.2 165 43 26.1 31 7 22.6
South Dakota 7 2 28.6 5 1 20.0 16 1 6.3 10 2 20.0
Tennessee 404 61 15.1 37 12 32.4 256 45 17.6 16 3 18.8
Texas 1,585 263 16.6 1,735 398 22.9 816 164 20.1 173 35 20.2
Utah 12 1 8.3 39 11 28.2 54 7 13.0 10 3 30.0
Vermont 2 2 100 2 0 0.0 16 7 43.8 2 0 0.0
Virginia 492 91 18.5 92 23 25.0 211 42 19.9 69 15 21.7
Washington 112 27 24.1 90 16 17.8 188 40 21.3 48 14 29.2
West Virginia 20 5 25.0 1 0 0.0 49 14 28.6 6 3 50.0
Wisconsin 107 16 15.0 34 8 23.5 101 21 20.8 16 5 31.3
Wyoming 0 0 0.0 1 0 0.0 9 4 44.4 0 0 0.0
Total 16,525 3,320 20.1 9,602 2,058 21.4 9,920 2,136 21.5 2,177 493 22.6
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic illness (i.e., AIDS-defining condition).
Note. Stage of disease at HIV diagnosis is based on the first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection. Data are based on 
residence at diagnosis. See Technical Notes for the list of areas that met the criteria for complete laboratory reporting.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not 
change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Hispanics/Latinos can be of any race.
d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the 
numbers were too small to be meaningful. 
Table 2a. Stage of disease at HIV diagnosis during 2017, among persons aged ≥ 13 years, by selected characteristics—41 states and the District 
of Columbia
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a
(CD4 ≥ 500 cells/µL 
or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
Sex 
Male 27,505 1,812 6.6 6,873 25.0 8,503 30.9 5,652 20.5 4,665 17.0
Female 6,450 310 4.8 1,805 28.0 1,806 28.0 1,429 22.2 1,100 17.1
Age at diagnosis (yr)
13–24 7,342 665 9.1 2,062 28.1 2,570 35.0 671 9.1 1,374 18.7
25–34 11,852 819 6.9 3,287 27.7 3,761 31.7 1,924 16.2 2,061 17.4
35–44 6,463 294 4.5 1,601 24.8 1,869 28.9 1,662 25.7 1,037 16.0
45–54 4,936  195 4.0  1,054 21.4 1,263 25.6 1,665 33.7  759 15.4
≥ 55 3,362 149 4.4 674 20.0 846 25.2  1,159 34.5 534 15.9
Race/ethnicity
American Indian/Alaska Native 158 12 7.6 48 30.4 44 27.8 30 19.0 24 15.2
Asian 855 41 4.8 168 19.6 310 36.3 212 24.8 124 14.5
Black/African American 14,909 855 5.7 3,493 23.4 4,616 31.0 3,002 20.1 2,943 19.7
Hispanic/Latinoc 8,517 543 6.4 2,166 25.4 2,676 31.4 1,825 21.4 1,307 15.3
Native Hawaiian/
Other Pacific Islander
43 5 11.6 7 16.3 12 27.9 13 30.2 6 14.0
White 8,578 592 6.9 2,558 29.8 2,375 27.7 1,818 21.2 1,235 14.4
Multiple races 895 74 8.3 238 26.6 276 30.8 181 20.2 126 14.1
Transmission categoryd
Male-to-male sexual contact 22,752 1,600 7.0 5,833 25.6 7,170 31.5 4,309 18.9 3,840 16.9
Injection drug use
Male 1,078 49 4.5 249 23.1 302 28.0 287 26.7 190 17.7
Female 858 55 6.4 250 29.1 212 24.7 175 20.4 166 19.4
Male-to-male sexual contact and 
injection drug use
 1,110 82 7.4 336 30.2 330 29.7 171 15.4 191 17.2
Heterosexual contacte
Male 2,533 79 3.1 452 17.8 695 27.4 873 34.5 435 17.2
Female 5,552 254 4.6 1,540 27.7 1,581 28.5 1,248 22.5  929 16.7
Totalf 33,955 2,122 6.2 8,678 25.6 10,309 30.4 7,081 20.9 5,765 17.0
HIV Surveillance Supplemental Report 23 Vol. 24, No. 3
Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic illness (i.e., AIDS-defining condition).
Note. Stage of disease at HIV diagnosis is based on the first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection. Data are based on 
residence at diagnosis. 
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not 
change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
Table 2b. Stage of disease at HIV diagnosis during 2017, among persons aged ≥ 13 years, by area of residence—41 states and the District 
of Columbia
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a (CD4 ≥ 500 cells/µL or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
Alabama 653 32 4.9 164 25.1 175 26.8 142 21.7 140 21.4
Alaska 29 3 10.3 10 34.5 7 24.1 7 24.1 2 6.9
California 4,767 392 8.2 1,179 24.7 1,392 29.2 908 19.0 896 18.8
Colorado 441 24 5.4 125 28.3 159 36.1 80 18.1 53 12.0
Connecticut 275 15 5.5 72 26.2 83 30.2 65 23.6 40 14.5
Delaware 125 6 4.8 33 26.4 35 28.0 32 25.6 19 15.2
District of Columbia 305 14 4.6 83 27.2 108 35.4 40 13.1 60 19.7
Florida 4,590 121 2.6 1,359 29.6 1,432 31.2 976 21.3 702 15.3
Georgia 2,584 83 3.2 637 24.7 795 30.8 567 21.9 502 19.4
Hawaii 78 11 14.1 25 32.1 21 26.9 13 16.7 8 10.3
Illinois 1,354 55 4.1 333 24.6 413 30.5 274 20.2 279 20.6
Indiana 516 10 1.9 122 23.6 143 27.7 124 24.0 117 22.7
Iowa 126 29 23.0 20 15.9 45 35.7 27 21.4 5 4.0
Louisiana 1,008 76 7.5 269 26.7 302 30.0 229 22.7 132 13.1
Maine 31 2 6.5 11 35.5 4 12.9 12 38.7 2 6.5
Maryland 1,020 79 7.7 230 22.5 341 33.4 249 24.4 121 11.9
Massachusetts 597 31 5.2 191 32.0 189 31.7 121 20.3 65 10.9
Michigan 761 62 8.1 205 26.9 267 35.1 149 19.6 78 10.2
Minnesota 276 22 8.0 65 23.6 85 30.8 76 27.5 28 10.1
Mississippi 426 20 4.7 66 15.5 90 21.1 115 27.0 135 31.7
Missouri 504 15 3.0 130 25.8 127 25.2 84 16.7 148 29.4
Montana 31 1 3.2 12 38.7 9 29.0 6 19.4 3 9.7
Nebraska 88 6 6.8 24 27.3 32 36.4 13 14.8 13 14.8
New Hampshire 35 3 8.6 10 28.6 12 34.3 5 14.3 5 14.3
New Mexico 135 6 4.4 39 28.9 46 34.1 29 21.5 15 11.1
New York 2,744 285 10.4 692 25.2 912 33.2 580 21.1 275 10.0
North Carolina 1,301 131 10.1 286 22.0 311 23.9 265 20.4 308 23.7
North Dakota 37 0 0.0 11 29.7 14 37.8 10 27.0 2 5.4
Ohio 1,006 19 1.9 288 28.6 316 31.4 212 21.1 171 17.0
Oklahoma 299 26 8.7 79 26.4 86 28.8 63 21.1 45 15.1
Oregon 202 17 8.4 53 26.2 59 29.2 49 24.3 24 11.9
Rhode Island 83 8 9.6 23 27.7 25 30.1 24 28.9 3 3.6
South Carolina 707 39 5.5 158 22.3 247 34.9 182 25.7 81 11.5
South Dakota 38 0 0.0 6 15.8 16 42.1 6 15.8 10 26.3
Tennessee 713 9 1.3 188 26.4 189 26.5 121 17.0 206 28.9
Texas 4,309 324 7.5 1,038 24.1 1,295 30.1 860 20.0 792 18.4
Utah 115 5 4.3 30 26.1 40 34.8 22 19.1 18 15.7
Virginia 864 58 6.7 207 24.0 236 27.3 171 19.8 192 22.2
Washington 438 44 10.0 134 30.6 133 30.4 97 22.1 30 6.8
West Virginia 76 2 2.6 17 22.4 24 31.6 22 28.9 11 14.5
Wisconsin 258 37 14.3 52 20.2 91 35.3 50 19.4 28 10.9
Wyoming 10 0 0.0 2 20.0 3 30.0 4 40.0 1 10.0
Total 33,955 2,122 6.2 8,678 25.6 10,309 30.4 7,081 20.9 5,765 17.0
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Table 2c. Stage of disease at HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected characteristics—41 states 
and the District of Columbia 
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a
(CD4 ≥ 500 cells/µL 
or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
 American Indian/Alaska Native
Sex
Male 121 11 9.1 37 30.6 34 28.1 22 18.2 17 14.0
Female 37 1 2.7 11 29.7 10 27.0 8 21.6 7 18.9
Age at diagnosis (yr)
13–24 20 2 10.0 10 50.0 5 25.0 1 5.0 2 10.0
25–34 65 6 9.2 24 36.9 21 32.3 7 10.8 7 10.8
35–44 35 2 5.7 7 20.0 11 31.4 7 20.0 8 22.9
45–54 27  2 7.4  6 22.2 5 18.5 12 44.4  2 7.4
≥ 55 11 0 0.0 1 9.1 2 18.2  3 27.3 5 45.5
Transmission categoryc
Male-to-male sexual contact 87 7 8.0 32 36.4 26 29.7 15 17.4 7 8.5
Injection drug use
Male 8 2 26.0 1 13.0 1 15.6 2 27.3 1 18.2
Female 13 0 0.0 5 34.3 3 20.9 2 17.2 4 27.6
Male-to-male sexual contact and 
injection drug use
 19 1 5.4 4 22.6 4 23.1 4 22.6 5 26.3
Heterosexual contactd
Male 7 1 13.9 0 0.0 2 33.3 1 6.9 3 45.8
Female 24 1 4.2 6 27.1 7 30.5 6 24.2  3 14.0
Totale 158 12 7.6 48 30.4 44 27.8 30 19.0 24 15.2
 Asian
Sex
Male 756 38 5.0 149 19.7 280 37.0 185 24.5 104 13.8
Female 99 3 3.0 19 19.2 30 30.3 27 27.3 20 20.2
Age at diagnosis (yr)
13–24 179 11 6.1 37 20.7 83 46.4 18 10.1 30 16.8
25–34 275 15 5.5 54 19.6 108 39.3 61 22.2 37 13.5
35–44 202 8 4.0 46 22.8 67 33.2 48 23.8 33 16.3
45–54 134  7 5.2  24 17.9 30 22.4 58 43.3  15 11.2
≥ 55 65 0 0.0 7 10.8 22 33.8  27 41.5 9 13.8
Transmission categoryc
Male-to-male sexual contact 689 37 5.3 136 19.8 256 37.1 164 23.8 96 14.0
Injection drug use
Male 12 0 1.6 3 20.2 5 41.1 3 22.6 2 14.5
Female 4 0 5.7 1 17.1 1 34.3 1 20.0 1 22.9
Male-to-male sexual contact and 
injection drug use
 16 1 6.2 4 27.3 7 44.1 3 16.1 1 6.2
Heterosexual contactd
Male 38 0 0.3 6 15.8 11 30.3 16 41.6 5 12.1
Female 95 3 3.0 18 19.5 28 30.0 26 27.6  19 20.0
Totale 855 41 4.8 168 19.6 310 36.3 212 24.8 124 14.5
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 Black/African American
Sex
Male 10,998 694 6.3 2,465 22.4 3,471 31.6 2,124 19.3 2,244 20.4
Female 3,911 161 4.1 1,028 26.3 1,145 29.3 878 22.4 699 17.9
Age at diagnosis (yr)
13–24 3,906 343 8.8 983 25.2 1,398 35.8 388 9.9 794 20.3
25–34 5,179 320 6.2 1,306 25.2 1,639 31.6 850 16.4 1,064 20.5
35–44 2,473 93 3.8 529 21.4 726 29.4 657 26.6 468 18.9
45–54 1,835  52 2.8  368 20.1 463 25.2 611 33.3  341 18.6
≥ 55 1,516 47 3.1 307 20.3 390 25.7  496 32.7 276 18.2
Transmission categoryc
Male-to-male sexual contact 8,810 623 7.1 2,067 23.5 2,856 32.4 1,466 16.6 1,797 20.4
Injection drug use
Male 338 15 4.5 56 16.5 96 28.6 92 27.3 78 23.1
Female 293 19 6.5 65 22.2 82 28.1 69 23.4 58 19.8
Male-to-male sexual contact and 
injection drug use
 230 11 4.9 52 22.5 64 28.0 43 18.7 60 26.0
Heterosexual contactd
Male 1,604 43 2.7 288 18.0 451 28.1 518 32.3 304 18.9
Female 3,590 142 3.9 951 26.5 1,054 29.4 805 22.4  638 17.8
Totale 14,909 855 5.7 3,493 23.4 4,616 31.0 3,002 20.1 2,943 19.7
 Hispanic/Latinof
Sex
Male 7,537 487 6.5 1,884 25.0 2,389 31.7 1,612 21.4 1,165 15.5
Female 980 56 5.7 282 28.8 287 29.3 213 21.7 142 14.5
Age at diagnosis (yr)
13–24 1,710 158 9.2 511 29.9 589 34.4 147 8.6 305 17.8
25–34 3,254 217 6.7 884 27.2 1,077 33.1 599 18.4 477 14.7
35–44 1,847 89 4.8 445 24.1 552 29.9 476 25.8 285 15.4
45–54 1,149  52 4.5  228 19.8 308 26.8 398 34.6  163 14.2
≥ 55 557 27 4.8 98 17.6 150 26.9  205 36.8 77 13.8
Transmission categoryc
Male-to-male sexual contact 6,542 439 6.7 1,691 25.8 2,100 32.1 1,311 20.0 1,001 15.3
Injection drug use
Male 267 11 4.0 54 20.1 79 29.4 80 29.8 45 16.6
Female 113 7 5.8 38 33.9 26 22.7 21 18.4 22 19.2
Male-to-male sexual contact and 
injection drug use
 269 16 5.8 72 26.7 86 31.9 44 16.3 52 19.2
Heterosexual contactd
Male 452 21 4.6 67 14.9 122 27.0 175 38.6 67 14.9
Female 863 49 5.7 241 27.9 260 30.2 192 22.3  120 13.9
Totale 8,517 543 6.4 2,166 25.4 2,676 31.4 1,825 21.4 1,307 15.3
Table 2c. Stage of disease at HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected characteristics—41 states 
and the District of Columbia (cont)
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a
(CD4 ≥ 500 cells/µL 
or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
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 Native Hawaiian/Other Pacific Islander
Sex
Male 33 4 12.1 7 21.2 11 33.3 8 24.2 3 9.1
Female 10 1 10.0 0 0.0 1 10.0 5 50.0 3 30.0
Age at diagnosis (yr)
13–24 8 1 12.5 4 50.0 3 37.5 0 0.0 0 0.0
25–34 19 3 15.8 2 10.5 6 31.6 5 26.3 3 15.8
35–44 10 1 10.0 1 10.0 2 20.0 4 40.0 2 20.0
45–54 5 0 0.0 0 0.0 1 20.0 3 60.0  1 20.0
≥ 55 1 0 0.0 0 0.0 0 0.0  1 100.0 0 0.0
Transmission categoryc
Male-to-male sexual contact 28 3 10.5 7 25.4 10 35.5 6 21.7 2 6.9
Injection drug use
Male 1 0 0.0 0 0.0 0 9.1 0 0.0 1 90.9
Female
Male-to-male sexual contact and 
injection drug use
 2 1 52.4 0 0.0 0 0.0 1 47.6 0 0.0
Heterosexual contactd
Male 2 0 0.0 0 0.0 1 50.0 1 45.5 0 4.5
Female 10 1 10.0 0 0.0 1 10.0 5 50.0  3 30.0
Totale 43 5 11.6 7 16.3 12 27.9 13 30.2 6 14.0
 White
Sex
Male 7,322 513 7.0 2,143 29.3 2,081 28.4 1,560 21.3 1,025 14.0
Female 1,256 79 6.3 415 33.0 294 23.4 258 20.5 210 16.7
Age at diagnosis (yr)
13–24 1,286 127 9.9 441 34.3 414 32.2 101 7.9 203 15.8
25–34 2,743 230 8.4 921 33.6 810 29.5 356 13.0 426 15.5
35–44 1,735 93 5.4 537 31.0 461 26.6 419 24.1 225 13.0
45–54 1,659  72 4.3  407 24.5 419 25.3 537 32.4  224 13.5
≥ 55 1,155 70 6.1 252 21.8 271 23.5  405 35.1 157 13.6
Transmission categoryc
Male-to-male sexual contact 5,971 436 7.3 1,744 29.2 1,716 28.7 1,237 20.7 839 14.1
Injection drug use
Male 426 19 4.5 130 30.5 114 26.7 101 23.8 62 14.6
Female 407 27 6.6 134 32.8 94 23.0 75 18.4 78 19.1
Male-to-male sexual contact and 
injection drug use
 534 48 9.0 189 35.4 156 29.2 71 13.2 70 13.1
Heterosexual contactd
Male 383 10 2.6 79 20.7 94 24.5 147 38.4 53 13.7
Female 846 52 6.1 281 33.2 200 23.6 182 21.6  131 15.5
Totale 8,578 592 6.9 2,558 29.8 2,375 27.7 1,818 21.2 1,235 14.4
Table 2c. Stage of disease at HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected characteristics—41 states 
and the District of Columbia (cont)
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a
(CD4 ≥ 500 cells/µL 
or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic illness (i.e., AIDS-defining condition).
Note. Stage of disease at HIV diagnosis is based on the first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection. Data are based on 
residence at diagnosis. See Technical Notes for the list of areas that met the criteria for complete laboratory reporting.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not 
change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the 
numbers were too small to be meaningful. 
f Hispanics/Latinos can be of any race.
 Multiple races
Sex
Male 738 65 8.8 188 25.5 237 32.1 141 19.1 107 14.5
Female 157 9 5.7 50 31.8 39 24.8 40 25.5 19 12.1
Age at diagnosis (yr)
13–24 233 23 9.9 76 32.6 78 33.5 16 6.9 40 17.2
25–34 317 28 8.8 96 30.3 100 31.5 46 14.5 47 14.8
35–44 161 8 5.0 36 22.4 50 31.1 51 31.7 16 9.9
45–54 127  10 7.9  21 16.5 37 29.1 46 36.2  13 10.2
≥ 55 57 5 8.8 9 15.8 11 19.3  22 38.6 10 17.5
Transmission categoryc
Male-to-male sexual contact 624 56 8.9 156 25.0 205 32.9 110 17.6 97 15.6
Injection drug use
Male 25 2 5.9 6 24.1 7 26.1 9 36.4 2 7.5
Female 29 2 7.7 8 26.5 7 22.6 8 28.6 4 14.6
Male-to-male sexual contact and 
injection drug use
 41 4 10.3 14 35.2 13 30.8 6 14.2 4 9.5
Heterosexual contactd
Male 47 4 7.4 12 24.5 13 26.6 16 34.0 4 7.4
Female 126 7 5.3 42 33.5 30 24.2 32 25.3  15 11.6
Totale 895 74 8.3 238 26.6 276 30.8 181 20.2 126 14.1
Table 2c. Stage of disease at HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected characteristics—41 states 
and the District of Columbia (cont)
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a
(CD4 ≥ 500 cells/µL 
or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic illness (i.e., AIDS-defining condition).
Note. Stage of disease at HIV diagnosis is based on the first CD4 test performed or documentation of an AIDS-defining condition ≤ 3 months after a diagnosis of HIV infection. Data are based on 
residence at diagnosis. See Technical Notes for the list of areas that met the criteria for complete laboratory reporting. Data have been statistically adjusted to account for missing transmission 
category; therefore, values may not sum to column total.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not 
change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Hispanics/Latinos can be of any race.
Table 2d. Stage of disease at HIV diagnosis during 2017, among males aged ≥ 13 years with infection attributed to male-to-male sexual contact, by 
race/ethnicity and age at diagnosis—41 states and the District of Columbia
Total No.
Stage 1 Stage 2 Stage 3 (AIDS)
Stage 0a
(CD4 ≥ 500 cells/µL 
or ≥ 26%) (CD4 200–499 cells/µL or 14%–25%) (OI or CD4 < 200 cells/µL or < 14%) Stage unknownb
No. % No. % No. % No. % No. %
American Indian/Alaska Native
13–24 15 2 13.8 7 48.3 5 33.1 0 0.0 1 4.8
25–34 39 3 7.6 18 45.3 11 27.0 5 12.7 3 7.4
35–44 19 1 5.3 4 21.4 7 36.4 6 30.5 1 6.4
45–54 12 1 8.1 3 24.4 4 30.9 4 28.5 1 8.1
≥ 55 3 0 0.0 0 0.0 0 0.0 1 38.5 2 61.5
Asian
13–24 168 10 5.9 36 21.4 77 46.0 17 10.1 28 16.6
25–34 240 13 5.4 45 18.6 98 40.7 52 21.7 33 13.6
35–44 149 7 4.7 34 22.9 51 34.3 36 24.0 21 14.1
45–54 98 7 6.9 19 18.9 21 21.0 42 42.5 11 10.7
≥ 55 33 0 0.0 3 7.6 9 27.4 17 52.3 4 12.8
Black/African American
13–24 3,117 300 9.6 743 23.8 1,148 36.8 300 9.6 625 20.1
25–34 3,575 244 6.8 896 25.1 1,127 31.5 559 15.6 749 20.9
35–44 1,119 41 3.7 244 21.8 331 29.6 283 25.3 220 19.7
45–54 636 23 3.6 124 19.5 151 23.7 208 32.6 131 20.6
≥ 55 363 15 4.1 60 16.6 100 27.4 116 32.1 72 19.8
Hispanic/Latinoc
13–24 1,454 135 9.3 433 29.8 509 35.0 117 8.0 260 17.9
25–34 2,683 187 7.0 719 26.8 901 33.6 481 17.9 395 14.7
35–44 1,348 68 5.0 338 25.0 410 30.4 337 25.0 197 14.6
45–54 775 38 5.0 151 19.4 208 26.9 263 33.9 115 14.8
≥ 55 283 11 3.7 51 17.9 73 25.7 114 40.2 35 12.4
Native Hawaiian/Other Pacific Islander
13–24 8 1 11.4 4 50.6 3 38.0 0 0.0 0 0.0
25–34 13 2 15.5 2 15.5 5 38.8 2 15.5 2 14.7
35–44 5 0 0.0 1 20.8 2 37.5 2 41.7 0 0.0
45–54 2 0 0.0 0 0.0 0 0.0 2 100.0 0 0.0
≥ 55 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
White
13–24 995 97 9.7 312 31.4 345 34.7 85 8.5 156 15.7
25–34 1,921 161 8.4 637 33.1 579 30.1 255 13.3 289 15.0
35–44 1,132 68 6.0 351 31.0 302 26.6 272 24.0 141 12.4
45–54 1,165 55 4.7 281 24.1 308 26.4 370 31.7 151 12.9
≥ 55 758 55 7.3 164 21.6 183 24.1 255 33.6 102 13.4
Multiple races
13–24 187 20 10.6 50 26.6 69 37.0 14 7.4 34 18.3
25–34 246 23 9.1 70 28.3 76 31.0 39 15.8 39 15.8
35–44 98 6 6.2 22 23.0 32 33.2 25 25.6 12 12.0
45–54 70 6 7.9 13 18.0 23 32.1 22 31.3 8 10.7
≥ 55 24 2 8.3 2 6.3 5 20.8 10 42.9 5 21.7
Total 22,752 1,600 7.0 5,833 25.6 7,170 31.5 4,309 18.9 3,840 16.9
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month or ≤ 3 months after HIV diagnosis. See Technical 
Notes for the list of areas that met the criteria for complete laboratory reporting.
a Represents percentage of the total number for the column. 
b Hispanics/Latinos can be of any race.
c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the 
numbers were too small to be meaningful. 
Table 3a. Linkage to HIV medical care after HIV diagnosis during 2017, among persons aged ≥ 13 years, by selected characteristics—41 states 
and the District of Columbia
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
Sex 
Male 27,505 81.0 21,505 78.2 6,000 21.8 23,823 86.6 3,682 13.4
Female 6,450 19.0 5,097 79.0 1,353 21.0 5,641 87.5 809 12.5
Age at diagnosis (yr)
13–24 7,342 21.6 5,510 75.0 1,832 25.0 6,248 85.1 1,094 14.9
25–34 11,852 34.9 9,182 77.5 2,670 22.5 10,224 86.3 1,628 13.7
35–44 6,463 19.0 5,149 79.7 1,314 20.3 5,632 87.1 831 12.9
45–54 4,936 14.5 4,017 81.4  919 18.6 4,359 88.3 577 11.7
≥ 55 3,362 9.9 2,744 81.6 618 18.4 3,001 89.3 361 10.7
Race/ethnicity
American Indian/Alaska Native 158 0.5 134 84.8 24 15.2 142 89.9 16 10.1
Asian 855 2.5 690 80.7 165 19.3 750 87.7 105 12.3
Black/African American 14,909 43.9 11,295 75.8 3,614 24.2 12,622 84.7 2,287 15.3
Hispanic/Latinob 8,517 25.1 6,750 79.3 1,767 20.7 7,429 87.2 1,088 12.8
Native Hawaiian/Other Pacific Islander 43 0.1 36 83.7 7 16.3 41 95.3 2 4.7
White 8,578 25.3 6,978 81.3 1,600 18.7 7,683 89.6 895 10.4
Multiple races 895 2.6 719 80.3 176 19.7 797 89.1 98 10.9
Transmission categoryc
Male-to-male sexual contact 22,752 67.0 17,862 78.5 4,890 21.5 19,753 86.8 2,999 13.2
Injection drug use
Male 1,078 3.2 823 76.4 255 23.6 915 84.9 163 15.1
Female 858 2.5 661 77.1 197 22.9 731 85.1 128 14.9
Male-to-male sexual contact and 
injection drug use
 1,110 3.3 836 75.3 274 24.7 945 85.1 165 14.9
Heterosexual contactd 
Male 2,533 7.5 1,959 77.3 575 22.7 2,183 86.2 350 13.8
Female 5,552 16.4 4,402 79.3 1,150 20.7 4,875 87.8 677 12.2
Totale 33,955 100.0 26,602 78.3 7,353 21.7 29,464 86.8 4,491 13.2
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month or ≤ 3 months after HIV diagnosis. 
a Represents percentage of the total number for the column.
Table 3b. Linkage to HIV medical care after HIV diagnosis during 2017, among persons aged ≥ 13 years, by area of residence—41 states 
and the District of Columbia
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
Alabama 653 1.9 502 76.9 151 23.1 555 85.0 98 15.0
Alaska 29 0.1 28 96.6 1 3.4 28 96.6 1 3.4
California 4,767 14.0 3,588 75.3 1,179 24.7 3,975 83.4 792 16.6
Colorado 441 1.3 370 83.9 71 16.1 408 92.5 33 7.5
Connecticut 275 0.8 232 84.4 43 15.6 249 90.5 26 9.5
Delaware 125 0.4 107 85.6 18 14.4 111 88.8 14 11.2
District of Columbia 305 0.9 245 80.3 60 19.7 257 84.3 48 15.7
Florida 4,590 13.5 3,580 78.0 1,010 22.0 3,995 87.0 595 13.0
Georgia 2,584 7.6 2,007 77.7 577 22.3 2,186 84.6 398 15.4
Hawaii 78 0.2 67 85.9 11 14.1 71 91.0 7 9.0
Illinois 1,354 4.0 1,108 81.8 246 18.2 1,184 87.4 170 12.6
Indiana 516 1.5 352 68.2 164 31.8 423 82.0 93 18.0
Iowa 126 0.4 116 92.1 10 7.9 122 96.8 4 3.2
Louisiana 1,008 3.0 801 79.5 207 20.5 891 88.4 117 11.6
Maine 31 0.1 29 93.5 2 6.5 31 100.0 0 0.0
Maryland 1,020 3.0 879 86.2 141 13.8 938 92.0 82 8.0
Massachusetts 597 1.8 526 88.1 71 11.9 551 92.3 46 7.7
Michigan 761 2.2 634 83.3 127 16.7 698 91.7 63 8.3
Minnesota 276 0.8 243 88.0 33 12.0 259 93.8 17 6.2
Mississippi 426 1.3 297 69.7 129 30.3 362 85.0 64 15.0
Missouri 504 1.5 365 72.4 139 27.6 441 87.5 63 12.5
Montana 31 0.1 27 87.1 4 12.9 28 90.3 3 9.7
Nebraska 88 0.3 69 78.4 19 21.6 78 88.6 10 11.4
New Hampshire 35 0.1 28 80.0 7 20.0 32 91.4 3 8.6
New Mexico 135 0.4 116 85.9 19 14.1 125 92.6 10 7.4
New York 2,744 8.1 2,330 84.9 414 15.1 2,495 90.9 249 9.1
North Carolina 1,301 3.8 982 75.5 319 24.5 1,115 85.7 186 14.3
North Dakota 37 0.1 33 89.2 4 10.8 35 94.6 2 5.4
Ohio 1,006 3.0 836 83.1 170 16.9 895 89.0 111 11.0
Oklahoma 299 0.9 203 67.9 96 32.1 259 86.6 40 13.4
Oregon 202 0.6 161 79.7 41 20.3 178 88.1 24 11.9
Rhode Island 83 0.2 77 92.8 6 7.2 82 98.8 1 1.2
South Carolina 707 2.1 608 86.0 99 14.0 650 91.9 57 8.1
South Dakota 38 0.1 32 84.2 6 15.8 36 94.7 2 5.3
Tennessee 713 2.1 429 60.2 284 39.8 551 77.3 162 22.7
Texas 4,309 12.7 3,144 73.0 1,165 27.0 3,583 83.2 726 16.8
Utah 115 0.3 105 91.3 10 8.7 109 94.8 6 5.2
Virginia 864 2.5 661 76.5 203 23.5 750 86.8 114 13.2
Washington 438 1.3 400 91.3 38 8.7 418 95.4 20 4.6
West Virginia 76 0.2 59 77.6 17 22.4 67 88.2 9 11.8
Wisconsin 258 0.8 217 84.1 41 15.9 234 90.7 24 9.3
Wyoming 10 0.0 9 90.0 1 10.0 9 90.0 1 10.0
Total 33,955 100.0 26,602 78.3 7,353 21.7 29,464 86.8 4,491 13.2
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Table 3c. Linkage to HIV medical care after HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected 
characteristics—41 states and the District of Columbia 
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
American Indian/Alaska Native
Sex 
Male 121 76.6 101 83.5 20 16.5 109 90.1 12 9.9
Female 37 23.4 33 89.2 4 10.8 33 89.2 4 10.8
Age at diagnosis (yr)
13–24 20 12.7 18 90.0 2 10.0 18 90.0 2 10.0
25–34 65 41.1 56 86.2 9 13.8 61 93.8 4 6.2
35–44 35 22.2 28 80.0 7 20.0 29 82.9 6 17.1
45–54 27 17.1 25 92.6  2 7.4 27 100.0 0 0.0
≥ 55 11 7.0 7 63.6 4 36.4 7 63.6 4 36.4
Transmission categoryb
Male-to-male sexual contact 87 55.3 77 88.3 10 11.7 82 93.8 5 6.2
Injection drug use
Male 8 4.9 6 81.8 1 18.2 6 81.8 1 18.2
Female 13 8.5 12 90.3 1 9.7 12 90.3 1 9.7
Male-to-male sexual contact and 
injection drug use
 19 11.8 14 72.6 5 27.4 17 89.8 2 10.2
Heterosexual contactc
Male 7 4.6 4 54.2 3 45.8 4 54.2 3 45.8
Female 24 14.9 21 88.6 3 11.4 21 88.6 3 11.4
Totald 158 100.0 134 84.8 24 15.2 142 89.9 16 10.1
Asian
Sex 
Male 756 88.4 615 81.3 141 18.7 670 88.6 86 11.4
Female 99 11.6 75 75.8 24 24.2 80 80.8 19 19.2
Age at diagnosis (yr)
13–24 179 20.9 141 78.8 38 21.2 156 87.2 23 12.8
25–34 275 32.2 232 84.4 43 15.6 243 88.4 32 11.6
35–44 202 23.6 155 76.7 47 23.3 176 87.1 26 12.9
45–54 134 15.7 110 82.1  24 17.9 119 88.8 15 11.2
≥ 55 65 7.6 52 80.0 13 20.0 56 86.2 9 13.8
Transmission categoryb
Male-to-male sexual contact 689 80.5 561 81.5 127 18.5 608 88.4 80 11.6
Injection drug use
Male 12 1.5 9 69.4 4 30.6 11 87.1 2 12.9
Female 4 0.4 3 74.3 1 25.7 3 77.1 1 22.9
Male-to-male sexual contact and 
injection drug use
 16 1.9 14 88.2 2 11.8 15 95.7 1 4.3
Heterosexual contactc
Male 38 4.4 30 79.2 8 20.8 35 91.3 3 8.7
Female 95 11.1 72 75.9 23 24.1 77 81.1 18 18.9
Totald 855 100.0 690 80.7 165 19.3 750 87.7 105 12.3
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Black/African American
Sex 
Male 10,998 73.8 8,213 74.7 2,785 25.3 9,212 83.8 1,786 16.2
Female 3,911 26.2 3,082 78.8 829 21.2 3,410 87.2 501 12.8
Age at diagnosis (yr)
13–24 3,906 26.2 2,880 73.7 1,026 26.3 3,270 83.7 636 16.3
25–34 5,179 34.7 3,880 74.9 1,299 25.1 4,348 84.0 831 16.0
35–44 2,473 16.6 1,902 76.9 571 23.1 2,100 84.9 373 15.1
45–54 1,835 12.3 1,429 77.9  406 22.1 1,572 85.7 263 14.3
≥ 55 1,516 10.2 1,204 79.4 312 20.6 1,332 87.9 184 12.1
Transmission categoryb
Male-to-male sexual contact 8,810 59.1 6,574 74.6 2,236 25.4 7,386 83.8 1,424 16.2
Injection drug use
Male 338 2.3 247 73.3 90 26.7 272 80.4 66 19.6
Female 293 2.0 230 78.5 63 21.5 250 85.5 42 14.5
Male-to-male sexual contact and 
injection drug use
 230 1.5 161 70.1 69 29.9 179 77.9 51 22.1
Heterosexual contactc
Male 1,604 10.8 1,218 75.9 387 24.1 1,362 84.9 242 15.1
Female 3,590 24.1 2,828 78.8 762 21.2 3,134 87.3 456 12.7
Totald 14,909 100.0 11,295 75.8 3,614 24.2 12,622 84.7 2,287 15.3
Hispanic/Latinoe
Sex 
Male 7,537 88.5 5,965 79.1 1,572 20.9 6,561 87.1 976 12.9
Female 980 11.5 785 80.1 195 19.9 868 88.6 112 11.4
Age at diagnosis (yr)
13–24 1,710 20.1 1,271 74.3 439 25.7 1,449 84.7 261 15.3
25–34 3,254 38.2 2,582 79.3 672 20.7 2,854 87.7 400 12.3
35–44 1,847 21.7 1,496 81.0 351 19.0 1,607 87.0 240 13.0
45–54 1,149 13.5 943 82.1  206 17.9 1,022 88.9 127 11.1
≥ 55 557 6.5 458 82.2 99 17.8 497 89.2 60 10.8
Transmission categoryb
Male-to-male sexual contact 6,542 76.8 5,189 79.3 1,353 20.7 5,708 87.2 834 12.8
Injection drug use
Male 267 3.1 214 79.9 54 20.1 229 85.8 38 14.2
Female 113 1.3 84 74.8 29 25.2 96 84.7 17 15.3
Male-to-male sexual contact and 
injection drug use
 269 3.2 200 74.3 69 25.7 224 83.5 44 16.5
Heterosexual contactc
Male 452 5.3 357 78.9 95 21.1 393 86.9 59 13.1
Female 863 10.1 696 80.7 167 19.3 768 89.0 95 11.0
Totald 8,517 100.0 6,750 79.3 1,767 20.7 7,429 87.2 1,088 12.8
Table 3c. Linkage to HIV medical care after HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected 
characteristics—41 states and the District of Columbia (cont)
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
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Native Hawaiian/Other Pacific Islander
Sex 
Male 33 76.7 28 84.8 5 15.2 31 93.9 2 6.1
Female 10 23.3 8 80.0 2 20.0 10 100.0 0 0.0
Age at diagnosis (yr)
13–24 8 18.6 7 87.5 1 12.5 8 100.0 0 0.0
25–34 19 44.2 16 84.2 3 15.8 18 94.7 1 5.3
35–44 10 23.3 9 90.0 1 10.0 10 100.0 0 0.0
45–54 5 11.6 3 60.0  2 40.0 4 80.0 1 20.0
≥ 55 1 2.3 1 100.0 0 0.0 1 100.0 0 0.0
Transmission categoryb
Male-to-male sexual contact 28 64.2 24 85.9 4 14.1 27 96.4 1 3.6
Injection drug use
Male 1 2.6 0 9.1 1 90.9 0 9.1 1 90.9
Female 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Male-to-male sexual contact and 
injection drug use
 2 4.9 2 95.2 0 4.8 2 100.0 0 0.0
Heterosexual contactc
Male 2 5.1 2 100.0 0 0.0 2 100.0 0 0.0
Female 10 23.3 8 80.0 2 20.0 10 100.0 0 0.0
Totald 43 100.0 36 83.7 7 16.3 41 95.3 2 4.7
White
Sex 
Male 7,322 85.4 5,992 81.8 1,330 18.2 6,588 90.0 734 10.0
Female 1,256 14.6 986 78.5 270 21.5 1,095 87.2 161 12.8
Age at diagnosis (yr)
13–24 1,286 15.0 1,007 78.3 279 21.7 1,144 89.0 142 11.0
25–34 2,743 32.0 2,166 79.0 577 21.0 2,420 88.2 323 11.8
35–44 1,735 20.2 1,427 82.2 308 17.8 1,564 90.1 171 9.9
45–54 1,659 19.3 1,400 84.4  259 15.6 1,497 90.2 162 9.8
≥ 55 1,155 13.5 978 84.7 177 15.3 1,058 91.6 97 8.4
Transmission categoryb
Male-to-male sexual contact 5,971 69.6 4,936 82.7 1,035 17.3 5,394 90.3 578 9.7
Injection drug use
Male 426 5.0 327 76.7 99 23.3 375 87.9 52 12.1
Female 407 4.7 312 76.7 95 23.3 344 84.5 63 15.5
Male-to-male sexual contact and 
injection drug use
 534 6.2 412 77.1 122 22.9 471 88.1 64 11.9
Heterosexual contactc
Male 383 4.5 311 81.2 72 18.8 343 89.5 40 10.5
Female 846 9.9 672 79.4 174 20.6 749 88.5 97 11.5
Totald 8,578 100.0 6,978 81.3 1,600 18.7 7,683 89.6 895 10.4
Table 3c. Linkage to HIV medical care after HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected 
characteristics—41 states and the District of Columbia (cont)
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month or ≤ 3 months after HIV diagnosis. See Technical 
Notes for the list of areas that met the criteria for complete laboratory reporting.
a Represents percentage of the total number for the column. 
b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
d Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the 
numbers were too small to be meaningful. 
e Hispanics/Latinos can be of any race.
Multiple races
Sex 
Male 738 82.5 591 80.1 147 19.9 652 88.3 86 11.7
Female 157 17.5 128 81.5 29 18.5 145 92.4 12 7.6
Age at diagnosis (yr)
13–24 233 26.0 186 79.8 47 20.2 203 87.1 30 12.9
25–34 317 35.4 250 78.9 67 21.1 280 88.3 37 11.7
35–44 161 18.0 132 82.0 29 18.0 146 90.7 15 9.3
45–54 127 14.2 107 84.3  20 15.7 118 92.9 9 7.1
≥ 55 57 6.4 44 77.2 13 22.8 50 87.7 7 12.3
Transmission categoryb
Male-to-male sexual contact 624 69.8 500 80.0 125 20.0 548 87.8 76 12.2
Injection drug use
Male 25 2.8 20 79.1 5 20.9 22 87.7 3 12.3
Female 29 3.2 20 71.1 8 28.9 26 89.5 3 10.5
Male-to-male sexual contact and 
injection drug use
 41 4.6 34 82.6 7 17.4 37 91.2 4 8.8
Heterosexual contactc
Male 47 5.3 38 79.8 10 20.2 44 93.4 3 6.6
Female 126 14.0 105 83.7 21 16.3 117 93.0 9 7.0
Totald 895 100.0 719 80.3 176 19.7 797 89.1 98 10.9
Table 3c. Linkage to HIV medical care after HIV diagnosis during 2017, among persons aged ≥ 13 years, by race/ethnicity and selected 
characteristics—41 states and the District of Columbia (cont)
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month or ≤ 3 months after HIV diagnosis. Data have been 
statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. See Technical Notes for the list of areas that met the criteria for complete 
laboratory reporting.
a Represents percentage of the total number for the column. 
b Hispanics/Latinos can be of any race.
Table 3d. Linkage to HIV medical care after HIV diagnosis during 2017, among males aged ≥ 13 years with infection attributed to male-to-male sexual 
contact, by race/ethnicity and age at diagnosis—41 states and the District of Columbia
Total
≤ 1 month ≤ 3 months
≥ 1 CD4 or VL tests No CD4 or VL test ≥ 1 CD4 or VL tests No CD4 or VL test
No. %a No. % No. % No. % No. %
American Indian/Alaska Native
13–24 15 16.6 14 95.2 1 4.8 14 95.2 1 4.8
25–34 39 45.0 35 88.0 5 12.0 37 95.2 2 4.8
35–44 19 21.4 18 93.6 1 6.4 18 93.6 1 6.4
45–54 12 14.1 10 83.7 2 16.3 12 100.0 0 0.0
≥ 55 3 3.0 1 38.5 2 61.5 1 38.5 2 61.5
Asian
13–24 168 24.4 132 78.6 36 21.4 147 87.5 21 12.5
25–34 240 34.8 202 84.3 38 15.7 211 87.9 29 12.1
35–44 149 21.7 119 79.5 31 20.5 134 89.7 15 10.3
45–54 98 14.3 81 82.5 17 17.5 88 89.3 11 10.7
≥ 55 33 4.8 27 82.7 6 17.3 29 87.2 4 12.8
Black/African American
13–24 3,117 35.4 2,288 73.4 829 26.6 2,606 83.6 510 16.4
25–34 3,575 40.6 2,651 74.1 924 25.9 2,986 83.5 589 16.5
35–44 1,119 12.7 858 76.7 261 23.3 937 83.7 182 16.3
45–54 636 7.2 494 77.6 143 22.4 541 85.0 95 15.0
≥ 55 363 4.1 284 78.3 79 21.7 316 87.0 47 13.0
Hispanic/Latinob
13–24 1,454 22.2 1,075 73.9 379 26.1 1,233 84.8 221 15.2
25–34 2,683 41.0 2,140 79.8 542 20.2 2,354 87.7 329 12.3
35–44 1,348 20.6 1,105 82.0 243 18.0 1,186 88.0 162 12.0
45–54 775 11.8 632 81.5 144 18.5 679 87.7 96 12.3
≥ 55 283 4.3 237 83.8 46 16.2 255 90.4 27 9.6
Native Hawaiian/Other Pacific Islander
13–24 8 28.6 7 88.6 1 11.4 8 100.0 0 0.0
25–34 13 46.7 10 76.7 3 23.3 12 92.2 1 7.8
35–44 5 17.4 5 100.0 0 0.0 5 100.0 0 0.0
45–54 2 7.2 2 100.0 0 0.0 2 100.0 0 0.0
≥ 55 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
White
13–24 995 16.7 784 78.8 211 21.2 888 89.2 107 10.8
25–34 1,921 32.2 1,548 80.6 372 19.4 1,713 89.2 207 10.8
35–44 1,132 19.0 957 84.5 176 15.5 1,037 91.5 96 8.5
45–54 1,165 19.5 1,001 85.9 164 14.1 1,058 90.8 107 9.2
≥ 55 758 12.7 646 85.1 113 14.9 698 92.0 61 8.0
Multiple races
13–24 187 29.9 149 79.7 38 20.3 162 86.5 25 13.5
25–34 246 39.4 191 77.5 55 22.5 215 87.2 32 12.8
35–44 98 15.6 83 84.9 15 15.1 86 88.0 12 12.0
45–54 70 11.2 59 84.4 11 15.6 66 94.9 4 5.1
≥ 55 24 3.8 18 75.0 6 25.0 20 83.3 4 16.7
Total 22,752 100.0 17,862 78.5 4,890 21.5 19,753 86.8 2,999 13.2
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2016 (i.e., most recent known address). See Technical Notes for the list of areas that met 
the criteria for complete laboratory reporting.
a Performed ≥ 3 months apart during 2016.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
g Includes 720 persons of unknown race/ethnicity. 
Table 4a. Receipt of HIV medical care among persons aged ≥ 13 years with infection diagnosed by year-end 2015 and alive 
at year-end 2016, by selected characteristics—41 states and the District of Columbia
Persons alive at year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa
Total No. No. % No. %
Sex 
Male 638,354 473,746 74.2 367,431 57.6
Female 198,286 146,682 74.0 114,275 57.6
Age at year-end 2015 (yr)
13–24 32,447 24,762 76.3 18,213 56.1
25–34 126,264 93,547 74.1 68,201 54.0
35–44 168,024 122,997 73.2 92,834 55.3
45–54 271,830 204,762 75.3 160,229 58.9
≥ 55 238,075 174,360 73.2 142,229 59.7
Race/ethnicity
American Indian/Alaska Native 2,021 1,483 73.4 1,136 56.2
Asianb 11,289 8,297 73.5 6,567 58.2
Black/African American 350,852 251,423 71.7 192,519 54.9
Hispanic/Latinoc 181,145 130,195 71.9 106,101 58.6
Native Hawaiian/Other Pacific Islander 702 501 71.4 358 51.0
White 252,832 196,616 77.8 149,933 59.3
Multiple races 37,079 31,844 85.9 25,034 67.5
Transmission categoryd
Male-to-male sexual contact 461,965 350,253 75.8 269,746 58.4
Injection drug use
Male 58,814 37,394 63.6 30,005 51.0
Female 41,293 29,927 72.5 23,585 57.1
Male-to-male sexual contact and injection drug use 46,714 36,645 78.4 28,863 61.8
Heterosexual contacte
Male 64,430 44,861 69.6 35,328 54.8
Female 151,019 112,269 74.3 87,149 57.7
Otherf
Male 6,431 4,593 71.4 3,489 54.3
Female 5,974 4,486 75.1 3,541 59.3
Totalg 836,640 620,428 74.2 481,706 57.6
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2016 (i.e., most recent known address).
a Performed ≥ 3 months apart during 2016.
Table 4b. Receipt of HIV medical care among persons aged ≥ 13 years with infection diagnosed by year-end 2015 and 
alive at year-end 2016, by area of residence—41 states and the District of Columbia
Persons alive at year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa
Total No. No. % No. %
Alabama 11,946 8,891 74.4 6,881 57.6
Alaska 654 587 89.8 396 60.6
California 120,666 91,791 76.1 70,474 58.4
Colorado 11,765 7,596 64.6 5,389 45.8
Connecticut 9,912 7,883 79.5 6,097 61.5
Delaware 3,049 2,453 80.5 1,811 59.4
District of Columbia 14,115 9,671 68.5 7,350 52.1
Florida 103,068 76,291 74.0 62,240 60.4
Georgia 48,718 34,854 71.5 27,614 56.7
Hawaii 2,530 1,874 74.1 1,353 53.5
Illinois 33,938 23,558 69.4 16,971 50.0
Indiana 10,420 7,871 75.5 5,810 55.8
Iowa 2,427 2,107 86.8 1,562 64.4
Louisiana 18,938 14,586 77.0 11,544 61.0
Maine 1,454 1,227 84.4 944 64.9
Maryland 31,324 21,201 67.7 15,129 48.3
Massachusetts 19,364 15,344 79.2 12,074 62.4
Michigan 14,501 12,066 83.2 8,877 61.2
Minnesota 7,732 5,875 76.0 4,061 52.5
Mississippi 8,905 6,189 69.5 4,740 53.2
Missouri 11,551 9,091 78.7 6,853 59.3
Montana 566 512 90.5 391 69.1
Nebraska 2,008 1,523 75.8 1,014 50.5
New Hampshire 1,131 863 76.3 674 59.6
New Mexico 3,126 2,472 79.1 1,951 62.4
New York 123,789 90,326 73.0 76,315 61.6
North Carolina 28,743 21,417 74.5 15,401 53.6
North Dakota 328 273 83.2 201 61.3
Ohio 20,282 12,912 63.7 8,753 43.2
Oklahoma 5,627 4,204 74.7 3,389 60.2
Oregon 6,501 5,736 88.2 4,069 62.6
Rhode Island 2,310 1,903 82.4 1,363 59.0
South Carolina 15,700 12,171 77.5 9,993 63.6
South Dakota 483 280 58.0 160 33.1
Tennessee 15,553 12,161 78.2 8,962 57.6
Texas 80,232 61,069 76.1 48,076 59.9
Utah 2,591 1,786 68.9 1,152 44.5
Virginia 20,611 13,109 63.6 9,316 45.2
Washington 12,309 10,568 85.9 7,744 62.9
West Virginia 1,702 1,246 73.2 800 47.0
Wisconsin 5,783 4,657 80.5 3,630 62.8
Wyoming 288 234 81.3 182 63.2
Total 836,640 620,428 74.2 481,706 57.6
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Table 4c. Receipt of HIV medical care and viral suppression among persons aged ≥ 13 years with infection 
diagnosed by year-end 2015 and alive at year-end 2016, by selected characteristics—41 states and the 
District of Columbia 
Persons alive at 
year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa VL of < 200 copies/mLb
Total No. No. % No. % No. %
American Indian/Alaska Native
Sex 
Male 1,440 1,038 72.1 806 56.0 864 60.0
Female 581 445 76.6 330 56.8 341 58.7
Age at year-end 2015 (yr)
13–24 79 64 81.0 49 62.0 45 57.0
25–34 321 240 74.8 179 55.8 186 57.9
35–44 444 314 70.7 225 50.7 245 55.2
45–54 700 519 74.1 408 58.3 426 60.9
≥ 55 477 346 72.5 275 57.7 303 63.5
Transmission categoryc
Male-to-male sexual contact 977 714 73.1 557 57.0 608 62.2
Injection drug use
Male 156 101 64.9 77 49.0 82 52.1
Female 190 140 73.4 95 49.7 100 52.5
Male-to-male sexual contact and 
injection drug use
176 130 74.3 103 58.5 104 59.4
Heterosexual contactd
Male 118 82 68.9 63 53.5 61 51.9
Female 374 293 78.3 226 60.5 232 62.0
Othere
Male 13 10 79.7 6 48.4 9 71.9
Female 17 12 73.3 9 54.5 9 55.2
Total 2,021 1,483 73.4 1,136 56.2 1,205 59.6
Asianf
Sex 
Male 9,297 6,895 74.2 5,448 58.6 6,265 67.4
Female 1,992 1,402 70.4 1,119 56.2 1,256 63.1
Age at year-end 2015 (yr)
13–24 422 341 80.8 276 65.4 300 71.1
25–34 2,014 1,505 74.7 1,142 56.7 1,344 66.7
35–44 3,372 2,475 73.4 1,921 57.0 2,231 66.2
45–54 3,290 2,457 74.7 1,982 60.2 2,242 68.1
≥ 55 2,191 1,519 69.3 1,246 56.9 1,404 64.1
Transmission categoryc
Male-to-male sexual contact 7,745 5,794 74.8 4,562 58.9 5,280 68.2
Injection drug use
Male 356 225 63.1 179 50.4 201 56.4
Female 154 100 64.9 77 50.1 86 55.4
Male-to-male sexual contact and 
injection drug use
329 260 79.1 200 60.9 224 68.3
Heterosexual contactd
Male 779 557 71.5 458 58.8 507 65.1
Female 1,769 1,260 71.2 1,007 56.9 1,131 63.9
Othere
Male 88 59 67.2 48 54.7 53 59.8
Female 69 42 61.6 35 50.3 40 57.7
Total 11,289 8,297 73.5 6,567 58.2 7,521 66.6
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Black/African American
Sex 
Male 231,029 163,880 70.9 125,049 54.1 127,875 55.4
Female 119,823 87,543 73.1 67,470 56.3 68,943 57.5
Age at year-end 2015 (yr)
13–24 19,179 14,250 74.3 10,247 53.4 9,481 49.4
25–34 62,611 44,959 71.8 32,116 51.3 32,029 51.2
35–44 71,037 50,741 71.4 37,691 53.1 38,726 54.5
45–54 103,790 75,719 73.0 59,216 57.1 61,142 58.9
≥ 55 94,235 65,754 69.8 53,249 56.5 55,440 58.8
Transmission categoryc
Male-to-male sexual contact 143,512 104,434 72.8 78,329 54.6 81,377 56.7
Injection drug use
Male 29,111 18,262 62.7 14,491 49.8 14,408 49.5
Female 20,849 14,839 71.2 11,651 55.9 11,587 55.6
Male-to-male sexual contact and 
injection drug use
13,816 10,354 74.9 8,179 59.2 7,852 56.8
Heterosexual contactd
Male 41,629 28,807 69.2 22,513 54.1 22,936 55.1
Female 95,606 70,166 73.4 53,819 56.3 55,743 58.3
Othere
Male 2,961 2,022 68.3 1,538 52.0 1,302 44.0
Female 3,367 2,537 75.4 2,000 59.4 1,613 47.9
Total 350,852 251,423 71.7 192,519 54.9 196,818 56.1
Hispanic/Latinog
Sex 
Male 145,972 103,604 71.0 84,025 57.6 89,007 61.0
Female 35,173 26,591 75.6 22,076 62.8 22,100 62.8
Age at year-end 2015 (yr)
13–24 6,893 5,396 78.3 4,167 60.5 4,036 58.6
25–34 30,091 22,362 74.3 17,098 56.8 18,105 60.2
35–44 43,668 30,819 70.6 24,648 56.4 25,923 59.4
45–54 58,255 42,114 72.3 34,777 59.7 36,598 62.8
≥ 55 42,238 29,504 69.9 25,411 60.2 26,445 62.6
Transmission categoryc
Male-to-male sexual contact 105,947 77,407 73.1 62,279 58.8 67,421 63.6
Injection drug use
Male 16,276 9,532 58.6 8,064 49.5 7,839 48.2
Female 7,899 5,874 74.4 4,930 62.4 4,691 59.4
Male-to-male sexual contact and 
injection drug use
10,099 7,650 75.8 6,294 62.3 6,139 60.8
Heterosexual contactd
Male 12,281 8,034 65.4 6,608 53.8 6,892 56.1
Female 25,983 19,720 75.9 16,321 62.8 16,703 64.3
Othere
Male 1,368 981 71.7 781 57.1 716 52.3
Female 1,292 996 77.1 825 63.9 707 54.7
Total 181,145 130,195 71.9 106,101 58.6 111,107 61.3
Table 4c. Receipt of HIV medical care and viral suppression among persons aged ≥ 13 years with infection 
diagnosed by year-end 2015 and alive at year-end 2016, by selected characteristics—41 states and the 
District of Columbia (cont)
Persons alive at 
year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa VL of < 200 copies/mLb
Total No. No. % No. % No. %
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Native Hawaiian/Other Pacific Islander
Sex 
Male 582 419 72.0 296 50.9 370 63.6
Female 120 82 68.3 62 51.7 75 62.5
Age at year-end 2015 (yr)
13–24 28 18 64.3 11 39.3 16 57.1
25–34 132 87 65.9 63 47.7 77 58.3
35–44 188 136 72.3 95 50.5 118 62.8
45–54 208 153 73.6 104 50.0 134 64.4
≥ 55 146 107 73.3 85 58.2 100 68.5
Transmission categoryc
Male-to-male sexual contact 500 353 70.5 250 50.1 312 62.4
Injection drug use
Male 20 15 74.8 13 62.4 15 74.8
Female 19 11 60.2 8 43.5 11 60.2
Male-to-male sexual contact and 
injection drug use
34 29 85.5 19 55.2 23 67.6
Heterosexual contactd
Male 26 20 78.1 13 50.8 18 70.4
Female 100 70 69.8 53 52.9 63 62.9
Othere
Male 2 2 95.5 1 50.0 2 95.5
Female 2 1 70.6 1 70.6 1 64.7
Total 702 501 71.4 358 51.0 445 63.4
Whites
Sex 
Male 221,047 173,403 78.4 132,594 60.0 152,223 68.9
Female 31,785 23,213 73.0 17,339 54.6 19,234 60.5
Age at year-end 2015 (yr)
13–24 4,177 3,321 79.5 2,404 57.6 2,644 63.3
25–34 24,758 19,191 77.5 13,787 55.7 15,767 63.7
35–44 41,600 32,106 77.2 23,380 56.2 26,937 64.8
45–54 93,244 73,187 78.5 55,322 59.3 64,101 68.7
≥ 55 89,053 68,811 77.3 55,040 61.8 62,008 69.6
Transmission categoryc
Male-to-male sexual contact 182,404 143,950 78.9 110,087 60.4 127,836 70.1
Injection drug use
Male 10,656 7,381 69.3 5,657 53.1 6,072 57.0
Female 9,832 6,969 70.9 5,214 53.0 5,549 56.4
Male-to-male sexual contact and 
injection drug use
18,936 15,289 80.7 11,721 61.9 12,506 66.0
Heterosexual contactd
Male 7,417 5,568 75.1 4,247 57.3 4,782 64.5
Female 21,055 15,619 74.2 11,671 55.4 13,172 62.6
Othere
Male 1,633 1,214 74.4 881 54.0 1,026 62.8
Female 897 625 69.7 454 50.6 513 57.2
Total 252,832 196,616 77.8 149,933 59.3 171,457 67.8
Table 4c. Receipt of HIV medical care and viral suppression among persons aged ≥ 13 years with infection 
diagnosed by year-end 2015 and alive at year-end 2016, by selected characteristics—41 states and the 
District of Columbia (cont)
Persons alive at 
year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa VL of < 200 copies/mLb
Total No. No. % No. % No. %
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2016 (i.e., most recent known address). See Technical Notes for the list of areas 
that met the criteria for complete laboratory reporting.
a Performed ≥ 3 months apart during 2016.
b VL test results are from the most recent test during 2016.
c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
f Includes Asian/Pacific Islander legacy cases (see Technical Notes).
g Hispanics/Latinos can be of any race.
Multiple races
Sex 
Male 28,476 24,451 85.9 19,165 67.3 20,104 70.6
Female 8,603 7,393 85.9 5,869 68.2 5,795 67.4
Age at year-end 2015 (yr)
13–24 1,658 1,370 82.6 1,057 63.8 938 56.6
25–34 6,327 5,203 82.2 3,816 60.3 3,951 62.4
35–44 7,653 6,400 83.6 4,868 63.6 5,052 66.0
45–54 12,086 10,590 87.6 8,400 69.5 8,748 72.4
≥ 55 9,355 8,281 88.5 6,893 73.7 7,210 77.1
Transmission categoryc
Male-to-male sexual contact 20,515 17,558 85.6 13,645 66.5 14,671 71.5
Injection drug use
Male 2,174 1,870 86.0 1,519 69.9 1,501 69.1
Female 2,285 1,990 87.1 1,609 70.4 1,530 66.9
Male-to-male sexual contact and 
injection drug use
3,285 2,930 89.2 2,345 71.4 2,251 68.5
Heterosexual contactd
Male 2,147 1,791 83.4 1,423 66.3 1,462 68.1
Female 6,002 5,132 85.5 4,044 67.4 4,083 68.0
Othere
Male 355 303 85.3 233 65.6 219 61.6
Female 315 271 85.9 216 68.4 183 57.9
Total 37,079 31,844 85.9 25,034 67.5 25,899 69.8
Table 4c. Receipt of HIV medical care and viral suppression among persons aged ≥ 13 years with infection 
diagnosed by year-end 2015 and alive at year-end 2016, by selected characteristics—41 states and the 
District of Columbia (cont)
Persons alive at 
year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa VL of < 200 copies/mLb
Total No. No. % No. % No. %
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Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2016 (i.e., most recent known address). Data have been statistically adjusted to account for 
missing transmission category; therefore, values may not sum to column total. See Technical Notes for the list of areas that met the criteria for complete laboratory 
reporting. Ages are as of year-end 2015.
a Performed ≥ 3 months apart during 2016.b VL test results are from the most recent test during 2016.c Includes Asian/Pacific Islander legacy cases (see Technical Notes).d Hispanics/Latinos can be of any race.
Table 4d. Receipt of HIV medical care and viral suppression among males aged ≥ 13 years with infection attributed to male-to-
male sexual contact, by selected characteristics—41 states and the District of Columbia
Males alive at 
year-end 2016 ≥ 1 CD4 or VL tests ≥ 2 CD4 or VL testsa VL of < 200 copies/mLb
Total No. No. % No. % No. %
American Indian/Alaska Native
13–24 51 42 83.0 33 65.3 31 61.6
25–34 190 146 76.8 104 54.8 118 61.8
35–44 211 144 68.2 108 51.1 125 59.0
45–54 336 245 73.0 202 60.3 212 63.2
≥ 55 189 138 72.6 110 57.9 122 64.6
Asianc
13–24 317 261 82.4 207 65.1 229 72.1
25–34 1,540 1,157 75.1 866 56.3 1,039 67.5
35–44 2,246 1,662 74.0 1,279 57.0 1,506 67.1
45–54 2,298 1,736 75.5 1,409 61.3 1,592 69.3
≥ 55 1,344 978 72.7 801 59.6 914 68.0
Black/African American
13–24 11,882 8,952 75.3 6,297 53.0 6,192 52.1
25–34 40,133 29,527 73.6 21,002 52.3 21,461 53.5
35–44 29,054 21,174 72.9 15,809 54.4 16,421 56.5
45–54 37,686 27,501 73.0 21,364 56.7 22,570 59.9
≥ 55 24,758 17,281 69.8 13,857 56.0 14,733 59.5
Hispanic/Latinod
13–24 4,568 3,631 79.5 2,780 60.9 2,801 61.3
25–34 22,109 16,724 75.6 12,694 57.4 13,855 62.7
35–44 27,550 19,586 71.1 15,694 57.0 16,982 61.6
45–54 33,210 24,272 73.1 19,869 59.8 21,690 65.3
≥ 55 18,511 13,194 71.3 11,241 60.7 12,094 65.3
Native Hawaiian/Other Pacific Islander
13–24 18 11 61.5 7 39.1 9 50.3
25–34 105 68 64.4 49 46.6 61 57.8
35–44 132 97 73.6 68 51.2 85 63.9
45–54 151 109 72.4 73 48.6 95 63.1
≥ 55 94 67 71.8 54 57.1 62 66.5
Whites
13–24 2,633 2,132 81.0 1,538 58.4 1,796 68.2
25–34 17,647 13,885 78.7 9,951 56.4 11,783 66.8
35–44 28,162 22,053 78.3 16,068 57.1 19,066 67.7
45–54 67,846 53,922 79.5 40,823 60.2 48,008 70.8
≥ 55 66,117 51,959 78.6 41,707 63.1 47,183 71.4
Multiple races
13–24 1,011 826 81.7 635 62.8 604 59.7
25–34 4,402 3,635 82.6 2,646 60.1 2,851 64.8
35–44 4,340 3,648 84.1 2,776 64.0 2,985 68.8
45–54 6,537 5,711 87.4 4,482 68.6 4,902 75.0
≥ 55 4,224 3,738 88.5 3,106 73.5 3,330 78.8
Total 461,965 350,253 75.8 269,746 58.4 297,546 64.4
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atory reporting. A VL test result of < 200 copies/mL indicates HIV 
, by selected characteristics—41 states and the 
VL of < 200 copies/mL
Among persons 
alive at year-
end 2016
Among persons 
with ≥ 1 CD4 or 
VL tests
Among persons 
with ≥ 1 VL tests
% % %
62.2 83.7 87.4
59.4 80.3 83.4
53.8 70.5 73.3
56.6 76.4 79.2
59.1 80.7 83.9
63.8 84.7 88.3
64.2 87.7 91.9
59.6 81.3 84.6
66.6 90.6 93.9
56.1 78.3 81.6
61.3 85.3 87.7
63.4 88.8 91.8
67.8 87.2 91.9
69.8 81.3 84.4
64.4 85.0 88.6
51.2 80.6 84.9
57.0 78.7 81.9
62.3 79.4 83.0
56.9 81.7 85.2
60.3 81.2 84.3
51.7 72.4 75.6
51.3 68.4 70.7
61.5 82.9 86.4
Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2016 (i.e., most recent known address). See Technical Notes for the list of areas that met the criteria for complete labor
viral suppression. VL test results are from the most recent test during 2016.
a Represents percentage of the total number for the column.b Includes Asian/Pacific Islander legacy cases (see Technical Notes).c Hispanics/Latinos can be of any race.d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.g Includes 720 persons of unknown race/ethnicity. 
Table 5a. HIV viral suppression during 2016 among persons aged ≥ 13 years with infection diagnosed by year-end 2015 and alive at year-end 2016
District of Columbia
Persons alive at year-end 2016
Persons with ≥ 1 CD4 or 
VL tests Persons with ≥ 1 VL tests
No. %a No. % No. % No.
Sex 
Male 638,354 76.3 473,746 74.2 453,953 71.1 396,762
Female 198,286 23.7 146,682 74.0 141,246 71.2 117,757
Age at year-end 2015 (yr)
13–24 32,447 3.9 24,762 76.3 23,807 73.4 17,462
25–34 126,264 15.1 93,547 74.1 90,244 71.5 71,459
35–44 168,024 20.1 122,997 73.2 118,330 70.4 99,238
45–54 271,830 32.5 204,762 75.3 196,472 72.3 173,413
≥ 55 238,075 28.5 174,360 73.2 166,346 69.9 152,947
Race/ethnicity
American Indian/Alaska Native 2,021 0.2 1,483 73.4 1,425 70.5  1,205 
Asianb 11,289 1.3 8,297 73.5 8,009 70.9 7,521
Black/African American 350,852 41.9 251,423 71.7 241,270 68.8 196,818
Hispanic/Latinoc 181,145 21.7 130,195 71.9 126,720 70.0 111,107
Native Hawaiian/Other Pacific Islander 702 0.1 501 71.4 485 69.1 445
White 252,832 30.2 196,616 77.8 186,540 73.8 171,457
Multiple races 37,079 4.4 31,844 85.9 30,681 82.7 25,899
Transmission categoryd
Male-to-male sexual contact 461,965 55.2 350,253 75.8 335,994 72.7 297,546
Injection drug use
Male 58,814 7.0 37,394 63.6 35,486 60.3 30,124
Female 41,293 4.9 29,927 72.5 28,773 69.7 23,556
Male-to-male sexual contact and 
injection drug use
46,714 5.6 36,645 78.4 35,053 75.0 29,103
Heterosexual contacte
Male 64,430 7.7 44,861 69.6 43,020 66.8 36,662
Female 151,019 18.1 112,269 74.3 108,135 71.6 91,135
Otherf
Male 6,431 0.8 4,593 71.4 4,400 68.4 3,327
Female 5,974 0.7 4,486 75.1 4,338 72.6 3,066
Totalg 836,640 100.0 620,428 74.2 595,199 71.1 514,519
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, by area of residence—41 states and the 
VL of < 200 copies/mL
mong persons 
alive at year-
end 2016
Among persons 
with ≥ 1 CD4 or 
VL tests
Among persons 
with ≥ 1 VL tests
% % %
61.1 82.1 84.3
76.6 85.3 87.6
66.2 87.1 89.9
56.4 87.4 89.7
64.9 81.6 88.0
67.3 83.7 85.8
55.2 80.5 83.5
61.8 83.6 86.1
57.1 79.8 82.7
67.5 91.1 92.6
53.5 77.0 86.0
61.8 81.8 87.2
78.9 90.8 91.8
62.6 81.3 82.5
76.3 90.4 92.0
54.5 80.6 83.2
68.3 86.2 90.5
70.7 85.0 87.5
68.1 89.6 91.2
53.3 76.7 81.9
62.3 79.2 87.4
79.7 88.1 91.1
63.1 83.3 89.4
68.3 89.6 90.6
70.4 89.0 90.2
62.9 86.2 86.9
62.1 83.4 86.0
72.6 87.2 90.2
51.7 81.2 85.5
58.7 78.6 84.7
56.0 63.5 88.7
74.9 91.0 91.8
61.8 79.7 84.3
45.1 77.9 84.2
55.0 70.3 82.4
60.5 79.4 83.2
51.7 75.0 76.6
51.8 81.4 87.8
76.5 89.1 92.7
57.5 78.5 88.3
69.2 85.9 90.0
68.4 84.2 86.0
61.5 82.9 86.4
Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL).
Note. Data are based on address of residence as of December 31, 2016 (i.e., most recent known address). A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test re
a Represents percentage of the total number for the column.
Table 5b. HIV viral suppression during 2016 among persons aged ≥ 13 years with infection diagnosed by year-end 2015 and alive at year-end 2016
District of Columbia
Persons alive at year-end 2016
Persons with ≥ 1 CD4 or 
VL tests Persons with ≥ 1 VL tests
A
No. %a No. % No. % No.
Alabama 11,946 1.4 8,891 74.4 8,654 72.4 7,297
Alaska 654 0.1 587 89.8 572 87.5 501
California 120,666 14.4 91,791 76.1 88,934 73.7 79,917
Colorado 11,765 1.4 7,596 64.6 7,402 62.9 6,640
Connecticut 9,912 1.2 7,883 79.5 7,312 73.8 6,435
Delaware 3,049 0.4 2,453 80.5 2,393 78.5 2,052
District of Columbia 14,115 1.7 9,671 68.5 9,328 66.1 7,787
Florida 103,068 12.3 76,291 74.0 74,059 71.9 63,746
Georgia 48,718 5.8 34,854 71.5 33,633 69.0 27,827
Hawaii 2,530 0.3 1,874 74.1 1,843 72.8 1,707
Illinois 33,938 4.1 23,558 69.4 21,104 62.2 18,141
Indiana 10,420 1.2 7,871 75.5 7,387 70.9 6,440
Iowa 2,427 0.3 2,107 86.8 2,085 85.9 1,914
Louisiana 18,938 2.3 14,586 77.0 14,378 75.9 11,862
Maine 1,454 0.2 1,227 84.4 1,206 82.9 1,109
Maryland 31,324 3.7 21,201 67.7 20,533 65.6 17,081
Massachusetts 19,364 2.3 15,344 79.2 14,627 75.5 13,234
Michigan 14,501 1.7 12,066 83.2 11,725 80.9 10,256
Minnesota 7,732 0.9 5,875 76.0 5,770 74.6 5,265
Mississippi 8,905 1.1 6,189 69.5 5,797 65.1 4,747
Missouri 11,551 1.4 9,091 78.7 8,238 71.3 7,198
Montana 566 0.1 512 90.5 495 87.5 451
Nebraska 2,008 0.2 1,523 75.8 1,418 70.6 1,268
New Hampshire 1,131 0.1 863 76.3 853 75.4 773
New Mexico 3,126 0.4 2,472 79.1 2,440 78.1 2,200
New York 123,789 14.8 90,326 73.0 89,513 72.3 77,823
North Carolina 28,743 3.4 21,417 74.5 20,777 72.3 17,861
North Dakota 328 0.0 273 83.2 264 80.5 238
Ohio 20,282 2.4 12,912 63.7 12,265 60.5 10,481
Oklahoma 5,627 0.7 4,204 74.7 3,902 69.3 3,305
Oregon 6,501 0.8 5,736 88.2 4,106 63.2 3,640
Rhode Island 2,310 0.3 1,903 82.4 1,886 81.6 1,731
South Carolina 15,700 1.9 12,171 77.5 11,498 73.2 9,696
South Dakota 483 0.1 280 58.0 259 53.6 218
Tennessee 15,553 1.9 12,161 78.2 10,378 66.7 8,552
Texas 80,232 9.6 61,069 76.1 58,321 72.7 48,519
Utah 2,591 0.3 1,786 68.9 1,750 67.5 1,340
Virginia 20,611 2.5 13,109 63.6 12,155 59.0 10,675
Washington 12,309 1.5 10,568 85.9 10,161 82.5 9,418
West Virginia 1,702 0.2 1,246 73.2 1,107 65.0 978
Wisconsin 5,783 0.7 4,657 80.5 4,442 76.8 3,999
Wyoming 288 0.0 234 81.3 229 79.5 197
Total 836,640 100.0 620,428 74.2 595,199 71.1 514,519
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death (where a person's death occurred) was used.
2015 2016
r 
 
a No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa
12,026 9.2 16.2 12,241 9.3 16.1
3,913 2.9 16.8 3,970 2.9 16.7
160 0.3 3.4 164 0.3 3.6
992 2.3 6.7 1,097 2.5 7.1
2,055 5.1 10.2 1,950 4.8 9.9
4,977 11.5 15.5 4,614 10.8 14.5
7,755 8.8 30.2 8,386 9.2 29.6
62 3.2 22.2 47 2.4 15.9
82 0.6 6.6 101 0.7 7.5
7,198 22.0 17.8 7,176 21.7 17.2
2,505 5.8 12.0 2,606 5.9 12.0
6 1.3 7.5 13 2.8 15.6
5,087 3.0 17.0 5,291 3.1 17.4
993 23.4 22.4 975 22.2 21.8
6,635 — 12.6 6,865 — 12.6
2,309 — 30.7 2,237 — 30.1
1,350 — 26.2 1,360 — 26.6
1,389 — 25.0 1,362 — 24.5
1,587 — 20.5 1,673 — 21.1
2,489 — 14.2 2,536 — 14.1
106 — 14.2 104 — 13.7
73 — 10.8 74 — 10.6
3,606 7.5 15.5 3,714 7.7 15.6
1,814 3.2 15.7 1,830 3.2 15.4
7,907 7.8 18.1 7,939 7.8 17.7
2,612 4.1 13.8 2,728 4.3 13.9
15,939 5.9 16.3 16,211 6.0 16.2
Abbreviation: PLWDH, persons living with diagnosed HIV infection.
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at a Denominator was calculated as (No. PLWDH at the end of [year X–1]) + (No. new diagnoses during year X).b Includes Asian/Pacific Islander legacy cases (see Technical Notes).c Hispanics/Latinos can be of any race.d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.g Includes persons of unknown race/ethnicity. 
Table 6a. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, 2010–2016—United States 
2010 2011 2012 2013 2014
No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate pe
1,000
PLWDH
Sex 
Male 12,480 10.0 19.6 12,173 9.6 18.5 11,897 9.3 17.5 11,940 9.3 17.1 12,025 9.3 16.7
Female 4,409 3.4 20.7 4,264 3.2 19.6 4,242 3.2 19.1 4,086 3.0 18.1 4,202 3.1 18.3
Age at death (yr)
13–24 242 0.5 5.4 228 0.4 4.9 195 0.4 4.1 180 0.3 3.8 188 0.4 3.9
25–34 1,173 2.8 9.4 1,101 2.6 8.6 1,112 2.6 8.4 1,058 2.5 7.7 1,006 2.3 7.1
35–44 3,260 8.0 13.5 2,894 7.1 12.6 2,569 6.3 11.6 2,322 5.7 10.9 2,251 5.6 10.9
45–54 6,303 14.0 21.6 5,992 13.4 19.7 5,738 13.0 18.3 5,527 12.6 17.4 5,185 11.9 16.2
≥ 55 5,911 7.7 39.8 6,222 7.8 37.2 6,525 8.0 34.8 6,939 8.3 33.1 7,597 8.8 32.7
Race/ethnicity
American Indian/Alaska Native 73 4.0 32.0 57 3.1 24.3 53 2.9 21.6 64 3.4 25.1 62 3.3 23.3
Asianb 69 0.6 8.1 85 0.7 9.2 71 0.5 7.2 74 0.5 6.9 63 0.4 5.5
Black/African American 8,171 26.6 23.1 7,835 25.2 21.5 7,622 24.2 20.3 7,464 23.4 19.4 7,416 23.0 18.8
Hispanic/Latinoc 2,646 7.0 15.2 2,706 6.9 15.0 2,458 6.1 13.1 2,551 6.2 13.1 2,659 6.3 13.2
Native Hawaiian/Other 
Pacific Islander
7 1.8 12.3 7 1.7 11.3 7 1.7 10.6 10 2.3 14.3 9 2.0 12.3
White 5,061 3.0 18.7 4,922 2.9 17.8 5,051 3.0 17.9 4,918 2.9 17.1 5,058 3.0 17.2
Multiple races 857 24.1 21.1 823 22.3 19.8 856 22.4 20.1 941 23.7 21.7 956 23.3 21.7
Transmission categoryd
Male-to-male sexual contact 6,487 — 15.2 6,370 — 14.3 6,327 — 13.6 6,448 — 13.3 6,574 — 13.0
Injection drug use
Male 2,821 — 34.9 2,624 — 33.0 2,516 — 32.0 2,405 — 31.1 2,441 — 32.0
Female 1,605 — 29.9 1,592 — 29.8 1,491 — 28.2 1,504 — 28.7 1,464 — 28.2
Male-to-male sexual contact 
and injection drug use
1,341 — 24.4 1,324 — 24.0 1,281 — 23.1 1,333 — 24.0 1,333 — 24.0
Heterosexual contacte
Male 1,716 — 25.1 1,732 — 24.6 1,657 — 23.0 1,643 — 22.2 1,583 — 20.9
Female 2,744 — 17.9 2,591 — 16.4 2,673 — 16.4 2,521 — 15.1 2,674 — 15.6
Otherf
Male 115 — 16.9 122 — 17.4 116 — 16.2 111 — 15.2 93 — 12.7
Female 60 — 10.5 82 — 13.6 78 — 12.5 62 — 9.6 64 — 9.7
Region of residence
Northeast 4,333 9.3 19.9 4,163 8.9 18.8 3,832 8.1 17.1 3,884 8.2 17.1 3,761 7.9 16.3
Midwest 1,944 3.5 19.4 1,886 3.4 18.2 1,913 3.4 17.9 1,794 3.2 16.3 1,847 3.3 16.4
South 8,172 8.6 22.1 7,896 8.2 20.6 7,915 8.1 19.9 7,794 7.9 19.0 8,022 8.1 19.0
West 2,440 4.1 14.9 2,492 4.2 14.8 2,479 4.1 14.3 2,554 4.2 14.4 2,597 4.2 14.2
Totalg 16,889 6.6 19.9 16,437 6.4 18.8 16,139 6.2 17.9 16,026 6.1 17.3 16,227 6.1 17.1
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death (where a person's death occurred) was used.
2015 2016
r 
 
a No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa
12,324 9.3 16.4 12,559 9.4 16.2
4,020 2.9 16.8 4,064 2.9 16.7
162 0.3 3.4 169 0.3 3.7
1,018 2.3 6.8 1,112 2.5 7.1
2,111 5.1 10.3 2,012 4.9 10.0
5,126 11.8 15.7 4,735 10.9 14.6
7,927 8.8 30.3 8,595 9.4 29.8
62 — 22.2 47 — 15.9
83 — 6.6 101 — 7.5
7,204 — 17.8 7,185 — 17.3
2,901 — 12.8 3,005 — 12.8
7 — 8.5 15 — 17.3
5,087 — 17.0 5,292 — 17.4
994 — 22.4 976 — 21.8
6,711 — 12.7 6,940 — 12.6
2,444 — 30.8 2,367 — 30.3
1,375 — 26.1 1,395 — 26.7
1,416 — 25.1 1,394 — 24.7
1,645 — 20.6 1,748 — 21.4
2,571 — 14.3 2,592 — 14.1
109 — 14.2 110 — 14.2
74 — 10.7 77 — 10.9
3,606 7.5 15.5 3,714 7.7 15.6
1,814 3.2 15.7 1,830 3.2 15.4
7,907 7.8 18.1 7,939 7.8 17.7
2,612 4.1 13.8 2,728 4.3 13.9
405 12.3 23.3 412 12.7 23.7
16,344 6.0 16.5 16,623 6.1 16.3
Abbreviation: PLWDH, persons living with diagnosed HIV infection.
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at a Denominator was calculated as (No. PLWDH at the end of [year X–1]) + (No. new diagnoses during year X).b Includes Asian/Pacific Islander legacy cases (see Technical Notes).c Hispanics/Latinos can be of any race.d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.g Includes persons of unknown race/ethnicity. 
Table 6b. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, 2010–2016—United States and 6 dependent areas 
2010 2011 2012 2013 2014
No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWDHa No.
Rate per 
100,000 
population
Rate pe
1,000
PLWDH
Sex 
Male 12,891 10.2 19.8 12,576 9.8 18.8 12,238 9.5 17.7 12,279 9.4 17.3 12,365 9.4 16.9
Female 4,555 3.4 20.9 4,398 3.3 19.7 4,362 3.2 19.2 4,209 3.1 18.2 4,334 3.1 18.4
Age at death (yr)
13–24 248 0.5 5.5 233 0.4 4.9 200 0.4 4.2 185 0.3 3.8 190 0.4 3.9
25–34 1,221 2.9 9.7 1,135 2.7 8.7 1,155 2.7 8.6 1,091 2.5 7.9 1,029 2.3 7.1
35–44 3,391 8.2 13.7 3,010 7.3 12.8 2,662 6.5 11.8 2,388 5.8 11.0 2,309 5.6 10.9
45–54 6,516 14.3 21.9 6,201 13.7 20.0 5,898 13.2 18.5 5,704 12.9 17.6 5,345 12.2 16.4
≥ 55 6,070 7.7 39.9 6,395 7.9 37.4 6,685 8.1 34.8 7,120 8.4 33.2 7,826 9.0 33.0
Race/ethnicity
American Indian/Alaska Native 73 — 32.0 57 — 24.3 53 — 21.6 64 — 25.1 62 — 23.3
Asianb 70 — 8.2 87 — 9.4 73 — 7.3 74 — 6.9 65 — 5.6
Black/African American 8,177 — 23.1 7,842 — 21.5 7,633 — 20.4 7,470 — 19.4 7,425 — 18.8
Hispanic/Latinoc 3,193 — 16.7 3,230 — 16.4 2,904 — 14.2 3,001 — 14.2 3,120 — 14.3
Native Hawaiian/Other 
Pacific Islander
8 — 13.5 10 — 15.6 7 — 10.3 12 — 16.6 9 — 11.9
White 5,062 — 18.7 4,922 — 17.8 5,052 — 17.9 4,920 — 17.1 5,058 — 17.2
Multiple races 858 — 21.1 824 — 19.8 857 — 20.1 943 — 21.7 956 — 21.7
Transmission categoryd
Male-to-male sexual contact 6,559 — 15.2 6,453 — 14.3 6,386 — 13.6 6,530 — 13.3 6,660 — 13.1
Injection drug use
Male 3,029 — 35.5 2,830 — 33.7 2,679 — 32.4 2,545 — 31.2 2,586 — 32.2
Female 1,647 — 30.0 1,637 — 30.0 1,525 — 28.2 1,546 — 28.8 1,505 — 28.3
Male-to-male sexual contact 
and injection drug use
1,384 — 24.7 1,361 — 24.2 1,311 — 23.3 1,363 — 24.1 1,361 — 24.1
Heterosexual contacte
Male 1,802 — 25.5 1,808 — 24.8 1,743 — 23.3 1,728 — 22.6 1,664 — 21.3
Female 2,845 — 18.1 2,676 — 16.5 2,757 — 16.5 2,600 — 15.2 2,764 — 15.8
Otherf
Male 116 — 16.7 123 — 17.2 119 — 16.2 113 — 15.2 95 — 12.7
Female 62 — 10.6 85 — 13.8 81 — 12.7 63 — 9.6 65 — 9.7
Region of residence
Northeast 4,333 9.3 19.9 4,163 8.9 18.8 3,832 8.1 17.1 3,884 8.2 17.1 3,761 7.9 16.3
Midwest 1,944 3.5 19.4 1,886 3.4 18.2 1,913 3.4 17.9 1,794 3.2 16.3 1,847 3.3 16.4
South 8,172 8.6 22.1 7,896 8.2 20.6 7,915 8.1 19.9 7,794 7.9 19.0 8,022 8.1 19.0
West 2,440 4.1 14.9 2,492 4.2 14.8 2,479 4.1 14.3 2,554 4.2 14.4 2,597 4.2 14.2
U.S. dependent areas 557 16.3 32.4 537 15.8 31.2 461 13.7 26.8 462 13.8 26.7 472 14.2 27.2
Totalg 17,446 6.7 20.1 16,974 6.5 19.0 16,600 6.3 18.1 16,488 6.2 17.5 16,699 6.2 17.3
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas 
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
2010
Alabama 274 6.9 7.0 24.9 25.5
Alaska 16 2.8 2.7 24.2 25.5
Arizona 202 3.9 3.9 16.2 15.5
Arkansas 114 4.7 4.8 25.9 26.0
California 1,546 5.0 5.0 14.3 13.8
Colorado 140 3.4 3.3 14.0 11.9
Connecticut 210 7.0 6.4 20.4 19.0
Delaware 77 10.2 9.9 25.4 26.1
District of Columbia 259 48.8 54.1 18.0 17.1
Florida 2,031 12.7 12.2 22.3 21.9
Georgia 911 11.5 11.5 22.0 23.8
Hawaii 36 3.1 3.0 14.6 12.1
Idaho 15 1.2 1.3 16.9 15.0
Illinois 665 6.3 6.2 21.2 22.8
Indiana 171 3.2 3.3 19.2 17.7
Iowa 28 1.1 1.0 13.9 13.8
Kansas 49 2.1 2.1 18.4 22.7
Kentucky 119 3.3 3.3 21.9 22.5
Louisiana 461 12.3 12.7 28.4 28.7
Maine 22 1.9 1.8 17.3 14.9
Maryland 615 12.7 12.2 21.7 21.0
Massachusetts 282 5.1 4.9 16.2 14.9
Michigan 313 3.8 3.8 23.0 23.5
Minnesota 77 1.8 1.7 11.7 12.5
Mississippi 208 8.6 8.9 25.6 27.0
Missouri 210 4.2 4.3 20.3 20.3
Montana 11 1.3 1.3 25.6 24.1
Nebraska 31 2.1 2.1 17.3 19.2
Nevada 126 5.7 5.6 18.1 17.0
New Hampshire 18 1.6 1.4 16.2 15.8
New Jersey 811 11.0 10.3 23.4 21.6
New Mexico 63 3.7 3.8 21.5 19.4
New York 2,235 13.7 13.1 18.7 16.6
North Carolina 582 7.3 7.2 23.4 23.0
North Dakota 6 1.1 1.2 28.7 29.3
Ohio 288 3.0 3.0 16.7 16.9
Oklahoma 108 3.5 3.6 21.8 21.6
Oregon 97 3.0 3.0 16.8 15.4
Pennsylvania 703 6.5 6.3 22.6 21.7
Rhode Island 37 4.1 4.2 17.5 17.4
South Carolina 336 8.7 8.8 23.5 22.8
South Dakota 12 1.8 1.8 31.9 29.4
Tennessee 377 7.1 7.2 25.1 27.1
Texas 1,356 6.7 6.9 20.4 21.3
Utah 24 1.1 1.3 11.1 8.4
Vermont 15 2.8 2.3 32.2 26.6
Virginia 316 4.7 4.6 17.1 16.9
Washington 156 2.8 2.7 14.7 14.3
West Virginia 28 1.8 1.7 17.7 16.6
Wisconsin 94 2.0 1.9 18.9 19.7
Wyoming 8 1.7 1.7 29.9 40.0
Subtotal 16,889 6.6 6.5 19.9 19.4
U.S. dependent areas
American Samoa 1 2.6 2.8 1,000.0 199.8
Guam 3 2.5 2.6 36.1 18.3
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 546 17.6 18.3 33.0 29.4
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 7 8.0 8.6 12.2 10.5
Subtotal 557 16.3 17.0 32.4 28.8
Total 17,446 6.7 6.6 20.1 19.6
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2011
Alabama 256 6.4 6.4 22.3 23.9
Alaska 12 2.1 2.0 17.8 13.3
Arizona 192 3.6 3.7 14.9 14.0
Arkansas 113 4.7 4.9 25.1 25.9
California 1,615 5.2 5.2 14.6 13.7
Colorado 127 3.0 2.9 12.3 10.6
Connecticut 219 7.2 6.7 21.3 18.8
Delaware 70 9.2 8.6 22.5 18.9
District of Columbia 279 51.4 56.2 19.3 18.3
Florida 2,023 12.4 12.0 21.7 20.7
Georgia 824 10.3 10.3 19.3 20.6
Hawaii 41 3.5 3.3 16.5 13.9
Idaho 15 1.2 1.3 16.2 12.6
Illinois 575 5.4 5.3 17.8 17.7
Indiana 201 3.7 3.8 21.7 22.3
Iowa 37 1.5 1.4 17.6 20.0
Kansas 47 2.0 2.1 17.2 13.9
Kentucky 110 3.0 3.0 19.5 18.8
Louisiana 473 12.6 12.7 27.7 28.9
Maine 24 2.1 1.9 18.6 17.6
Maryland 585 12.0 11.4 20.0 18.8
Massachusetts 262 4.7 4.5 14.5 13.1
Michigan 306 3.7 3.6 21.9 21.6
Minnesota 89 2.0 2.0 13.0 13.1
Mississippi 211 8.7 8.7 24.7 26.3
Missouri 184 3.7 3.6 17.2 17.1
Montana 8 1.0 0.9 16.6 19.6
Nebraska 24 1.6 1.6 13.1 17.0
Nevada 132 5.9 5.9 18.3 16.8
New Hampshire 14 1.2 1.1 12.4 16.8
New Jersey 767 10.4 9.7 22.1 19.3
New Mexico 51 3.0 3.1 16.9 14.7
New York 2,168 13.2 12.6 17.9 16.2
North Carolina 543 6.8 6.6 21.1 21.4
North Dakota 4 0.7 0.6 18.3 29.2
Ohio 314 3.3 3.2 17.5 18.0
Oklahoma 122 3.9 4.1 23.7 23.9
Oregon 99 3.0 2.9 16.6 15.5
Pennsylvania 657 6.1 5.8 20.7 19.8
Rhode Island 46 5.1 4.7 21.6 23.1
South Carolina 327 8.4 8.4 19.3 19.4
South Dakota 7 1.0 1.0 17.8 14.1
Tennessee 323 6.1 6.0 20.9 22.0
Texas 1,285 6.2 6.4 18.5 19.3
Utah 24 1.1 1.3 10.6 8.4
Vermont 6 1.1 0.9 12.1 8.9
Virginia 315 4.7 4.5 16.6 15.6
Washington 170 3.0 2.9 15.7 13.8
West Virginia 37 2.3 2.3 21.9 19.9
Wisconsin 98 2.1 2.0 19.1 17.5
Wyoming 6 1.3 1.1 23.4 27.7
Subtotal 16,437 6.4 6.2 18.8 18.0
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 5 4.1 4.5 63.3 30.3
Northern Mariana Islands 1 2.5 1.8 100.0 165.7
Puerto Rico 522 16.9 17.4 31.6 27.4
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 9 10.2 9.7 15.8 12.5
Subtotal 537 15.8 16.3 31.2 27.0
Total 16,974 6.5 6.4 19.0 18.2
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas (cont)
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
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Alabama 282 7.0 7.0 23.9 24.6
Alaska 11 1.9 1.9 16.6 12.8
Arizona 212 3.9 3.9 15.8 15.5
Arkansas 90 3.7 3.8 19.3 17.7
California 1,558 5.0 4.9 13.7 12.4
Colorado 112 2.6 2.5 10.6 8.5
Connecticut 193 6.3 5.7 18.8 16.3
Delaware 77 10.0 9.4 24.3 21.9
District of Columbia 231 41.7 46.6 15.3 14.1
Florida 1,980 12.0 11.5 20.3 19.0
Georgia 846 10.4 10.4 18.8 19.8
Hawaii 50 4.3 4.0 20.1 15.5
Idaho 24 1.9 1.9 24.3 24.3
Illinois 559 5.2 5.1 16.9 16.5
Indiana 169 3.1 3.1 17.7 18.1
Iowa 43 1.7 1.8 19.5 15.8
Kansas 44 1.9 1.8 15.8 15.8
Kentucky 118 3.2 3.2 20.1 19.8
Louisiana 470 12.4 12.6 27.1 27.2
Maine 19 1.7 1.4 14.6 12.7
Maryland 637 12.9 12.3 21.3 19.9
Massachusetts 267 4.7 4.4 14.2 11.8
Michigan 340 4.1 4.1 23.5 22.3
Minnesota 86 1.9 1.8 12.0 12.5
Mississippi 199 8.1 8.4 22.9 23.7
Missouri 191 3.8 3.8 17.3 17.0
Montana 5 0.6 0.7 10.1 5.7
Nebraska 32 2.1 2.1 17.1 16.5
Nevada 160 7.0 7.0 21.4 22.3
New Hampshire 22 1.9 1.8 19.1 15.9
New Jersey 658 8.8 8.1 18.8 16.5
New Mexico 58 3.4 3.5 19.3 18.3
New York 2,043 12.3 11.6 16.7 14.3
North Carolina 525 6.5 6.2 19.5 19.0
North Dakota 3 0.5 0.5 12.2 16.9
Ohio 350 3.6 3.5 18.8 18.9
Oklahoma 115 3.7 3.7 21.7 19.6
Oregon 111 3.4 3.3 18.0 16.0
Pennsylvania 581 5.4 5.1 17.8 16.2
Rhode Island 43 4.8 4.4 19.9 19.6
South Carolina 317 8.0 7.9 20.2 19.2
South Dakota 10 1.5 1.8 23.9 18.0
Tennessee 343 6.4 6.4 21.3 20.7
Texas 1,312 6.3 6.4 18.0 18.8
Utah 25 1.1 1.3 10.8 9.5
Vermont 6 1.1 1.0 10.8 8.3
Virginia 334 4.9 4.7 16.7 15.5
Washington 151 2.6 2.5 13.5 12.2
West Virginia 39 2.5 2.2 22.0 20.2
Wisconsin 86 1.8 1.7 16.4 15.2
Wyoming 2 0.4 0.4 7.8 3.7
Subtotal 16,139 6.2 6.0 17.9 16.7
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 1 0.8 0.9 12.0 7.7
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 445 14.5 14.9 26.9 23.6
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 15 17.0 15.6 26.9 36.1
Subtotal 461 13.7 13.9 26.8 23.8
Total 16,600 6.3 6.1 18.1 16.9
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas (cont)
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
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Alabama 243 6.0 6.1 20.0 19.5
Alaska 16 2.7 2.7 24.1 23.2
Arizona 221 4.1 4.1 15.8 14.4
Arkansas 123 5.0 5.3 25.3 23.2
California 1,616 5.1 5.0 13.8 12.3
Colorado 115 2.6 2.6 10.7 9.2
Connecticut 174 5.7 5.2 16.6 13.2
Delaware 72 9.2 8.5 22.7 19.7
District of Columbia 202 35.8 39.5 13.4 12.9
Florida 2,006 12.0 11.2 20.1 18.1
Georgia 848 10.3 10.2 17.5 17.7
Hawaii 40 3.4 3.1 15.8 10.3
Idaho 14 1.1 1.1 13.7 11.9
Illinois 517 4.8 4.6 15.3 14.5
Indiana 181 3.3 3.3 18.3 18.4
Iowa 43 1.7 1.6 18.8 17.9
Kansas 56 2.4 2.4 19.9 19.1
Kentucky 120 3.3 3.3 18.8 16.7
Louisiana 418 10.9 11.3 23.1 22.5
Maine 30 2.6 2.5 22.2 18.4
Maryland 619 12.5 11.7 20.4 18.2
Massachusetts 269 4.7 4.3 14.0 11.7
Michigan 281 3.4 3.2 19.0 18.4
Minnesota 78 1.7 1.6 10.6 11.7
Mississippi 229 9.3 9.4 25.9 25.6
Missouri 186 3.7 3.6 16.5 16.4
Montana 13 1.5 1.6 24.2 19.8
Nebraska 33 2.2 2.3 17.3 15.2
Nevada 146 6.3 6.1 18.9 16.9
New Hampshire 15 1.3 1.2 12.9 10.8
New Jersey 739 9.9 9.0 20.6 17.8
New Mexico 46 2.7 2.7 15.5 12.8
New York 1,981 11.9 11.1 16.1 13.4
North Carolina 534 6.5 6.3 19.2 17.8
North Dakota 5 0.8 0.8 19.3 22.1
Ohio 313 3.2 3.2 16.3 15.0
Oklahoma 126 4.0 4.1 22.8 21.7
Oregon 112 3.4 3.3 18.1 14.8
Pennsylvania 634 5.8 5.4 19.1 17.3
Rhode Island 34 3.8 3.5 15.5 12.9
South Carolina 320 8.0 8.0 20.4 18.7
South Dakota 9 1.3 1.3 20.0 11.8
Tennessee 336 6.2 6.1 20.5 20.1
Texas 1,230 5.8 5.9 16.2 16.5
Utah 44 2.0 2.2 17.4 15.2
Vermont 8 1.5 1.2 13.3 9.5
Virginia 326 4.7 4.5 16.1 14.6
Washington 165 2.8 2.7 14.2 12.7
West Virginia 42 2.7 2.6 24.0 20.4
Wisconsin 92 1.9 1.8 16.0 14.4
Wyoming 6 1.2 1.3 22.9 17.5
Subtotal 16,026 6.1 5.9 17.3 15.8
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 2 1.6 1.7 24.1 14.0
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 449 14.8 14.6 26.9 22.8
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 11 12.5 11.1 19.5 25.1
Subtotal 462 13.8 13.7 26.7 22.8
Total 16,488 6.2 6.0 17.5 15.9
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas (cont)
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
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Alabama 279 6.9 6.8 22.1 21.8
Alaska 12 2.0 2.0 18.8 17.6
Arizona 220 4.0 4.0 15.0 13.8
Arkansas 120 4.9 5.0 23.2 21.8
California 1,641 5.1 5.0 13.7 12.1
Colorado 148 3.3 3.3 13.3 12.1
Connecticut 186 6.1 5.4 18.2 14.5
Delaware 88 11.2 10.2 27.8 23.5
District of Columbia 211 36.9 39.9 14.5 13.2
Florida 1,972 11.6 10.8 19.0 16.7
Georgia 923 11.1 10.9 19.0 19.3
Hawaii 44 3.7 3.6 17.1 11.4
Idaho 21 1.6 1.6 20.4 29.4
Illinois 526 4.9 4.6 15.2 14.7
Indiana 180 3.3 3.3 17.5 16.9
Iowa 54 2.1 2.0 22.6 19.6
Kansas 46 1.9 2.0 16.0 15.0
Kentucky 119 3.2 3.2 18.1 16.5
Louisiana 424 11.0 11.2 22.3 22.5
Maine 19 1.7 1.2 13.5 10.3
Maryland 595 11.9 11.1 18.8 16.4
Massachusetts 266 4.6 4.2 13.6 11.4
Michigan 288 3.4 3.3 19.4 18.3
Minnesota 97 2.1 2.0 12.8 12.8
Mississippi 238 9.7 9.6 26.0 26.5
Missouri 172 3.4 3.4 14.8 13.4
Montana 10 1.2 1.1 18.1 16.7
Nebraska 30 1.9 2.0 15.0 14.2
Nevada 131 5.6 5.6 15.8 14.7
New Hampshire 13 1.1 1.1 10.7 7.9
New Jersey 667 8.9 8.0 18.5 15.3
New Mexico 67 3.9 3.9 21.4 18.5
New York 1,921 11.5 10.6 15.2 12.6
North Carolina 550 6.6 6.4 19.1 17.6
North Dakota 7 1.1 1.2 23.0 27.0
Ohio 348 3.6 3.5 17.4 16.3
Oklahoma 140 4.4 4.5 24.6 22.4
Oregon 103 3.1 2.9 16.4 14.2
Pennsylvania 649 6.0 5.5 19.2 16.3
Rhode Island 37 4.1 3.6 16.1 13.5
South Carolina 332 8.2 7.8 20.7 19.8
South Dakota 9 1.3 1.4 18.1 11.8
Tennessee 334 6.1 5.9 20.6 21.0
Texas 1,348 6.2 6.3 16.9 16.7
Utah 22 1.0 1.1 8.5 6.7
Vermont 3 0.6 0.4 4.7 3.2
Virginia 311 4.5 4.2 14.9 13.7
Washington 173 2.9 2.8 14.3 12.6
West Virginia 38 2.4 2.3 21.2 21.3
Wisconsin 90 1.9 1.8 15.3 14.6
Wyoming 5 1.0 1.1 18.7 13.7
Subtotal 16,227 6.1 5.9 17.1 15.4
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 2 1.6 1.9 24.1 32.8
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 459 15.2 14.6 27.5 22.4
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 11 12.5 10.9 19.1 16.0
Subtotal 472 14.2 13.6 27.2 22.1
Total 16,699 6.2 6.0 17.3 15.5
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas (cont)
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
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Alabama 277 6.8 6.7 22.3 21.0
Alaska 12 2.0 2.1 18.1 17.3
Arizona 214 3.8 3.7 14.0 12.4
Arkansas 110 4.5 4.6 20.7 18.8
California 1,706 5.3 5.1 13.8 11.8
Colorado 124 2.7 2.7 10.8 8.1
Connecticut 184 6.0 5.2 17.8 13.9
Delaware 70 8.8 7.8 22.0 16.6
District of Columbia 254 43.8 47.4 17.4 15.2
Florida 2,089 12.0 11.1 19.5 16.9
Georgia 831 9.9 9.7 16.5 16.0
Hawaii 32 2.7 2.4 12.1 8.9
Idaho 14 1.0 1.1 13.3 10.1
Illinois 549 5.1 4.8 15.5 13.9
Indiana 177 3.2 3.2 16.5 16.9
Iowa 36 1.4 1.2 14.7 13.6
Kansas 52 2.2 2.1 18.2 17.0
Kentucky 123 3.3 3.3 18.2 16.9
Louisiana 423 10.9 11.0 21.4 20.9
Maine 19 1.7 1.4 13.2 8.2
Maryland 553 11.0 10.1 16.7 14.0
Massachusetts 298 5.1 4.6 14.9 11.6
Michigan 298 3.6 3.3 20.3 19.6
Minnesota 97 2.1 2.0 12.4 12.9
Mississippi 217 8.8 8.8 23.1 22.9
Missouri 171 3.4 3.2 14.3 13.5
Montana 13 1.5 1.4 22.4 19.5
Nebraska 28 1.8 1.9 13.7 13.3
Nevada 128 5.3 5.1 14.6 13.6
New Hampshire 29 2.5 2.2 24.6 19.0
New Jersey 652 8.6 7.8 18.1 14.7
New Mexico 75 4.3 4.4 22.9 20.3
New York 1,804 10.7 9.8 14.2 11.4
North Carolina 562 6.7 6.3 18.9 16.5
North Dakota 8 1.3 1.6 23.6 25.1
Ohio 307 3.2 3.0 14.8 13.4
Oklahoma 143 4.5 4.5 24.3 22.2
Oregon 111 3.3 3.1 16.7 13.2
Pennsylvania 589 5.4 4.9 17.2 14.1
Rhode Island 26 2.9 2.5 11.2 9.9
South Carolina 292 7.1 6.8 17.9 16.5
South Dakota 7 1.0 0.9 13.5 13.7
Tennessee 341 6.2 6.2 20.4 18.9
Texas 1,312 5.9 6.0 15.8 15.3
Utah 31 1.3 1.5 11.6 9.7
Vermont 5 0.9 0.7 7.7 5.2
Virginia 280 4.0 3.7 13.1 11.2
Washington 148 2.5 2.3 11.8 10.9
West Virginia 30 1.9 1.6 17.1 15.3
Wisconsin 84 1.7 1.6 14.1 12.4
Wyoming 4 0.8 0.8 13.8 10.9
Subtotal 15,939 5.9 5.7 16.3 14.3
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 2 1.6 1.8 22.2 13.5
Northern Mariana Islands 1 2.5 3.7 83.3 23.8
Puerto Rico 393 13.2 12.9 23.5 18.9
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 9 10.2 9.8 16.2 11.4
Subtotal 405 12.3 12.0 23.3 18.7
Total 16,344 6.0 5.7 16.5 14.4
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas (cont)
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
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Abbreviations: PLWDH, persons living with diagnosed HIV infection; pop, population.
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death 
was not available, state at death (where a person's death occurred) was used.a Denominator was calculated as (No. PLWDH at the end of [year X–1]) + (No. new diagnoses during year X).
2016
Alabama 265 6.5 6.2 20.6 19.5
Alaska 12 2.0 1.9 17.1 16.2
Arizona 241 4.2 4.0 15.3 13.1
Arkansas 92 3.7 3.6 16.6 15.0
California 1,770 5.4 5.2 13.9 11.7
Colorado 124 2.7 2.6 10.1 8.0
Connecticut 196 6.4 5.5 18.9 13.4
Delaware 54 6.7 5.9 16.8 15.8
District of Columbia 246 41.7 45.4 16.7 13.9
Florida 2,166 12.2 11.2 19.7 16.9
Georgia 824 9.7 9.4 15.8 15.2
Hawaii 35 2.9 2.7 13.3 9.6
Idaho 11 0.8 0.8 10.0 9.2
Illinois 523 4.9 4.6 14.5 13.1
Indiana 198 3.6 3.5 17.9 16.5
Iowa 32 1.2 1.2 12.4 10.5
Kansas 46 1.9 1.9 15.5 13.2
Kentucky 122 3.3 3.2 17.5 15.6
Louisiana 422 10.9 10.9 20.6 19.3
Maine 23 2.0 1.8 14.9 10.1
Maryland 522 10.3 9.5 15.8 13.6
Massachusetts 291 5.0 4.4 14.3 10.3
Michigan 285 3.4 3.1 18.4 17.0
Minnesota 75 1.6 1.5 9.2 9.1
Mississippi 206 8.3 8.2 21.6 20.6
Missouri 198 3.9 3.7 16.2 14.7
Montana 13 1.5 1.6 21.7 14.6
Nebraska 29 1.9 1.8 13.8 13.3
Nevada 150 6.1 5.9 16.2 15.1
New Hampshire 19 1.6 1.7 16.0 12.9
New Jersey 666 8.8 7.8 18.4 14.4
New Mexico 48 2.8 2.5 14.4 12.4
New York 1,868 11.1 10.0 14.5 11.6
North Carolina 520 6.1 5.7 17.0 15.5
North Dakota 4 0.6 0.7 10.6 7.6
Ohio 343 3.5 3.4 15.9 14.3
Oklahoma 122 3.8 3.7 20.2 18.3
Oregon 98 2.8 2.7 14.4 12.0
Pennsylvania 602 5.5 5.0 16.5 14.0
Rhode Island 39 4.3 3.7 16.1 11.8
South Carolina 337 8.1 7.5 20.1 17.8
South Dakota 11 1.6 1.5 20.6 19.7
Tennessee 325 5.8 5.5 19.7 18.8
Texas 1,359 6.0 6.1 15.8 15.4
Utah 47 2.0 2.2 16.9 16.3
Vermont 10 1.8 1.4 15.0 9.5
Virginia 318 4.5 4.2 14.6 12.9
Washington 174 2.9 2.7 13.5 12.5
West Virginia 39 2.5 2.3 21.6 20.4
Wisconsin 86 1.8 1.6 14.1 11.7
Wyoming 5 1.0 1.1 15.9 12.0
Subtotal 16,211 6.0 5.6 16.2 14.1
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 3 2.4 2.9 31.3 31.3
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 398 13.6 12.8 23.9 19.3
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 11 12.5 10.2 19.8 48.2
Subtotal 412 12.7 12.0 23.7 19.8
Total 16,623 6.1 5.7 16.3 14.2
Table 6c. Deaths of persons aged ≥ 13 years with diagnosed HIV infection, by year of death and area of residence, 2010–
2016—United States and 6 dependent areas (cont)
No.
Rate per 
100,000 pop
Age-adjusted rate 
per 100,000 pop
Rate per 
1,000 PLWDHa
Age-adjusted rate 
per 1,000 PLWDH
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death (where a person's death occurred) was used.
tates 
2015 2016
r 
 
a No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa
9,732 7.4 24.1 9,719 7.3 23.8
3,118 2.3 24.8 3,117 2.3 24.6
115 0.2 11.0 93 0.2 10.0
756 1.7 15.1 768 1.7 15.3
1,645 4.1 16.2 1,528 3.8 15.9
4,147 9.6 21.0 3,787 8.8 19.6
6,187 7.0 36.5 6,660 7.3 35.8
51 2.7 35.1 37 1.9 24.6
64 0.4 10.6 81 0.5 12.8
5,751 17.6 26.4 5,675 17.2 25.7
2,119 4.9 17.8 2,152 4.9 17.8
4 0.9 10.1 9 2.0 22.0
4,012 2.3 25.4 4,066 2.4 25.6
849 20.0 32.2 816 18.6 31.0
5,298 — 19.9 5,339 — 19.7
1,911 — 37.8 1,824 — 36.8
1,100 — 34.7 1,102 — 35.1
1,171 — 33.1 1,133 — 32.3
1,261 — 26.6 1,339 — 27.7
1,950 — 21.7 1,950 — 21.3
91 — 20.0 84 — 18.4
68 — 17.6 66 — 16.7
2,909 6.1 21.6 2,924 6.1 21.5
1,427 2.5 24.1 1,424 2.5 23.6
6,361 6.3 27.6 6,282 6.2 27.0
2,153 3.4 20.6 2,206 3.5 20.8
12,850 4.8 24.3 12,836 4.7 24.0
Abbreviation: PLWA, persons living with diagnosed HIV infection ever classified as stage 3 (AIDS).
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at a Denominator was calculated as (No. PLWDH at the end of [year X–1]) + (No. new diagnoses during year X).b Includes Asian/Pacific Islander legacy cases (see Technical Notes).c Hispanics/Latinos can be of any race.d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.g Includes persons of unknown race/ethnicity. 
Table 6d. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death, 2010–2016—United S
2010 2011 2012 2013 2014
No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate pe
1,000
PLWA
Sex 
Male 10,269 8.2 27.9 9,963 7.9 26.4 9,754 7.7 25.3 9,721 7.6 24.6 9,772 7.5 24.5
Female 3,558 2.7 31 3,502 2.6 29.7 3,403 2.5 28.2 3,340 2.5 27.2 3,348 2.5 26.9
Age at death (yr)
13–24 179 0.3 14.3 169 0.3 13.2 145 0.3 11.3 129 0.2 10.1 127 0.2 10.9
25–34 923 2.2 19.0 863 2.1 17.5 874 2.1 17.5 829 1.9 16.4 765 1.8 15.2
35–44 2,755 6.7 20.3 2,420 6.0 19.0 2,115 5.2 17.7 1,917 4.7 16.9 1,827 4.5 17.0
45–54 5,238 11.6 28.1 5,029 11.2 25.9 4,798 10.8 24.1 4,598 10.5 22.9 4,319 10.0 21.6
≥ 55 4,732 6.1 47.4 4,984 6.3 44.5 5,225 6.4 41.6 5,588 6.7 39.9 6,082 7.1 39.4
Race/ethnicity
American Indian/Alaska Native 56 3.1 44.6 47 2.6 36.3 41 2.2 30.6 52 2.8 37.7 44 2.3 31.2
Asianb 55 0.4 11.8 68 0.5 13.8 61 0.5 11.7 65 0.5 11.8 48 0.3 8.3
Black/African American 6,674 21.7 34.0 6,367 20.5 31.6 6,192 19.6 29.9 6,027 18.9 28.4 5,978 18.5 27.8
Hispanic/Latinoc 2,284 6.0 21.5 2,308 5.9 21.1 2,109 5.3 18.8 2,180 5.3 19.0 2,248 5.3 19.2
Native Hawaiian/Other 
Pacific Islander
6 1.5 18.8 6 1.5 17.5 6 1.4 16.8 7 1.6 18.8 6 1.4 15.7
White 4,013 2.4 26.7 3,948 2.3 25.9 4,015 2.4 25.9 3,910 2.3 25.0 3,982 2.3 25.3
Multiple races 739 20.7 30.1 721 19.5 28.7 733 19.2 28.6 819 20.7 31.3 814 19.8 30.9
Transmission categoryd
Male-to-male sexual contact 5,270 — 22.7 5,178 — 21.6 5,135 — 20.7 5,197 — 20.3 5,262 — 20.2
Injection drug use
Male 2,324 — 42.7 2,145 — 39.9 2,074 — 39.0 1,989 — 37.9 2,001 — 38.8
Female 1,319 — 40.1 1,331 — 40.5 1,232 — 37.7 1,260 — 38.7 1,200 — 37.4
Male-to-male sexual contact 
and injection drug use
1,164 — 32.4 1,140 — 31.6 1,098 — 30.4 1,129 — 31.3 1,141 — 31.9
Heterosexual contacte
Male 1,410 — 33.8 1,392 — 32.3 1,346 — 30.2 1,319 — 28.8 1,289 — 27.7
Female 2,186 — 27.9 2,100 — 25.8 2,100 — 25.0 2,023 — 23.4 2,092 — 23.7
Otherf
Male 101 — 23.3 107 — 24.2 101 — 22.6 87 — 19.4 80 — 17.6
Female 54 — 15.7 71 — 20.1 71 — 19.5 57 — 15.3 55 — 14.6
Region of residence
Northeast 3,577 7.7 27.1 3,429 7.3 25.8 3,188 6.7 23.8 3,203 6.7 23.8 3,031 6.3 22.4
Midwest 1,576 2.8 29.5 1,523 2.7 27.6 1,506 2.7 26.7 1,427 2.5 24.7 1,447 2.6 24.7
South 6,656 7.0 33.1 6,448 6.7 30.9 6,403 6.6 29.6 6,321 6.4 28.4 6,490 6.5 28.6
West 2,018 3.4 20.8 2,065 3.4 20.9 2,060 3.4 20.5 2,110 3.4 20.6 2,152 3.5 20.8
Totalg 13,827 5.4 28.6 13,465 5.2 27.2 13,157 5.0 26.0 13,061 5.0 25.2 13,120 4.9 25.0
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death (where a person's death occurred) was used.
tates and 6 dependent areas 
2015 2016
r 
 
a No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa
9,958 7.5 24.3 9,944 7.4 24.0
3,195 2.3 24.9 3,180 2.3 24.5
117 0.2 11.0 98 0.2 10.4
776 1.7 15.3 776 1.7 15.3
1,682 4.1 16.3 1,570 3.8 16.1
4,261 9.8 21.2 3,875 8.9 19.7
6,317 7.0 36.5 6,805 7.4 35.9
51 — 35.0 37 — 24.6
64 — 10.6 81 — 12.8
5,755 — 26.4 5,684 — 25.7
2,416 — 18.9 2,427 — 18.7
5 — 12.1 11 — 25.8
4,012 — 25.3 4,067 — 25.6
850 — 32.2 817 — 31.1
5,357 — 20.0 5,392 — 19.8
2,010 — 38.0 1,914 — 36.9
1,116 — 34.4 1,127 — 35.2
1,195 — 33.2 1,162 — 32.7
1,303 — 26.7 1,387 — 27.9
2,010 — 21.8 1,986 — 21.2
92 — 19.8 88 — 18.9
69 — 17.5 68 — 16.8
2,909 6.1 21.6 2,924 6.1 21.5
1,427 2.5 24.1 1,424 2.5 23.6
6,361 6.3 27.6 6,282 6.2 27.0
2,153 3.4 20.6 2,206 3.5 20.8
303 9.2 31.8 288 8.9 30.6
13,153 4.8 24.4 13,124 4.8 24.1
Abbreviation: PLWA, persons living with diagnosed HIV infection ever classified as stage 3 (AIDS).
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at a Denominator was calculated as (No. PLWDH at the end of [year X–1]) + (No. new diagnoses during year X).b Includes Asian/Pacific Islander legacy cases (see Technical Notes).c Hispanics/Latinos can be of any race.d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.g Includes persons of unknown race/ethnicity. 
Table 6e. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death, 2010–2016—United S
2010 2011 2012 2013 2014
No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate per 
1,000 
PLWAa No.
Rate per 
100,000 
population
Rate pe
1,000
PLWA
Sex 
Male 10,582 8.4 28.2 10,275 8.0 26.7 10,001 7.7 25.5 9,968 7.7 24.8 10,021 7.6 24.7
Female 3,676 2.8 31.2 3,604 2.7 29.9 3,491 2.6 28.3 3,423 2.5 27.2 3,454 2.5 27.1
Age at death (yr)
13–24 182 0.3 14.3 172 0.3 13.3 149 0.3 11.5 134 0.3 10.3 129 0.2 10.9
25–34 952 2.3 19.3 887 2.1 17.8 899 2.1 17.8 846 2.0 16.6 781 1.8 15.4
35–44 2,850 6.9 20.6 2,504 6.1 19.3 2,180 5.3 17.9 1,961 4.8 17.0 1,868 4.6 17.1
45–54 5,418 11.9 28.4 5,204 11.5 26.3 4,923 11.0 24.3 4,727 10.7 23.1 4,437 10.1 21.8
≥ 55 4,856 6.2 47.5 5,112 6.3 44.6 5,341 6.4 41.6 5,723 6.7 40.0 6,260 7.2 39.7
Race/ethnicity
American Indian/Alaska Native 56 — 44.6 47 — 36.3 41 — 30.6 52 — 37.7 44 — 31.2
Asianb 56 — 12.0 70 — 14.1 62 — 11.8 65 — 11.7 49 — 8.5
Black/African American 6,680 — 34.0 6,374 — 31.6 6,201 — 29.9 6,030 — 28.4 5,982 — 27.8
Hispanic/Latinoc 2,706 — 23.5 2,709 — 22.9 2,432 — 20.0 2,501 — 20.1 2,598 — 20.6
Native Hawaiian/Other 
Pacific Islander
7 — 20.9 9 — 25.2 6 — 16.2 9 — 23.4 6 — 15.3
White 4,014 — 26.7 3,948 — 25.9 4,016 — 25.9 3,912 — 25.0 3,982 — 25.3
Multiple races 739 — 30.1 722 — 28.7 734 — 28.6 821 — 31.3 814 — 30.9
Transmission categoryd
Male-to-male sexual contact 5,330 — 22.8 5,249 — 21.7 5,175 — 20.7 5,262 — 20.4 5,322 — 20.2
Injection drug use
Male 2,481 — 43.4 2,295 — 40.7 2,195 — 39.4 2,083 — 37.9 2,111 — 39.1
Female 1,353 — 40.2 1,371 — 40.8 1,258 — 37.6 1,290 — 38.8 1,237 — 37.7
Male-to-male sexual contact 
and injection drug use
1,198 — 32.8 1,173 — 32.0 1,125 — 30.7 1,154 — 31.5 1,164 — 32.1
Heterosexual contacte
Male 1,471 — 34.2 1,450 — 32.6 1,402 — 30.6 1,380 — 29.3 1,342 — 27.9
Female 2,267 — 28.2 2,160 — 25.9 2,160 — 25.0 2,075 — 23.4 2,161 — 23.9
Otherf
Male 102 — 23.1 108 — 23.9 104 — 22.8 89 — 19.4 82 — 17.7
Female 56 — 15.9 73 — 20.1 74 — 19.8 58 — 15.2 56 — 14.5
Region of residence
Northeast 3,577 7.7 27.1 3,429 7.3 25.8 3,188 6.7 23.8 3,203 6.7 23.8 3,031 6.3 22.4
Midwest 1,576 2.8 29.5 1,523 2.7 27.6 1,506 2.7 26.7 1,427 2.5 24.7 1,447 2.6 24.7
South 6,656 7.0 33.1 6,448 6.7 30.9 6,403 6.6 29.6 6,321 6.4 28.4 6,490 6.5 28.6
West 2,018 3.4 20.8 2,065 3.4 20.9 2,060 3.4 20.5 2,110 3.4 20.6 2,152 3.5 20.8
U.S. dependent areas 431 12.6 44.7 414 12.2 43.1 335 9.9 35.2 330 9.8 34.3 355 10.7 36.9
Totalg 14,258 5.5 28.9 13,879 5.3 27.5 13,492 5.1 26.1 13,391 5.0 25.4 13,475 5.0 25.3
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas 
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
2010
Alabama 188 4.7 4.8 40.0 41.1
Alaska 12 2.1 2.1 31.3 35.2
Arizona 170 3.3 3.3 25.9 23.6
Arkansas 87 3.6 3.7 39.9 42.7
California 1,280 4.2 4.2 19.3 19.1
Colorado 115 2.8 2.7 25.4 22.6
Connecticut 183 6.1 5.6 26.9 22.6
Delaware 62 8.2 8.0 32.3 31.8
District of Columbia 221 41.6 46.2 26.7 24.7
Florida 1,721 10.7 10.4 32.8 31.6
Georgia 742 9.4 9.4 32.6 33.1
Hawaii 33 2.9 2.8 21.3 16.6
Idaho 12 1.0 1.1 26.5 22.5
Illinois 541 5.1 5.1 31.5 34.0
Indiana 148 2.8 2.8 30.4 27.3
Iowa 23 0.9 0.9 18.9 17.2
Kansas 40 1.7 1.7 26.3 34.5
Kentucky 95 2.6 2.6 31.9 29.7
Louisiana 370 9.9 10.2 41.6 40.5
Maine 18 1.6 1.5 25.4 19.8
Maryland 511 10.6 10.1 31.9 30.0
Massachusetts 229 4.1 3.9 21.8 19.4
Michigan 253 3.1 3.1 33.9 32.2
Minnesota 67 1.5 1.5 21.2 19.7
Mississippi 156 6.4 6.6 40.5 41.4
Missouri 175 3.5 3.6 30.6 30.8
Montana 10 1.2 1.2 37.3 31.5
Nebraska 26 1.7 1.8 26.8 28.8
Nevada 101 4.5 4.5 27.5 25.2
New Hampshire 18 1.6 1.4 28.7 25.9
New Jersey 650 8.8 8.3 34.4 30.8
New Mexico 47 2.8 2.8 25.9 23.8
New York 1,870 11.4 11.0 25.1 21.1
North Carolina 418 5.3 5.2 38.0 34.3
North Dakota 5 0.9 1.0 47.6 54.2
Ohio 218 2.3 2.3 25.5 26.4
Oklahoma 84 2.7 2.8 32.6 28.3
Oregon 80 2.5 2.5 22.3 19.2
Pennsylvania 563 5.2 5.0 30.8 29.1
Rhode Island 33 3.7 3.7 25.5 27.8
South Carolina 288 7.5 7.5 35.4 32.3
South Dakota 6 0.9 1.0 36.8 34.5
Tennessee 297 5.6 5.6 38.8 43.1
Texas 1,154 5.7 5.9 30.8 30.5
Utah 21 1.0 1.2 17.0 11.8
Vermont 13 2.4 2.0 48.0 31.1
Virginia 240 3.6 3.5 26.3 23.8
Washington 130 2.3 2.3 20.7 18.4
West Virginia 22 1.4 1.4 23.8 22.5
Wisconsin 74 1.6 1.5 29.2 28.8
Wyoming 7 1.5 1.5 49.0 75.7
Subtotal 13,827 5.4 5.3 28.6 27.3
U.S. dependent areas
American Samoa 1 2.6 2.8 1,000.0 199.8
Guam 2 1.6 1.7 58.8 31.7
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 422 13.6 14.1 45.5 39.3
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 6 6.8 7.5 18.6 18.2
Subtotal 431 12.6 13.1 44.7 38.7
Total 14,258 5.5 5.4 28.9 27.5
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Alabama 184 4.6 4.6 36.2 39.6
Alaska 9 1.5 1.5 23.2 17.5
Arizona 157 3.0 3.0 23.3 22.2
Arkansas 92 3.8 4.0 41.5 46.3
California 1,341 4.3 4.3 19.9 18.1
Colorado 107 2.5 2.5 22.8 19.8
Connecticut 181 6.0 5.5 26.8 23.4
Delaware 56 7.4 6.9 28.7 20.8
District of Columbia 228 42.0 46.2 27.8 25.9
Florida 1,729 10.6 10.3 32.2 31.2
Georgia 667 8.3 8.3 28.7 29.6
Hawaii 32 2.8 2.6 20.9 16.7
Idaho 12 0.9 1.0 25.2 17.3
Illinois 459 4.3 4.2 26.1 23.2
Indiana 171 3.2 3.2 33.6 32.7
Iowa 29 1.1 1.1 23.1 29.8
Kansas 41 1.8 1.8 26.3 19.0
Kentucky 92 2.5 2.5 30.0 27.6
Louisiana 406 10.8 10.9 43.4 42.3
Maine 15 1.3 1.1 21.2 17.9
Maryland 486 10.0 9.5 29.6 25.9
Massachusetts 222 3.9 3.8 20.5 18.5
Michigan 244 3.0 2.9 32.0 27.0
Minnesota 70 1.6 1.6 21.2 23.2
Mississippi 156 6.4 6.4 38.1 37.7
Missouri 156 3.1 3.0 26.4 25.8
Montana 7 0.8 0.8 23.3 23.7
Nebraska 20 1.3 1.4 20.0 22.5
Nevada 111 5.0 5.0 29.5 26.2
New Hampshire 13 1.2 1.0 20.6 33.4
New Jersey 606 8.2 7.7 32.0 26.6
New Mexico 44 2.6 2.6 23.8 20.5
New York 1,829 11.1 10.6 24.4 21.8
North Carolina 372 4.6 4.5 32.6 31.5
North Dakota 4 0.7 0.6 37.4 40.4
Ohio 246 2.6 2.5 27.7 28.0
Oklahoma 94 3.0 3.2 35.6 36.6
Oregon 84 2.6 2.5 22.8 22.6
Pennsylvania 519 4.8 4.6 28.0 25.5
Rhode Island 38 4.2 3.8 29.3 25.8
South Carolina 283 7.3 7.2 28.5 28.3
South Dakota 5 0.7 0.7 27.3 28.6
Tennessee 242 4.5 4.5 30.9 29.4
Texas 1,093 5.3 5.4 28.0 27.7
Utah 16 0.7 0.9 12.6 8.8
Vermont 6 1.1 0.9 21.3 13.0
Virginia 238 3.5 3.4 25.5 23.6
Washington 140 2.5 2.4 22.0 17.6
West Virginia 30 1.9 1.8 30.6 24.8
Wisconsin 78 1.6 1.6 29.5 25.6
Wyoming 5 1.1 0.9 34.7 36.2
Subtotal 13,465 5.2 5.1 27.2 25.4
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 5 4.1 4.5 151.5 66.6
Northern Mariana Islands 1 2.5 1.8 333.3 0.0
Puerto Rico 399 12.9 13.3 43.1 37.1
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 9 10.2 9.7 28.7 20.1
Subtotal 414 12.2 12.5 43.1 36.9
Total 13,879 5.3 5.2 27.5 25.6
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas (cont)
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
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Alabama 202 5.0 5.1 38.1 38.4
Alaska 8 1.3 1.3 21.0 11.6
Arizona 168 3.1 3.1 24.0 24.8
Arkansas 73 3.0 3.1 32.3 30.9
California 1,308 4.2 4.2 19.1 17.6
Colorado 86 2.0 2.0 17.9 14.8
Connecticut 171 5.6 5.1 25.4 23.4
Delaware 70 9.1 8.5 35.4 28.9
District of Columbia 191 34.5 38.6 22.7 20.8
Florida 1,682 10.2 9.8 30.0 27.9
Georgia 677 8.3 8.3 27.7 28.3
Hawaii 44 3.8 3.6 28.8 21.4
Idaho 17 1.3 1.3 33.5 50.1
Illinois 435 4.1 4.0 24.3 21.5
Indiana 145 2.7 2.6 27.8 28.3
Iowa 36 1.4 1.5 27.4 22.2
Kansas 39 1.7 1.6 24.9 22.8
Kentucky 88 2.4 2.4 28.0 27.0
Louisiana 393 10.4 10.6 41.0 38.6
Maine 17 1.5 1.3 23.7 23.8
Maryland 508 10.3 9.8 30.4 27.5
Massachusetts 222 3.9 3.7 19.8 17.2
Michigan 274 3.3 3.3 35.1 31.8
Minnesota 68 1.5 1.4 19.7 18.8
Mississippi 145 5.9 6.2 34.7 31.8
Missouri 154 3.1 3.1 25.4 22.8
Montana 4 0.5 0.6 13.2 7.5
Nebraska 24 1.6 1.5 23.8 19.4
Nevada 136 6.0 5.9 35.1 40.5
New Hampshire 16 1.4 1.2 25.1 18.2
New Jersey 538 7.2 6.6 28.4 24.9
New Mexico 42 2.5 2.6 22.8 19.1
New York 1,714 10.3 9.7 22.8 19.1
North Carolina 364 4.5 4.3 29.8 27.3
North Dakota 3 0.5 0.5 25.9 29.7
Ohio 254 2.6 2.5 27.8 25.4
Oklahoma 93 3.0 3.0 34.1 29.1
Oregon 90 2.7 2.7 24.1 19.3
Pennsylvania 473 4.4 4.2 25.1 21.7
Rhode Island 34 3.8 3.5 26.0 23.5
South Carolina 266 6.7 6.6 29.5 27.3
South Dakota 7 1.0 1.3 35.9 26.8
Tennessee 259 4.8 4.9 31.6 28.3
Texas 1,105 5.3 5.4 27.2 26.4
Utah 24 1.1 1.2 18.3 14.6
Vermont 3 0.6 0.6 9.8 7.8
Virginia 255 3.7 3.6 25.6 23.5
Washington 132 2.3 2.2 20.4 16.5
West Virginia 32 2.0 1.8 30.9 25.8
Wisconsin 67 1.4 1.3 24.8 20.2
Wyoming 1 0.2 0.2 6.7 2.6
Subtotal 13,157 5.0 4.9 26.0 23.7
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 1 0.8 0.9 33.3 25.0
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 321 10.5 10.7 35.0 32.3
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 13 14.7 13.8 41.7 63.0
Subtotal 335 9.9 10.1 35.2 33.4
Total 13,492 5.1 5.0 26.1 23.8
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas (cont)
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
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Alabama 186 4.6 4.7 34.0 32.5
Alaska 13 2.2 2.2 34.3 34.4
Arizona 179 3.3 3.3 24.8 22.1
Arkansas 93 3.8 4.1 39.3 36.7
California 1,347 4.2 4.2 19.3 17.2
Colorado 96 2.2 2.1 19.6 19.1
Connecticut 156 5.1 4.6 22.9 17.5
Delaware 62 8.0 7.2 31.2 27.4
District of Columbia 166 29.4 32.4 19.8 18.5
Florida 1,678 10.0 9.4 29.3 26.0
Georgia 658 8.0 8.0 24.8 23.7
Hawaii 29 2.5 2.3 18.7 11.5
Idaho 11 0.8 0.8 21.0 16.5
Illinois 402 3.7 3.6 22.2 19.0
Indiana 152 2.8 2.8 28.6 27.7
Iowa 38 1.5 1.4 28.1 23.3
Kansas 42 1.8 1.8 26.8 24.6
Kentucky 90 2.5 2.5 26.7 23.2
Louisiana 357 9.3 9.7 35.8 34.3
Maine 24 2.1 1.9 32.2 25.1
Maryland 500 10.1 9.4 29.5 24.4
Massachusetts 220 3.8 3.5 19.4 16.1
Michigan 230 2.8 2.7 28.9 25.3
Minnesota 65 1.4 1.4 18.5 18.4
Mississippi 178 7.2 7.4 40.6 39.0
Missouri 153 3.0 3.0 24.9 24.3
Montana 12 1.4 1.4 36.6 25.9
Nebraska 27 1.8 1.9 26.2 22.2
Nevada 118 5.1 5.0 29.8 25.9
New Hampshire 12 1.1 1.0 18.8 13.4
New Jersey 565 7.6 6.9 29.1 25.6
New Mexico 39 2.3 2.3 21.5 17.7
New York 1,677 10.1 9.4 22.4 17.7
North Carolina 395 4.8 4.7 31.0 28.5
North Dakota 3 0.5 0.5 23.3 22.1
Ohio 234 2.4 2.4 24.9 21.7
Oklahoma 107 3.4 3.4 38.0 35.9
Oregon 95 2.9 2.8 25.6 19.9
Pennsylvania 511 4.7 4.4 26.9 23.3
Rhode Island 31 3.4 3.1 23.4 16.3
South Carolina 253 6.3 6.3 28.3 25.2
South Dakota 5 0.7 0.8 24.9 13.9
Tennessee 258 4.8 4.7 30.4 27.5
Texas 1,049 4.9 5.0 24.9 24.9
Utah 31 1.4 1.6 22.0 17.3
Vermont 7 1.3 1.0 21.5 12.8
Virginia 260 3.8 3.6 26.1 22.6
Washington 134 2.3 2.2 20.2 15.8
West Virginia 31 2.0 1.9 30.5 22.9
Wisconsin 76 1.6 1.5 25.1 21.5
Wyoming 6 1.2 1.3 39.2 35.2
Subtotal 13,061 5.0 4.8 25.2 22.4
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 2 1.6 1.7 66.7 44.3
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 320 10.5 10.3 34.5 31.3
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 8 9.1 8.3 25.9 45.0
Subtotal 330 9.8 9.7 34.3 32.0
Total 13,391 5.0 4.9 25.4 22.6
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas (cont)
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
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Alabama 210 5.2 5.1 37.0 36.3
Alaska 10 1.7 1.7 28.2 24.9
Arizona 172 3.1 3.1 23.1 22.1
Arkansas 96 3.9 4.0 38.8 34.6
California 1,387 4.3 4.2 19.9 17.5
Colorado 121 2.7 2.7 24.0 28.5
Connecticut 161 5.2 4.7 24.5 20.0
Delaware 70 8.9 8.0 35.4 27.6
District of Columbia 173 30.3 32.8 21.8 19.5
Florida 1,659 9.7 9.1 28.2 24.7
Georgia 740 8.9 8.8 28.5 26.7
Hawaii 36 3.0 3.0 23.1 15.0
Idaho 16 1.2 1.2 30.4 25.2
Illinois 425 4.0 3.7 23.2 20.4
Indiana 142 2.6 2.6 26.3 25.1
Iowa 49 1.9 1.9 35.2 27.0
Kansas 35 1.5 1.5 21.9 20.4
Kentucky 87 2.4 2.4 25.3 22.8
Louisiana 342 8.9 9.1 33.2 33.3
Maine 15 1.3 0.9 19.8 13.2
Maryland 483 9.6 8.9 27.7 22.0
Massachusetts 215 3.7 3.4 18.8 15.8
Michigan 219 2.6 2.5 27.5 23.4
Minnesota 70 1.5 1.5 19.3 19.4
Mississippi 192 7.8 7.8 42.0 38.6
Missouri 135 2.7 2.6 21.6 18.6
Montana 7 0.8 0.8 21.3 17.5
Nebraska 23 1.5 1.6 21.7 16.1
Nevada 107 4.5 4.6 25.4 25.8
New Hampshire 9 0.8 0.7 13.9 12.5
New Jersey 514 6.8 6.1 26.6 23.1
New Mexico 52 3.0 3.1 28.0 24.1
New York 1,579 9.4 8.7 20.9 16.8
North Carolina 402 4.8 4.7 30.4 26.9
North Dakota 6 1.0 1.1 39.7 38.0
Ohio 260 2.7 2.6 26.9 24.0
Oklahoma 116 3.6 3.7 40.1 31.2
Oregon 81 2.4 2.3 21.7 21.0
Pennsylvania 502 4.6 4.3 26.2 21.7
Rhode Island 33 3.6 3.1 24.6 19.1
South Carolina 275 6.8 6.5 30.9 29.2
South Dakota 6 0.9 0.9 26.4 19.5
Tennessee 262 4.8 4.6 31.2 29.9
Texas 1,117 5.1 5.3 25.8 23.6
Utah 17 0.7 0.9 12.0 8.1
Vermont 3 0.6 0.4 8.8 5.0
Virginia 237 3.4 3.2 23.4 21.7
Washington 141 2.4 2.3 20.6 16.8
West Virginia 29 1.8 1.7 28.2 28.8
Wisconsin 77 1.6 1.5 25.3 27.5
Wyoming 5 1.0 1.1 32.9 22.0
Subtotal 13,120 4.9 4.7 25.0 22.1
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 1 0.8 0.9 34.5 37.5
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 349 11.6 11.0 37.6 31.7
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 5 5.7 4.4 16.0 10.6
Subtotal 355 10.7 10.1 36.9 30.9
Total 13,475 5.0 4.8 25.3 22.2
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas (cont)
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
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Alabama 211 5.2 5.2 37.3 33.4
Alaska 9 1.5 1.6 24.2 20.8
Arizona 174 3.1 3.0 22.9 20.5
Arkansas 83 3.4 3.5 33.2 30.9
California 1,415 4.4 4.3 20.1 16.7
Colorado 103 2.3 2.2 19.9 14.6
Connecticut 159 5.2 4.5 24.2 21.9
Delaware 57 7.1 6.4 28.8 19.9
District of Columbia 191 32.9 35.9 24.1 22.2
Florida 1,737 10.0 9.3 29.0 25.7
Georgia 654 7.8 7.6 24.8 22.4
Hawaii 27 2.3 2.1 17.6 12.4
Idaho 7 0.5 0.5 13.3 10.0
Illinois 453 4.2 4.0 24.6 20.5
Indiana 138 2.5 2.5 25.0 28.8
Iowa 29 1.1 1.0 20.9 17.2
Kansas 44 1.8 1.8 28.7 23.6
Kentucky 93 2.5 2.5 26.8 23.8
Louisiana 350 9.1 9.1 33.4 32.8
Maine 15 1.3 1.2 19.7 10.9
Maryland 460 9.1 8.4 25.3 19.9
Massachusetts 225 3.9 3.5 19.6 14.9
Michigan 238 2.8 2.6 30.5 28.0
Minnesota 68 1.5 1.4 18.2 23.7
Mississippi 175 7.1 7.1 37.7 34.9
Missouri 127 2.5 2.4 19.8 18.1
Montana 11 1.3 1.2 32.0 27.3
Nebraska 22 1.4 1.4 20.3 26.3
Nevada 104 4.3 4.2 23.8 22.7
New Hampshire 24 2.1 1.8 38.2 28.2
New Jersey 524 6.9 6.3 27.3 22.6
New Mexico 68 3.9 3.9 35.9 37.3
New York 1,477 8.8 8.0 19.6 15.8
North Carolina 407 4.8 4.6 29.8 23.9
North Dakota 7 1.1 1.3 40.5 39.3
Ohio 230 2.4 2.3 23.1 20.6
Oklahoma 122 3.8 3.9 41.5 39.1
Oregon 88 2.6 2.4 22.7 16.5
Pennsylvania 464 4.3 3.9 24.1 18.0
Rhode Island 18 2.0 1.6 13.4 10.4
South Carolina 232 5.6 5.4 25.8 24.7
South Dakota 6 0.9 0.7 25.6 26.0
Tennessee 252 4.6 4.6 29.6 28.2
Texas 1,089 4.9 5.0 24.6 21.9
Utah 27 1.2 1.3 18.7 13.4
Vermont 3 0.6 0.4 8.5 5.1
Virginia 220 3.1 2.9 21.5 17.9
Washington 119 2.0 1.9 17.1 16.4
West Virginia 28 1.8 1.5 28.1 22.0
Wisconsin 65 1.3 1.2 21.6 18.9
Wyoming 1 0.2 0.2 6.5 2.8
Subtotal 12,850 4.8 4.6 24.3 21.1
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 2 1.6 1.8 60.6 32.6
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 295 9.9 9.6 32.2 29.0
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 6 6.8 6.2 19.4 13.2
Subtotal 303 9.2 8.9 31.8 28.4
Total 13,153 4.8 4.6 24.4 21.2
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas (cont)
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
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Abbreviations: PLWA, persons living with diagnosed HIV infection ever classified as stage 3 (AIDS); pop, population.
Note. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS) may be due to any cause. Data are based on residence at death. When 
information on residence at death was not available, state at death (where a person's death occurred) was used.a Denominator was calculated as (No. PLWA at the end of [year X–1]) + (No. new diagnoses during year X).
2016
Alabama 198 4.9 4.7 34.3 32.4
Alaska 7 1.2 1.1 18.0 14.2
Arizona 193 3.4 3.2 25.0 19.8
Arkansas 66 2.7 2.5 25.8 20.2
California 1,453 4.4 4.3 20.4 17.5
Colorado 96 2.1 2.0 17.5 13.4
Connecticut 161 5.2 4.6 24.7 16.8
Delaware 46 5.7 5.0 23.2 25.7
District of Columbia 189 32.1 35.0 23.9 19.3
Florida 1,762 10 9.1 29.2 24.8
Georgia 645 7.6 7.4 24.1 22.0
Hawaii 28 2.3 2.2 18.5 12.9
Idaho 8 0.6 0.5 14.4 10.9
Illinois 409 3.8 3.6 22.2 18.6
Indiana 159 2.9 2.8 28.4 24.6
Iowa 28 1.1 1.0 19.1 15.3
Kansas 34 1.4 1.4 21.9 16.6
Kentucky 94 2.5 2.4 26.5 22.6
Louisiana 333 8.6 8.6 31.2 29.4
Maine 16 1.4 1.2 20.2 11.7
Maryland 423 8.4 7.7 23.9 19.9
Massachusetts 216 3.7 3.2 18.8 12.2
Michigan 224 2.7 2.5 27.5 22.8
Minnesota 58 1.3 1.2 15.2 14.8
Mississippi 164 6.6 6.5 34.8 30.5
Missouri 165 3.2 3.0 25.6 22.0
Montana 9 1.0 1.1 26.0 15.7
Nebraska 26 1.7 1.6 24.0 21.4
Nevada 117 4.8 4.6 25.6 25.9
New Hampshire 14 1.2 1.2 22.4 17.7
New Jersey 484 6.4 5.7 25.7 21.2
New Mexico 41 2.4 2.1 21.8 17.6
New York 1,535 9.1 8.2 20.4 16.3
North Carolina 381 4.5 4.2 27.4 25.6
North Dakota 3 0.5 0.5 16.2 10.2
Ohio 246 2.5 2.5 23.8 19.3
Oklahoma 93 2.9 2.8 31.2 25.7
Oregon 78 2.3 2.1 19.9 13.9
Pennsylvania 454 4.2 3.8 22.2 18.9
Rhode Island 34 3.7 3.2 24.7 14.7
South Carolina 276 6.6 6.2 30.3 25.1
South Dakota 6 0.9 0.8 24.9 23.6
Tennessee 242 4.3 4.2 28.9 25.3
Texas 1,089 4.8 4.9 24.2 21.9
Utah 36 1.5 1.7 24.6 19.3
Vermont 10 1.8 1.4 27.7 14.8
Virginia 248 3.5 3.3 23.9 21.8
Washington 136 2.2 2.0 19.3 17.5
West Virginia 33 2.1 1.9 32.4 25.8
Wisconsin 66 1.4 1.2 21.7 17.0
Wyoming 4 0.8 0.9 22.7 12.5
Subtotal 12,836 4.7 4.5 24.0 20.4
U.S. dependent areas
American Samoa 0 0.0 0.0 0.0 0.0
Guam 3 2.4 2.9 81.1 69.1
Northern Mariana Islands 0 0.0 0.0 0.0 0.0
Puerto Rico 274 9.3 8.8 30.2 27.5
Republic of Palau 0 0.0 0.0 0.0 0.0
U.S. Virgin Islands 11 12.5 10.2 35.3 99.5
Subtotal 288 8.9 8.4 30.6 30.5
Total 13,124 4.8 4.5 24.1 20.6
Table 6f. Deaths of persons aged ≥ 13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death 
and area of residence, 2010–2016—United States and 6 dependent areas (cont)
No.
Rate per 100,000 
pop
Age-adjusted rate 
per 100,000 pop
Rate per 1,000 
PLWAa
Age-adjusted rate 
per 1,000 PLWA
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Abbreviation: asterisk (*) indicates sample too small (< 600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data are based on residence at diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.a Hispanics/Latinos can be of any race.b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Table 7a. Persons surviving > 3 years after a diagnosis of HIV infection during 2008–2013, by year of diagnosis and 
selected characteristics—United States  
Proportion survived > 3 years
No. 2008 2009 2010 2011 2012 2013
Sex 
Male 199,874 0.92 0.93 0.94 0.94 0.94 0.94
Female 55,379 0.92 0.92 0.93 0.93 0.93 0.93
Age at diagnosis (yr)
13–24 52,955 0.98 0.98 0.99 0.99 0.99 0.99
25–34 70,896 0.96 0.97 0.97 0.97 0.97 0.97
35–44 59,549 0.93 0.93 0.94 0.94 0.95 0.94
45–54 48,358 0.88 0.88 0.89 0.89 0.90 0.90
≥ 55 23,495 0.76 0.78 0.79 0.8 0.81 0.81
Race/ethnicity
American Indian/Alaska Native 901 0.89 0.87 0.88 0.91 0.92 0.90
Asian 4,150 0.93 0.94 0.95 0.96 0.97 0.96
Black/African American 115,310 0.91 0.92 0.93 0.94 0.94 0.94
Hispanic/Latinoa 55,055 0.94 0.94 0.95 0.95 0.95 0.95
Native Hawaiian/Other 
Pacific Islander
292 * * * * * *
White 68,280 0.92 0.93 0.93 0.93 0.94 0.93
Multiple races 11,265 0.94 0.94 0.94 0.95 0.95 0.94
Transmission categoryb
Male-to-male sexual contact 154,963 0.94 0.94 0.95 0.95 0.96 0.95
Injection drug use
Male 11,017 0.84 0.85 0.85 0.86 0.86 0.85
Female 8,344 0.89 0.88 0.89 0.89 0.89 0.88
Male-to-male sexual contact 
and injection drug use
9,819 0.93 0.94 0.93 0.95 0.94 0.94
Heterosexual contactc
Male 23,805 0.88 0.88 0.90 0.90 0.90 0.89
Female 46,798 0.93 0.93 0.94 0.93 0.94 0.93
Totald 255,253 0.92 0.93 0.93 0.94 0.94 0.94
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Abbreviation: asterisk (*) indicates sample too small (< 600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data are based on residence at diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.a Hispanics/Latinos can be of any race.b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Table 7b. Persons surviving > 3 years after a diagnosis of HIV infection during 2008–2013, by year of diagnosis and 
selected characteristics—United States and 6 dependent areas  
Proportion survived > 3 years
No. 2008 2009 2010 2011 2012 2013
Sex 
Male 203,389 0.92 0.93 0.93 0.94 0.94 0.94
Female 56,680 0.92 0.92 0.93 0.92 0.93 0.92
Age at diagnosis (yr)
13–24 53,593 0.98 0.98 0.99 0.99 0.99 0.99
25–34 72,125 0.96 0.96 0.97 0.97 0.97 0.97
35–44 60,783 0.93 0.93 0.94 0.94 0.95 0.94
45–54 49,438 0.88 0.88 0.89 0.89 0.90 0.90
≥ 55 24,130 0.75 0.77 0.78 0.80 0.81 0.80
Race/ethnicity
American Indian/Alaska Native 901 0.89 0.87 0.88 0.91 0.92 0.90
Asian 4,155 0.93 0.94 0.95 0.96 0.97 0.96
Black/African American 115,402 0.91 0.92 0.93 0.94 0.94 0.94
Hispanic/Latinoa 59,740 0.93 0.93 0.94 0.94 0.94 0.94
Native Hawaiian/Other 
Pacific Islander
304 * * * * * *
White 68,296 0.92 0.93 0.93 0.93 0.94 0.93
Multiple races 11,271 0.94 0.94 0.94 0.95 0.95 0.94
Transmission categoryb
Male-to-male sexual contact 156,643 0.94 0.94 0.95 0.95 0.96 0.95
Injection drug use
Male 11,816 0.84 0.84 0.84 0.84 0.85 0.84
Female 8,536 0.89 0.88 0.89 0.89 0.89 0.88
Male-to-male sexual contact 
and injection drug use
9,984 0.93 0.94 0.93 0.95 0.94 0.94
Heterosexual contactc
Male 24,670 0.87 0.88 0.89 0.89 0.90 0.89
Female 47,904 0.93 0.93 0.93 0.93 0.94 0.93
Totald 260,069 0.92 0.93 0.93 0.93 0.94 0.94
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Abbreviation: asterisk (*) indicates sample too small (< 600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data are based on residence at diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.
Table 7c. Persons surviving > 3 years after a diagnosis of HIV infection during 2008–2013, by year of diagnosis and 
area of residence—United States and 6 dependent areas  
Proportion survived > 3 years
No. 2008 2009 2010 2011 2012 2013
Alabama 4,064 0.92 0.90 0.93 0.93 0.93 0.93
Alaska 169 * * * * * *
Arizona 3,803 0.92 0.91 0.94 0.93 0.92 0.94
Arkansas 1,502 0.88 0.88 0.94 0.91 0.96 0.92
California 30,790 0.94 0.94 0.94 0.94 0.95 0.94
Colorado 2,271 0.95 0.94 0.96 0.95 0.97 0.97
Connecticut 2,034 0.96 0.95 0.96 0.93 0.95 0.94
Delaware 784 0.91 0.89 0.91 0.94 0.93 0.96
District of Columbia 4,328 0.93 0.93 0.95 0.95 0.96 0.97
Florida 28,673 0.91 0.92 0.93 0.92 0.94 0.93
Georgia 16,509 0.91 0.92 0.93 0.93 0.93 0.94
Hawaii 531 * * * * * *
Idaho 239 * * * * * *
Illinois 10,114 0.93 0.93 0.93 0.95 0.96 0.95
Indiana 2,832 0.92 0.92 0.93 0.94 0.95 0.93
Iowa 681 0.93 0.90 0.89 0.95 0.93 0.92
Kansas 860 0.93 0.93 0.95 0.96 0.95 0.90
Kentucky 2,049 0.90 0.93 0.92 0.93 0.93 0.92
Louisiana 6,703 0.89 0.91 0.93 0.93 0.92 0.94
Maine 285 * * * * * *
Maryland 9,501 0.91 0.92 0.94 0.94 0.95 0.94
Massachusetts 4,141 0.95 0.96 0.97 0.96 0.98 0.97
Michigan 4,627 0.93 0.93 0.94 0.93 0.95 0.93
Minnesota 1,949 0.96 0.97 0.97 0.96 0.97 0.93
Mississippi 2,907 0.90 0.89 0.92 0.91 0.94 0.92
Missouri 3,149 0.95 0.96 0.95 0.95 0.95 0.94
Montana 136 * * * * * *
Nebraska 558 * * * * * *
Nevada 2,302 0.89 0.93 0.91 0.92 0.92 0.94
New Hampshire 251 * * * * * *
New Jersey 7,891 0.92 0.90 0.93 0.91 0.93 0.91
New Mexico 854 0.89 0.86 0.90 0.95 0.97 0.94
New York 22,857 0.92 0.94 0.93 0.94 0.95 0.95
North Carolina 8,661 0.92 0.94 0.93 0.93 0.94 0.95
North Dakota 81 * * * * * *
Ohio 6,170 0.94 0.94 0.96 0.95 0.95 0.95
Oklahoma 1,795 0.91 0.92 0.93 0.91 0.94 0.92
Oregon 1,480 0.95 0.94 0.93 0.94 0.93 0.96
Pennsylvania 8,988 0.91 0.93 0.91 0.93 0.93 0.93
Rhode Island 603 0.92 0.97 0.93 0.99 1.00 0.99
South Carolina 4,380 0.91 0.92 0.94 0.93 0.95 0.93
South Dakota 160 * * * * * *
Tennessee 5,251 0.92 0.91 0.92 0.94 0.92 0.92
Texas 25,746 0.92 0.93 0.93 0.94 0.94 0.94
Utah 675 0.98 0.97 0.96 0.96 0.95 0.94
Vermont 92 * * * * * *
Virginia 5,786 0.92 0.94 0.95 0.94 0.94 0.95
Washington 3,005 0.94 0.93 0.95 0.94 0.97 0.95
West Virginia 471 * * * * * *
Wisconsin 1,466 0.95 0.95 0.97 0.95 0.96 0.95
Wyoming 99 * * * * * *
Subtotal 255,253 0.92 0.93 0.93 0.94 0.94 0.94
U.S. dependent areas
American Samoa 0 * * * * * *
Guam 22 * * * * * *
Northern Mariana Islands 4 * * * * * *
Puerto Rico 4,622 0.83 0.81 0.86 0.86 0.88 0.86
Republic of Palau 3 * * * * * *
U.S. Virgin Islands 165 * * * * * *
Subtotal 4,816 0.83 0.82 0.86 0.86 0.88 0.86
Total 260,069 0.92 0.93 0.93 0.93 0.94 0.94
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Abbreviation: asterisk (*) indicates sample too small (< 600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data are based on residence at diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.a Hispanics/Latinos can be of any race.b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Table 7d. Persons with HIV surviving > 3 years after stage 3 (AIDS) classification during 2008–2013, by year of 
diagnosis and selected characteristics—United States  
Proportion survived > 3 years
No. 2008 2009 2010 2011 2012 2013
Sex 
Male 121,985 0.85 0.86 0.86 0.86 0.87 0.86
Female 41,103 0.84 0.85 0.85 0.85 0.85 0.85
Age at year-end 2015 (yr)
13–24 14,339 0.94 0.95 0.95 0.96 0.95 0.96
25–34 37,407 0.90 0.92 0.92 0.92 0.93 0.92
35–44 46,814 0.87 0.88 0.89 0.89 0.89 0.89
45–54 43,345 0.81 0.82 0.83 0.82 0.83 0.83
≥ 55 21,183 0.68 0.70 0.69 0.70 0.72 0.71
Race/ethnicity
American Indian/Alaska Native 582 * * * * * *
Asian 2,096 0.90 0.90 0.91 0.92 0.94 0.91
Black/African American 76,600 0.83 0.84 0.85 0.85 0.86 0.86
Hispanic/Latinoa 34,200 0.88 0.88 0.88 0.88 0.89 0.88
Native Hawaiian/Other 
Pacific Islander
153 * * * * * *
White 40,844 0.84 0.86 0.85 0.85 0.85 0.84
Multiple races 8,613 0.88 0.87 0.87 0.88 0.88 0.88
Transmission categoryb
Male-to-male sexual contact 83,258 0.87 0.88 0.88 0.88 0.89 0.88
Injection drug use
Male 11,067 0.77 0.77 0.78 0.77 0.77 0.76
Female 8,405 0.79 0.80 0.80 0.80 0.80 0.79
Male-to-male sexual contact 
and injection drug use
8,622 0.86 0.87 0.86 0.86 0.86 0.84
Heterosexual contactc
Male 18,297 0.81 0.82 0.83 0.83 0.84 0.83
Female 31,982 0.85 0.86 0.86 0.86 0.86 0.85
Totald 163,088 0.85 0.86 0.86 0.86 0.86 0.86
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Abbreviation: asterisk (*) indicates sample too small (< 600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data are based on residence at diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.a Hispanics/Latinos can be of any race.b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
Table 7e. Persons with HIV surviving > 3 years after stage 3 (AIDS) classification during 2008–2013, by year of 
diagnosis and selected characteristics—United States and 6 dependent areas  
Proportion survived > 3 years
No. 2008 2009 2010 2011 2012 2013
Sex 
Male 124,300 0.85 0.86 0.86 0.86 0.87 0.86
Female 42,080 0.83 0.84 0.85 0.85 0.85 0.84
Age at year-end 2015 (yr)
13–24 14,487 0.94 0.95 0.95 0.96 0.95 0.96
25–34 37,982 0.90 0.92 0.92 0.92 0.93 0.92
35–44 47,784 0.87 0.88 0.88 0.89 0.89 0.89
45–54 44,386 0.81 0.82 0.82 0.82 0.83 0.83
≥ 55 21,741 0.67 0.70 0.69 0.70 0.71 0.71
Race/ethnicity
American Indian/Alaska Native 582 * * * * * *
Asian 2,102 0.90 0.90 0.91 0.91 0.94 0.91
Black/African American 76,658 0.83 0.84 0.85 0.85 0.86 0.86
Hispanic/Latinoa 37,405 0.86 0.87 0.87 0.87 0.88 0.87
Native Hawaiian/Other 
Pacific Islander
161 * * * * * *
White 40,855 0.84 0.86 0.85 0.85 0.85 0.84
Multiple races 8,617 0.88 0.87 0.87 0.88 0.88 0.88
Transmission categoryb
Male-to-male sexual contact 84,042 0.87 0.88 0.88 0.88 0.89 0.88
Injection drug use
Male 11,828 0.76 0.76 0.77 0.77 0.76 0.75
Female 8,609 0.78 0.80 0.80 0.80 0.79 0.79
Male-to-male sexual contact 
and injection drug use
8,786 0.86 0.87 0.85 0.86 0.86 0.84
Heterosexual contactc
Male 18,881 0.80 0.82 0.83 0.82 0.84 0.82
Female 32,745 0.85 0.86 0.86 0.86 0.86 0.85
Totald 166,380 0.84 0.85 0.86 0.86 0.86 0.86
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Abbreviation: asterisk (*) indicates sample too small (< 600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data are based on residence at diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.
Table 7f. Persons with HIV surviving > 3 years after stage 3 (AIDS) classification during 2008–2013, by year of 
diagnosis and area of residence—United States and 6 dependent areas  
Proportion survived > 3 years
No. 2008 2009 2010 2011 2012 2013
Alabama 2,182 0.82 0.79 0.81 0.84 0.81 0.82
Alaska 120 * * * * * *
Arizona 2,512 0.83 0.87 0.87 0.85 0.82 0.84
Arkansas 852 0.76 0.80 0.78 0.78 0.87 0.87
California 18,357 0.88 0.88 0.88 0.88 0.87 0.87
Colorado 1,491 0.91 0.88 0.90 0.87 0.91 0.89
Connecticut 1,540 0.83 0.88 0.91 0.90 0.89 0.88
Delaware 582 * * * * * *
District of Columbia 2,416 0.83 0.87 0.87 0.88 0.88 0.89
Florida 19,831 0.82 0.84 0.83 0.82 0.85 0.82
Georgia 10,364 0.83 0.84 0.85 0.85 0.85 0.86
Hawaii 363 * * * * * *
Idaho 161 * * * * * *
Illinois 6,024 0.85 0.87 0.85 0.88 0.89 0.89
Indiana 1,860 0.87 0.81 0.85 0.86 0.87 0.85
Iowa 458 * * * * * *
Kansas 537 * * * * * *
Kentucky 1,188 0.83 0.85 0.83 0.85 0.84 0.81
Louisiana 4,667 0.80 0.83 0.83 0.83 0.83 0.84
Maine 183 * * * * * *
Maryland 5,560 0.83 0.84 0.86 0.88 0.87 0.88
Massachusetts 2,624 0.90 0.92 0.90 0.91 0.93 0.91
Michigan 2,905 0.85 0.83 0.85 0.87 0.86 0.85
Minnesota 1,139 0.89 0.90 0.91 0.90 0.91 0.90
Mississippi 1,999 0.80 0.79 0.84 0.86 0.82 0.84
Missouri 2,012 0.87 0.87 0.86 0.88 0.91 0.86
Montana 97 * * * * * *
Nebraska 373 * * * * * *
Nevada 1,408 0.80 0.81 0.81 0.80 0.80 0.87
New Hampshire 163 * * * * * *
New Jersey 5,529 0.82 0.83 0.85 0.81 0.85 0.84
New Mexico 569 * * * * * *
New York 16,462 0.86 0.88 0.89 0.88 0.88 0.88
North Carolina 5,077 0.83 0.86 0.85 0.85 0.86 0.87
North Dakota 47 * * * * * *
Ohio 3,560 0.88 0.87 0.87 0.91 0.86 0.89
Oklahoma 1,011 0.85 0.83 0.84 0.81 0.81 0.76
Oregon 1,049 0.90 0.87 0.88 0.86 0.87 0.89
Pennsylvania 5,624 0.85 0.86 0.84 0.86 0.88 0.85
Rhode Island 393 * * * * * *
South Carolina 3,375 0.85 0.84 0.85 0.85 0.88 0.84
South Dakota 85 * * * * * *
Tennessee 3,410 0.82 0.83 0.86 0.83 0.85 0.85
Texas 16,054 0.84 0.86 0.86 0.87 0.86 0.86
Utah 399 * * * * * *
Vermont 44 * * * * * *
Virginia 3,229 0.85 0.84 0.89 0.85 0.84 0.90
Washington 1,873 0.89 0.88 0.90 0.86 0.92 0.91
West Virginia 322 * * * * * *
Wisconsin 927 0.88 0.85 0.90 0.89 0.91 0.86
Wyoming 81 * * * * * *
Subtotal 163,088 0.85 0.86 0.86 0.86 0.86 0.86
U.S. dependent areas
American Samoa 0 * * * * * *
Guam 16 * * * * * *
Northern Mariana Islands 3 * * * * * *
Puerto Rico 3,173 0.70 0.71 0.70 0.74 0.74 0.76
Republic of Palau 2 * * * * * *
U.S. Virgin Islands 98 * * * * * *
Subtotal 3,292 0.69 0.71 0.71 0.74 0.74 0.77
Total 166,380 0.84 0.85 0.86 0.86 0.86 0.86
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2015 2016
No. Rate No. Rate
36 6.1 30 5.4
8 0.9 12 1.3
8 0.4 3 0.1
5 1.7 3 0.7
57 1.4 48 1.2
/ethnicity, 2010–2016—United States  
2015 2016
No. Rate No. Rate
33 5.6 28 5.0
8 0.9 10 1.1
8 0.4 3 0.1
5 1.7 3 0.7
54 1.4 44 1.1
Note. Rates are per 100,000 live births.
a Live-birth data reflect race/ethnicity of the infant’s mother. 
b Hispanics/Latinos can be of any race.
Note. Rates are per 100,000 live births.
a Live-birth data reflect race/ethnicity of the infant’s mother. 
b Hispanics/Latinos can be of any race.
Table 8a. Perinatally acquired HIV infection, by year of birth and mother’s race/ethnicity, 2010–2016—United States  
2010 2011 2012 2013 2014
Race/ethnicitya No. Rate No. Rate No. Rate No. Rate No. Rate
Black/African American 62 10.5 62 10.6 72 12.3 38 6.5 39 6.6
Hispanic/Latinob 19 2.0 20 2.2 9 1.0 9 1.0 8 0.9
White 15 0.7 4 0.2 7 0.3 5 0.2 5 0.2
Other 12 4.4 11 3.9 14 4.7 7 2.4 5 1.6
Total 108 2.7 97 2.5 102 2.6 59 1.5 57 1.4
Table 8b. Perinatally acquired HIV infection among persons born in the United States, by year of birth and mother’s race
2010 2011 2012 2013 2014
Race/ethnicitya No. Rate No. Rate No. Rate No. Rate No. Rate
Black/African American 40 6.8 38 6.5 51 8.7 26 4.5 34 5.8
Hispanic/Latinob 16 1.7 14 1.5 8 0.9 8 0.9 6 0.7
White 8 0.4 1 0.0 4 0.2 5 0.2 5 0.2
Other 6 2.2 7 2.5 8 2.7 6 2.1 3 1.0
Total 70 1.8 60 1.5 71 1.8 45 1.1 48 1.2
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s of > 1,000 and to the nearest 10 for estimates of 
eports/hiv-surveillance.html.2019. Accessed April 29, 
/hiv/library/reports/hiv-surveillance.html.2019. 
jurisdictions (found in Tables 4a and 5a) to the total 
or estimates of ≤ 1,000 to reflect model uncertainty.
own.
 2016, by selected characteristics—United States
 carec Viral suppressionc
% No. %
49 465,700 53
51 136,200 53
31 15,300 30
38 81,500 40
47 111,600 50
54 196,900 59
56 197,700 60
46 1,700 49
47 8,900 54
47 227,600 48
49 129,900 51
43 540 54
53 203,700 60
58 29,100 60
49 349,000 54
48 37,400 48
54 28,600 54
57 33,700 58
45 44,100 46
50 107,200 53
49 601,400 53
a Estimates derived by using HIV surveillance and CD4 data for persons aged ≥ 13 years at diagnosis. Estimates rounded to the nearest 100 for estimate
≤ 1,000 to reflect model uncertainty. Data previously published in HIV Surveillance Supplemental Report 2019;24(No. 1). http://www.cdc.gov/hiv/library/r
2019. Rates are per 100,000 population.
b Reported to National HIV Surveillance System. Data previously published in HIV Surveillance Supplemental Report 2019;24(No. 1). http://www.cdc.gov
Accessed April 29, 2019.
c Estimates are the result of extrapolating data from the 42 jurisdictions with complete CD4 and viral load reporting by applying the percentage in the 42 
number of people living with diagnosed HIV in the United States. Estimates rounded to the nearest 100 for estimates of > 1,000 and to the nearest 10 f
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanics/Latinos can be of any race.
f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
h Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified. Includes persons whose race/ethnicity is unkn
Table 9. Prevalence-based HIV care continuum for persons aged ≥ 13 years living with HIV infection (diagnosed or undiagnosed) at year-end
Persons with HIV 
infection alive at 
year-end 2016a
Persons with diagnosed HIV 
infection alive at year-end 2016b Receipt of carec Retention in
Total No. No. % No. % No.
Sex 
Male 882,300 748,652 84.8 555,500 63 431,200
Female 258,000 229,231 88.8 169,600 66 132,000
Age at year-end 2016 (yr)
13–24 50,900 28,485 56.0 21,700 43 16,000
25–34 203,300 144,049 70.9 106,700 53 77,800
35–44 223,000 188,796 84.6 138,200 62 104,400
45–54 336,100 308,597 91.8 232,400 69 181,800
≥ 55 327,000 307,956 94.2 225,400 69 183,800
Race/ethnicity
American Indian/Alaska Native 3,600 2,930 81.6 2,200 60 1,600
Asiand 16,600 13,411 80.9 9,900 59 7,800
Black/African American 476,100 405,738 85.2 290,900 61 222,800
Hispanic/Latinoe 254,600 211,956 83.3 152,400 60 124,200
Native Hawaiian/Other Pacific Islander 1,000 845 82.4 600 60 430
White 339,400 300,483 88.5 233,800 69 178,200
Multiple races 48,200 41,647 86.4 35,800 74 28,100
Transmission categoryf
Male-to-male sexual contact 648,500 542,000 83.6 410,800 63 316,500
Injection drug use
Male 78,000 72,956 93.5 46,400 59 37,200
Female 52,900 50,155 94.7 36,400 69 28,600
Male-to-male sexual contact and 
injection drug use
58,600 54,138 92.3 42,400 72 33,500
Heterosexual contactg
Male 95,000 77,510 81.6 53,900 57 42,500
Female 203,700 177,783 87.3 132,100 65 102,600
Totalh 1,140,400 977,883 85.8 725,600 64 563,300
Table 10.Status of CD4 and viral load reporting by HIV surveillance reporting area, as of December 2018—
50 states, District of Columbia, and U.S. dependent areas 
CD4 count (cells/µL) or CD4 percentage Viral load
Lab reporting requireda  Reportable levelb Lab reporting requireda Reportable levelb
Alabama Yes All values Yes Any result
Alaska Yes All values Yes Any result
American Samoa No — No —
Arizona Yes All values Yes Any result
Arkansas Yes All values Yes Any result
California Yes All values Yes Any result
Colorado Yes All values Yes Any result
Connecticut Yes All values Yes Any result
Delaware Yes All values Yes Any result
District of Columbia Yes All values Yes Any result
Federated States of Micronesia No — No —
Florida Yes All values Yes Any result
Georgia Yes All values Yes Any result
Guam Yes All values Yes Any result
Hawaii Yes All values Yes Any result
Idaho Yes < 200 or < 14% Yes Detectable
Illinois Yes All values Yes Any result
Indiana Yes All values Yes Any result
Iowa Yes All values Yes Any result
Kansas Yes All values Yes Any result
Kentucky Yes All values Yes Any result
Louisiana Yes All values Yes Any result
Maine Yes All values Yes Any result
Marshall Islands No — No —
Maryland Yes All values Yes Any result
Massachusetts Yes All values Yes Any result
Michigan Yes All values Yes Any result
Minnesota Yes All values Yes Any result
Mississippi Yes All values Yes Any result
Missouri Yes All values Yes Any result
Montana Yes All values Yes Any result
Nebraska Yes All values Yes Any result
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Abbreviation: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage.
a Laws, regulations, or statutes in most areas require laboratories to report, but in some instances, the language is not specific.
b Level at which CD4 or viral load reporting is required by laws, regulations, or statutes.
Nevada Yes All values Yes Any result
New Hampshire Yes All values Yes Any result
New Jersey Yes < 200 or < 14% Yes Any result
New Mexico Yes All values Yes Any result
New York Yes All values Yes Any result
North Carolina Yes All values Yes Any result
North Dakota Yes All values Yes Any result
Northern Mariana Islands No — No —
Ohio Yes All values Yes Any result
Oklahoma Yes All values Yes Any result
Oregon Yes All values Yes Any result
Pennsylvania Yes < 200 or < 14% Yes Detectable
Puerto Rico Yes All values Yes Any result
Republic of Palau No — No —
Rhode Island Yes All values Yes Any result
South Carolina Yes All values Yes Any result
South Dakota Yes All values Yes Any result
Tennessee Yes All values Yes Any result
Texas Yes All values Yes Any result
U.S. Virgin Islands Yes < 200 or < 14% Yes Detectable
Utah Yes All values Yes Any result
Vermont Yes < 200 or < 14% Yes Any result
Virginia Yes All values Yes Any result
Washington Yes All values Yes Any result
West Virginia Yes All values Yes Any result
Wisconsin Yes All values Yes Any result
Wyoming Yes All values Yes Any result
Table 10.Status of CD4 and viral load reporting by HIV surveillance reporting area, as of December 2018—
50 states, District of Columbia, and U.S. dependent areas (cont)
CD4 count (cells/µL) or CD4 percentage Viral load
Lab reporting requireda  Reportable levelb Lab reporting requireda Reportable levelb
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Table 11. Monitoring national HIV prevention goals by using data from the National HIV Surveillance System and other 
surveillance systems
Abbreviation: n/a, not available.
Note. National-level indicators adapted from National HIV/AIDS Strategy for the United States: Updated to 2020 [NHAS 2020]—Indicator Supplement. For the list of NHAS 2020 indicators and 
information on the rationale, data sources, and measures for each indicator, see http://www.hiv.gov/sites/default/files/nhas-indicators-supplement-dec-2016.pdf.
a CDC. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report 2019;24(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. 
Published February 2019.
b Preliminary data.
c The 2013 estimate is based on data from 15 large urban school districts; the 2015 estimate is a national estimate. For more information about the Youth Risk Behavior Surveillance System (YRBSS), 
see http://www.cdc.gov/yrbs.
d Prior to 2015, the Medical Monitoring Project (MMP) used 3-stage sampling to collect data from a representative sample of adults receiving HIV medical care during 2010–2014 in the United States 
and Puerto Rico. Starting in 2015, MMP samples HIV diagnoses from the National HIV Surveillance System. The homelessness estimate provided is subset to persons receiving HIV medical care in 
the past 12 months. For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/. 
e Death rate is age-adjusted and measured per 1,000 persons with diagnosed HIV infection in the United States. 
f Measures shown are ratios of the disparity rate in the specified group to the overall rate. Population data from Vintage 2014 Census data were used to calculate rates for 2010–2013; Vintage 2015 
Census data were used for 2014; Vintage 2016 Census data were used for 2015; Vintage 2017 Census data were used for 2016 and 2017.
g Health Resources and Services Administration. Ryan White HIV/AIDS Program annual client-level data report 2016. http://hab.hrsa.gov/data/data-reports. Published December 2018. Accessed April 
23, 2019. For 2010 baseline data, see http://www.hiv.gov/sites/default/files/nhas-indicators-supplement-dec-2016.pdf.
h Data licensed from MarketScan Commercial Claims and Encounter Database (Truven Health Analytics, Ann Arbor, MI) are analyzed by CDC. Estimates are for persons aged ≥ 16 years.
i The stigma scale used for this indicator is a 10-item scale, ranging from 0 (no stigma) to 100 (high stigma) and measured among persons aged > 18 years with diagnosed HIV infection living in the 
United States and Puerto Rico. The scale used for this indicator is discussed in Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of 
stigma for HIV+ youth. J Adolesc Health 2007;40(1):96–98. Data are collected through MMP. The 2015 median score is weighted. The previously published median score was unweighted.
Indicator 2010 2011 2012 2013 2014 2015 2016 2017
Increase the percentage of persons living with HIV who know their serostatus to at least 
90 percenta
82.8% 83.4% 83.9% 84.3% 84.8% 85.3% 85.8% n/a
Reduce the number of new diagnoses by at least 25 percent 43,806 42,218 42,616 40,628 40,873 40,442 40,142 38,739b
Reduce the percentage of young gay and bisexual males who have engaged in HIV risk 
behaviors by at least 10 percentc
n/a n/a n/a 34.1% n/a 35.2% n/a 29.1%
Increase the percentage of newly diagnosed persons linked to HIV medical care within one 
month of diagnosis to at least 85 percent
70.2% 70.4% 71.4% 72.6% 74.5% 75.0% 75.9% 78.3%
Increase the percentage of persons with diagnosed HIV infection who are retained in HIV 
medical care to at least 90 percent
54.7% 53.6% 55.3% 56.5% 56.9% 57.2% 57.6% n/a
Increase the percentage of persons with diagnosed HIV infection who are virally suppressed 
to at least 80 percent
46.0% 48.5% 51.6% 54.7% 57.9% 59.8% 61.5% n/a
Reduce the percentage of persons in HIV medical care who are homeless to no more than 
5 percentd
7.7% 8.1% 8.3% 7.9% 9.0% 8.4% 8.4% n/a
Reduce the death rate among persons with diagnosed HIV infection by at least 33 percente  19.4  18.0  16.7  15.8 15.4 14.3 14.1 n/a
Reduce disparities in the rate of new diagnoses by at least 15 percent among gay and 
bisexual menf
 20.5  21.2  21.9  22.1 22.5 22.6 22.4 22.6b
Reduce disparities in the rate of new diagnoses by at least 15 percent among young black 
gay and bisexual menf
 109.4  112.4  112.9  117.2 118.5 118.0 115.7 112.3b
Reduce disparities in the rate of new diagnoses by at least 15 percent among black femalesf  1.7  1.5  1.4  1.3 1.2 1.1 1.1 1.1b
Reduce disparities in the rate of new diagnoses by at least 15 percent among persons living 
in the southern United Statesf
 0.33  0.35  0.33  0.35 0.35 0.36 0.36 0.37b
Increase the percentage of youth with diagnosed HIV infection who are virally suppressed to 
at least 80 percent
30.9% 34.3% 38.9% 43.7% 48.1% 51.2% 53.8% n/a
Increase the percentage of persons who inject drugs with diagnosed HIV infection who are 
virally suppressed to at least 80 percent
39.6% 40.6% 44.1% 47.1% 50.3% 52.1% 53.6% n/a
Increase the percentage of transgender women in HIV medical care who are virally 
suppressed to at least 90 percent (developmental)g
62.2% 65.3% 68.5% 72.0% 73.9% 77.0% 79.0% 80.5%
Increase the number of adults prescribed preexposure prophylaxis (PrEP) by at least 500 
percent (developmental)h
n/a n/a n/a n/a 7,972 33,273 64,763 99,647
Decrease stigma among persons with diagnosed HIV infection by at least 25 percent, from a 
baseline median score of 38.3 to 28.7 (developmental)i
n/a n/a n/a n/a n/a 38.3 39.0 n/a
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